Report Sections

See All Reports

  • drug1520: Hydroxychloroquine
  • Placebo (462) Hydroxychloroquine (99) Azithromycin (37) Standard of Care (37) Tocilizumab (36) Placebo oral tablet (31) Questionnaire (30) Convalescent Plasma (27) Ivermectin (22) Remdesivir (22) No intervention (21) Standard of care (21) Convalescent plasma (20) Favipiravir (20) Placebos (17) Survey (15) Enoxaparin (14) Methylprednisolone (14) placebo (14) Nitazoxanide (13) Vitamin C (13) Hydroxychloroquine Sulfate (12) Colchicine (11) Blood sample (10) Control (10) Lopinavir/ritonavir (10) Dexamethasone (9) Ruxolitinib (9) Saline (9) Usual Care (9) Anakinra (8) Losartan (8) Standard care (8) Vitamin D (8) Zinc (8) blood sample (8) no intervention (8) Baricitinib (7) Camostat Mesilate (7) Chloroquine (7) Oseltamivir (7) Questionnaire Administration (7) Questionnaires (7) Clazakizumab (6) DAS181 (6) LY3819253 (6) Prednisone (6) Saliva collection (6) Standard treatment (6) Vitamin D3 (6) blood sampling (6) survey (6) Best Practice (5) COVID-19 Convalescent Plasma (5) COVID-19 convalescent plasma (5) Cyclosporine (5) Doxycycline (5) Hydroxychloroquine (HCQ) (5) Lopinavir / Ritonavir (5) Lung ultrasound (5) Midazolam (5) Nasopharyngeal swab (5) Normal Saline (5) Normal saline (5) Online Survey (5) Rivaroxaban (5) Sarilumab (5) Standard Medical Treatment (5) Standard of Care (SOC) (5) UC-MSCs (5) convalescent plasma (5) questionnaire assesment (5) Acalabrutinib (4) Ad26.COV2.S (4) Alirocumab (4) Ascorbic Acid (4) BCG Vaccine (4) Blood draw (4) Cholecalciferol (4) Colchicine Tablets (4) Evolocumab (4) Famotidine (4) HCQ (4) Hydrocortisone (4) Interferon Beta-1A (4) Interferon beta-1a (4) Lopinavir/Ritonavir (4) Mavrilimumab (4) Mepolizumab (4) Methotrexate (4) Nitric Oxide (4) Online questionnaire (4) Online survey (4) Ontamalimab (4) Opaganib (4) Oxygen (4) Peginterferon beta-1a (4) Placebo Administration (4) Povidone-Iodine (4) Presatovir (4) Prone position (4) Quality-of-Life Assessment (4) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (4) Reslizumab (4) Rifampin (4) Standard Care (4) Telemedicine (4) Telerehabilitation (4) Yoga (4) anti-SARS-CoV-2 convalescent plasma (4) hydroxychloroquine (4) questionnaire (4) standard care (4) 3D Telemedicine (3) ACE inhibitor (3) AG0302-COVID19 (3) Allopurinol (3) Anti-SARS-CoV2 Serology (3) Aspirin (3) BCG vaccine (3) BI 894999 (3) BNT162b1 (3) Best Supportive Care (3) Biospecimen Collection (3) Blood sampling (3) COVID-19 (3) COVID-19 RT-PCR (3) COViage (3) Chloroquine or Hydroxychloroquine (3) Chloroquine phosphate (3) Clinical data (3) Control group (3) Data collection (3) EIDD-2801 (3) Echocardiography (3) Eltrombopag (3) Exercise (3) Gam-COVID-Vac (3) Heparin (3) Interferon Beta-1B (3) Interview (3) Itraconazole (3) Lanadelumab (3) Matching placebo (3) Melatonin (3) Mesenchymal Stromal Cells (3) Nafamostat Mesilate (3) Nitric Oxide Gas (3) Nivolumab (3) No Intervention (3) No intervention, observational study (3) Observational (3) Phase 2 (3) Placebo oral capsule (3) Plasma (3) Probiotic (3) Prone Positioning (3) Prone positioning (3) Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health (3) Relamorelin (3) Remestemcel-L (3) Ribavirin (3) SARS-CoV-2 convalescent plasma (3) Sargramostim (3) Selinexor (3) Serological test (3) SnPP Protoporphyrin plus Sunlight exposure (3) Supportive Care (3) Survey Administration (3) Suspension of heat killed (autoclaved) Mycobacterium w (3) TAK-788 (3) Telmisartan (3) Usual care (3) VPM1002 (3) Verinurad (3) Vitamin Super B-Complex (3) blood donation SMS (3) exhaled breath sampling (3) observational (3) self-administered questionnaire (3) standard of care (3) standard therapy (3) 100 mg/mL Virazole (2) 2D Telemedicine (2) 50 mg/mL Virazole (2) AG0301-COVID19 (2) ARB (2) ATI-450 (2) AZD1222 (2) Abatacept (2) Abidol hydrochloride (2) Acalabrutinib Treatment A (2) Acalabrutinib Treatment B (2) Acalabrutinib Treatment C (2) Aeonose (2) Angiotensin II (2) Arbidol (2) Assessment of behavioral response to emotional stimulation (2) Assessment of work-related stress (2) Ayurveda (2) Azithromycin Tablets (2) BAY1817080 (2) BCG-Denmark (2) BI 474121 (2) BI 764198 (2) BIIB091 (2) BNT162b2 (2) Bacille Calmette-Guérin (BCG) (2) Baloxavir Marboxil (2) Baricitinib Oral Tablet (2) Bemiparin (2) Bevacizumab Injection (2) Bicalutamide 150 Mg Oral Tablet (2) Biological data (2) Biological sample collection (2) Blood samples (2) Blood test (2) Blood tests (2) Breath Biopsy face masks with removable filters and fitted PVA strip (2) Brief cognitive intervention (2) Bucillamine (2) CELLECTRA® 2000 (2) COVID Convalescent Plasma (2) COVID-19 Serology (2) COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (2) COVID-19 pandemic (2) COVID-19 patients (2) CT-Scan (2) CYT107 (2) Cabotegravir Tablets (2) Canakinumab (2) Cannabidiol (2) Carboplatin (2) Cardiac and electrodermal recordings (2) ChAdOx1 MERS (2) ChAdOx1 nCoV-19 (2) Chemotherapy (2) Chloroquine Sulfate (2) Chloroquine or hydroxychloroquine (2) Ciclesonide (2) Clinical Examination (2) Clinical assessment (2) Clopidogrel (2) Cognitive Behavioral Therapy (2) Convalescent COVID 19 Plasma (2) Convalescent Plasma (CP) (2) Convalescent Plasma (anti-SARS-CoV-2 plasma) (2) Convalescent Plasma Transfusion (2) Conventional treatment (2) Corticosteroid (2) DWRX2003 (2) Daclatasvir (2) Data Collection (2) Data record (2) Deferoxamine (2) Dexamethasone injection (2) Dornase Alfa Inhalation Solution [Pulmozyme] (2) Duvelisib (2) ECG (2) EDP1815 (2) Early-Dexamethasone (2) Ebselen (2) Eculizumab (2) Electronic questionnaire (2) Enhanced Usual Care (2) Enoxaparin 40 Mg/0.4 mL Injectable Solution (2) Ensifentrine (2) Exposure (2) Famotidine 20 MG (2) Favipiravir Placebo (2) Fiberoptic Endoscopic Evaluation of Swallowing (2) Fisetin (2) Flow cytometric analysis (2) Follow up (2) Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale (2) GLS-5300 (2) GSK3640254 (2) Guduchi Ghan Vati (2) HB-adMSCs (2) HFNC (2) High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Human immunoglobulin (2) Hydroxychloroquine + azithromycin (2) Hydroxychloroquine - Weekly Dosing (2) Hydroxychloroquine 200 Mg Oral Tablet (2) Hydroxychloroquine Sulfate 200 MG (2) Hydroxychloroquine Sulfate 200 MG [Plaquenil] (2) Hydroxychloroquine Sulfate Loading Dose (2) Hydroxychloroquine Sulfate Regular dose (2) Hydroxychloroquine Sulfate Tablets (2) Hydroxychloroquine and Azithromycin (2) Hypothermia (2) IMU-838 (2) INO-4800 (2) Ibrutinib (2) Icosapent ethyl (2) Imatinib (2) Inactivated SARS-CoV-2 Vaccine (Vero cell) (2) Interferon beta-1b (2) Interleukin-7 (2) Iodine Complex (2) Ivermectin Oral Product (2) Ivermectin Pill (2) Ivermectin and Doxycycline (2) Ixazomib (2) KB109 + Self Supportive Care (SSC) (2) Ketogenic diet (2) L-ascorbic acid (2) LY3832479 (2) Leflunomide (2) Lenzilumab (2) Leronlimab (700mg) (2) Lopinavir-Ritonavir (2) Low Dose Radiation Therapy (2) Low Dose Radiotherapy (2) Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Low molecular weight heparin (2) M5049 (2) MagPro X100 Stimulator, B70 Fluid-Cooled Coil (2) Matched Placebo (2) Meaning Centered Psychotherapy for Latinos (2) Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients (2) Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Mesenchymal stromal cells (2) Methylprednisolone Sodium Succinate (2) Mindfulness (2) Moxifloxacin (2) N-Acetyl cysteine (2) N-acetylcysteine (2) NORS (Nitric Oxide Releasing Solution) (2) Nasal swab (2) Neuromuscular Blocking Agents (2) Niclosamide Oral Tablet (2) Nigella Sativa / Black Cumin (2) Nitrogen gas (2) Observation (2) Olokizumab 64 mg (2) PLACEBO (2) PUL-042 Inhalation Solution (2) Paracetamol (2) Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances (2) Peginterferon Lambda-1A (2) Pembrolizumab (2) Pentoxifylline (2) Peripheral blood draw (2) Phase 1 (2) Phone call (2) Physiotherapy (2) Placebo Comparator (2) Placebo on a 0- and 28-day schedule (2) Postcard (2) Povidone-Iodine Nasal Spray and Gargle (2) Practice details (2) Prazosin (2) Pre-assessment questionnaire (2) Psychoeducation (2) Pulmozyme (2) RECOP unit patient (2) REGN10933+REGN10987 combination therapy (2) RLF-100 (aviptadil) (2) RT-PCR (2) Rabeprazole (2) Radiation therapy (2) Radiotherapy (2) Ravulizumab (2) Recombinant new coronavirus vaccine (CHO cell) low-dose group (2) Recombinant new coronavirus vaccine (CHO cells) high-dose group (2) Recombinant new coronavirus vaccine (CHO cells) placebo group (2) Remdesivir placebo (2) Rifampicin (2) Rilpivirine Tablets (2) Rosuvastatin (2) Routine care for COVID-19 patients (2) Ruxolitinib Oral Tablet (2) SAB-185 (2) SARS-CoV-2 (2) SARS-CoV-2 diagnostic rapid test (2) SARS-Cov2 testing (2) SOC + Placebo (2) Saline solution (2) Saliva sample collection (2) Sample collection (2) Sampling (2) Self Supportive Care (SSC) Alone (2) Seraph 100 (2) Sevoflurane (2) Siltuximab (2) Simvastatin (2) Single Dose of Hydroxychloroquine (2) Sirolimus (2) SivoMixx (200 billion) (2) Spirometry (2) Standard of care (SOC) (2) Standard of care treatment (2) Stellate Ganglion Block (2) T3011 (2) TD-0903 (2) Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. (2) Telehealth (2) Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg (2) Tezepelumab (2) Therapeutic Plasma Exchange (2) Therapeutic anticoagulation (2) Throat swab (2) Thymalfasin (2) Tocilizumab (TCZ) (2) Tocilizumab Injection (2) Tofacitinib (2) Tofacitinib 10 mg (2) Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit (2) Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (2) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (2) Two doses of placebo at the schedule of day 0,28 (2) Unfractionated heparin (2) Volitional help sheet (2) Vonoprazan (2) basic treatment (2) blood draw (2) blood samples (2) blood test (2) mRNA-1273 (2) nasopharyngeal swab (2) other (2) oxygen therapy (2) placebo for risankizumab (2) pregnant women with laboratory-confirmed 2019-n-CoV (2) prone position (2) retrospective analysis (2) rhTPO (2) risankizumab IV (2) risankizumab SC (2) serology (2) survey work (2) tabelecleucel (2) tocilizumab (2) unfractionated Heparin (2) venous ultrasound (2) vv-ECMO + cytokine adsorption (Cytosorb adsorber) (2) vv-ECMO only (no cytokine adsorption) (2) "Calm" is a mindfulness meditation mobile app (1) "Vernonia amygdalina" (1) (Standard of Care) SoC (1) - Synthetic anti-malarial drugs (1) 0.12% Chlorhexidine oral/nasal rinse (1) 0.5% Povidone/Iodine oral/nasal rinse (1) 0.9% Saline (1) 0.9% Sodium-chloride (1) 0.9% saline (1) 0.9% sodium chloride (normal saline) (1) 0.9%NaCl (1) 0.9%sodium chloride (1) 1. Characterize the immune response after infection with SARS-CoV-2 (1) 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse (1) 12-page health warning leaflet (1) 14C-lazertinib (1) 150 ppm Nitric Oxide delivered through LungFit Delivery System (1) 18F-DX600 PET/CT (1) 18F-GP1 PET CT (1) 18F-αvβ6-BP (1) 1: ILT101 (1) 1: Naproxen (1) 1: Prone positioning (1) 1: Usual practice (1) 1: discontinuation of RAS blocker therapy (1) 1D (1) 20 Mg Prednisone for 14 days (1) 20 mg MitoQ (1) 2019-nCoV IgG/IgM Rapid Test Cassette (1) 2019-nCoV PCR (1) 25-OH cholecalciferol (1) 2: No instruction regarding positioning (1) 2: Placebo Comparator (1) 2: Standard of care (1) 2: Usual practice + SYMBICORT RAPIHALER (1) 2: continuation of RAS blocker therapy (1) 30 Gy over 3 weeks (1) 300 mg of omega3-FA (1) 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients) (1) 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ) (1) 38 questions questionnaire (1) 38-questions questionnaire (1) 3D (1) 40mg of MitoQ (1) 40ml blood sample (1) 4Plants/Azythromycin (1) 5-ALA-Phosphate + SFC (5-ALA + SFC) (1) 50 Gy Radiation Therapy (1) 55 Gy Radiation Therapy (1) 5Fluorouracil (1) 6 minute walk test (1) 60 Gy Radiation Therapy (1) 68Ga-DX600 PET/CT (1) 7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted) (1) 80 ppm Nitric Oxide delivered through LungFit Delivery System (1) A short video intervention (1) A vignette intervention (1) AAZ Covid-19 rapid test (1) ABC/3TC (1) ABPM (1) ABTL0812 (1) ABX464 (1) ACE Inhibitors and Calcium Channel Blockers (1) ACE inhibitor, angiotensin receptor blocker (1) ACEI (1) ACEI/ARB (1) ACEIs (1) ACT-20-CM (1) ACT-20-MSC (1) ACT-541478 10 mg (1) ACT-541478 100 mg (1) ACT-541478 1000 mg (1) ACT-541478 30 mg (1) ACT-541478 300 mg (1) ACT-541478 dose E1 (1) ACT-541478 high or low dose (or placebo) (1) ADAM Sensor (1) ADCT-301 (1) AI model (1) AK119 (1) ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS (1) ALX148 (1) AMA Acknowledgement Drug Pricing (1) AMY-101 (1) APL-9 (1) APPS (1) ARALAST NP (1) ARBIDOL 100 MG KAPSUL (1) ARBOX (1) ARBs and/or ACE inhibitors (1) ARCT-021 Dose 1 (1) ARCT-021 Dose 2 (1) ARCT-021 Dose 3 (1) ARCT-021 Dose 4 (1) ARCT-021 Dose Regimen 1 (1) ARCT-021 Dose Regimen 2 (1) ARDSNet (1) ARFC mask (1) ARGX-117 (1) ARGX-117 + rHuPH20 (1) ASC09/ritonavir group (1) ASC09F+Oseltamivir (1) ASP0367 (1) ASP2390 (1) ASP7317 (1) ASP8374 (1) ASSIST (1) ASTX660 (1) AT-001 (1) AT-527 (1) ATAFENOVIR 200 MG KAPSUL (1) ATV (1) ATYR1923 1 mg/kg (1) ATYR1923 3 mg/kg (1) AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong (1) AV-COVID-19 (1) AVIGAN (1) AVIGAN 200 MG Film Tablets (1) AVIGAN 200 mg FT (1) AVIGAN 200 mg Film Tablets (1) AVM0703 (1) AWARD advice (1) AWARD plus COVID-specific advice (1) AZD1390 (1) AZD1656 (1) AZD5718 (1) AZD7442 (1) AZD8154 Monodose DPI presented in capsules (1) AZD8154 Placebo Monodose DPI presented in capsules (1) AZD8154 nebuliser (1) AZD9567 (1) AZD9833 Oral Solution (1) AZD9833 film-coated tablet A Dose 1 (1) AZD9833 film-coated tablet A Dose 2 (1) AZD9833 film-coated tablet B Dose 1 (1) AZD9833 film-coated tablet B Dose 2 (1) Abdominal ultrasound (1) Abidol Hydrochloride combined with Interferon atomization (1) Abiraterone Acetate (1) Abivertinib (1) Acacia Senegal (1) Acalabrutinib Treatment D (1) Acceptability questionnaire (1) Access to training facility (1) Accuchek Inform II platform (1) Acetazolamide + supplemental oxygen + PAP therapy (1) Acetylsalicylic acid (1) Acknowledgement Racial Injustice AMA (1) Acthar Gel (1) Actigraph (1) Active COVID-19 disease (1) Active Choice (1) Active Comparator (1) Active Control (1) Active PBMT/sMF (1) Active control condition (1) Active control:Healthy Living (1) Activity (1) Acyclovir (1) Ad26.ZEBOV (1) Ad5-nCoV (1) Ad5FGF-4 (1) Adalimumab (1) Additional biological samples (1) AdimrSC-2f (1) Admission to ICU for COVID-19 (1) Adsorbed COVID-19 (inactivated) Vaccine (1) Aerobic Exercise Training (1) Aerolized Hydroxychloroquine Sulfate (1) Aerosol Box (1) Aerosol-reducing Mask (1) Aerosolized 13 cis retinoic acid (1) Aerosolized All trans retinoic acid (1) Aerosolized Isotretinoin plus Tamoxifen (1) African American Sender Acknowledgement (1) African American Sender in Informational Videos. (1) After COVID-19 Pandemic (1) AirGo Respiratory Monitor (1) Airwave Oscillometry (1) Airway pressure release ventilation (1) Albendazole (1) Albuterol - Control (1) Albuterol - Experimental (1) Alcohol (1) Alcohol brief intervention (1) Alexa Amazon (1) Alferon LDO (1) Algorithm-based recommendation (1) AlloStim (1) Allocetra-OTS (1) Allogeneic NK transfer (1) Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells (1) Allogenic pooled olfactory mucosa-derived mesenchymal stem cells (1) Almitrine (1) Alteplase 100 MG [Activase] (1) Alteplase 50 MG [Activase] (1) Alternating face-to-face medical visits and video medical consultations (1) Aluminum adjuvant (1) Aluminum hydroxide (1) Aluminum hydroxide adjuvant (Alhydrogel®) (1) Alvelestat (1) Ambrisentan (1) Amiodarone (1) Amlodipine (1) Amlodipine 2.5 mg/indapamide 1.25 mg (1) Amoxicillin-clavulanate (1) Ampion (1) An auto-questionnaire comprising three psychometric scales (1) Anakinra +/- Ruxolitinib (stages 2b/3) (1) Anakinra 100Mg/0.67Ml Inj Syringe (1) Anakinra 149 MG/ML Prefilled Syringe [Kineret] (1) Anakinra Prefilled Syringe (1) Anakinra alone (stages 2b/3) (1) Anakinra and Ruxolitinib (Advanced stage 3) (1) Anakinra and Ruxolitinib (overcome stage 3) (1) Anakinra and Zinc (1) Anakinra plus oSOC (1) Analogs, Prostaglandin E1 (1) Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage. (1) Anatomic Pulmonary Resection (1) Anger message (1) Angiography (1) Angiography scanner (1) Angiotensin 1-7 (1) Angiotensin Receptor Blockers (1) Angiotensin converting enzyme inhibitor (1) Angiotensin receptor blocker (1) Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB) (1) Anluohuaxian (1) Anthocyanins (1) Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients (1) Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients (1) Anti- SARS-CoV-2 Plasma (1) Anti-COVID-19 human immunoglobulin (1) Anti-Human Thymocyte Immunoglobulin, Rabbit (1) Anti-SARS-CoV-2 Human Convalescent Plasma (1) Anti-SARS-CoV-2 IgT seropositivity (1) Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS) (1) Anti-SARS-CoV2 serological controls and serum neutralization (1) Anti-Sars-CoV-2 Convalescent Plasma (1) Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients (1) Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients (1) Antibiotics (1) Antibody Test (1) Antibody test (SARS-CoV2) (1) Antibody testing (1) Antibody titration (1) Antibody-Rich Plasma from COVID-19 recovered patients (1) Anticoagulant Therapy (1) Anticoagulation Agents (Edoxaban and/or high dose LMWH) (1) Antihemophilic Factor (Recombinant) (1) Antihypertensive Agents (1) Antioxidation Therapy (1) Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19 (1) Antroquinonol (1) Anxiety Reduction Training (1) Any drug used to treat Covid-19 (1) Apilimod Dimesylate Capsule (1) Apixaban (1) Apixaban 2.5 MG (1) Apixaban 5MG (1) Apo-Hydroxychloroquine (1) Appeals (1) Appendectomy (1) Apple Watch Series 5 (1) Application of tele-rehabilitation (1) Apramycin injection (1) Apremilast (1) Aprepitant injectable emulsion (1) Aprotinin (1) Arbidol Hydrochloride Granules (1) Argatroban (1) Arm exercise electrocardiographic stress test (1) Artemesia annua (1) ArtemiC (1) Artemisia Annua Leaf (1) Artemisinin / Artesunate (1) Arterial Blood Gas test (ABG) (1) Artesunate-amodiaquine (1) Ascorbic Acid and Zinc Gluconate (1) Aspirin 100mg (1) Aspirin 75mg (1) Aspirin 81 mg (1) Assembled mask (1) Assessing antibody responses, neutralizing capacity and memory B-cell function (1) Assessing impact of COVID19 (1) Assessment of Dietary Changes in Adults in the Quarantine (1) Assessment of cardiovascular diseases and cardiovascular risk factors (1) Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery (1) Assessment of ventilator-associated pneumonia criteria (1) Assigned Strategies: Active Choice (1) Assigned Strategies: Enhanced Active Choice (1) Assigned Strategies: Opt-in (1) Association of diltiazem and niclosamide (1) Asthma controller therapies (incl. prednisone/prednisolone) (1) Asthma reliever therapies (1) AstroStem-V (1) Asunercept (1) Asynchronies detection (1) Atazanavir (1) Atazanavir and Dexamethasone (1) Atezolizumab (1) Atomoxetine hydrochloride (1) Atorvastatin (1) Atorvastatin 20 Mg Oral Tablet (1) Atorvastatin 20mg (1) Atorvastatin 40mg (1) Atovaquone/Azithromycin (1) Attention Bias Modification (ABM) (1) Attention Control Group (1) Attention Control Intervention 4 (1) Attention Placebo (1) Attention Training Program (1) Audit and Feedback (1) Auditory Evoked Potentials (AEP) (1) Auricular neuromodulation (1) Auricular percutaneous neurostimulation (1) Auto-questionnaires (patients co infected HIV Sras-CoV-2) (1) Autologous Adipose MSC's (1) Autologous Bone Graft (1) Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) (1) Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells (1) Automated oxygen administration - FreeO2 (1) Auxora (1) Avdoralimab (1) Aviptadil 67μg (1) Aviptadil by intravenous infusion + standard of care (1) Awake Prone Positioning (1) Awake Proning (1) Awake prone positioning (1) Awake proning (1) Ayurvedic Kadha (1) Azacitidine (1) Azinc (1) Azithromycin (Azithro) (1) Azithromycin 250 MG (1) Azithromycin 250 MG Oral Capsule (1) Azithromycin 500 milligram (mg) oral Tablet (1) Azithromycin 500Mg Oral Tablet (1) Azithromycin Capsule (1) Azithromycin and hydroxychloroquine (1) Azithromycin with amoxicillin/clavulanate (1) Açaí palm berry extract - natural product (1) BACMUNE (MV130) (1) BAT (1) BAT + Calcifediol (1) BAT2020 (1) BAX 888 (1) BAY1237592 (1) BAY2328065 LSF (1) BAY2328065 tablet (1) BBV152A (1) BBV152B (1) BBV152C (1) BCG (1) BCG GROUP (1) BCG vaccine (Freeze-dried) (1) BDB-001 Injection (1) BGB DXP593 (1) BGB-DXP593 (1) BI 1015550 (1) BI 1569912 (1) BI 425809 (1) BI 706321 (1) BIKTARVY Tablets (BIK) (1) BIO 300 Oral Suspension (1) BIO101 (1) BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM (1) BIOVITALS (1) BLAfit® (1) BLD-2660 (1) BM-Allo.MSC (1) BM-MSCs (1) BMS-986253 (1) BMS-986256 (1) BMS-986259 (1) BMS-986322 (1) BMS-986322 Placebo (1) BMS-986337 (1) BMS-986337 Placebo (1) BNT162a1 (1) BNT162b3 (1) BNT162c2 (1) BR (1) BRII-196 (1) BRII-198 (1) BTL-TML-COVID (1) BVA-100 (1) BVRS-GamVac (1) BVRS-GamVac-Combi (1) Bacillus Calmette-Guerin (BCG) (1) Back Side of the Moon (1) Background questionnaire (1) Bactek-R (1) Bacterial species isolated (1) Bardoxolone methyl (1) Bariatric procedures (1) Baricitinib (janus kinase inhibitor) (1) Baricitinib 4 MG Oral Tablet (1) Baricitinib or Anakinra (1) Barrier box (1) Base therapy (1) Baseline message (1) Basic Body Awareness Therapy (1) Basic Go NAPSACC (1) Beck Depression Inventory (BDI) (1) Bedside lung ultrasound (1) Behavioral Activation in real-life (1) Behavioral activation, evidence-based sleep strategies including sleep restriction, exposure-based strategies, promotion of physical activity and recuperating activities, psychoeducational material (1) Behavioral: OCAT (1) Behavioral: OCAT-sham (1) Behaviour Change Technique Intervention to Improve Quality of Life (1) Berberine (1) Berzosertib (1) Best Available Therapy (1) Best Message + Augmented Message or Implementation Strategy (1) Best Message Alone (1) Best Standard of Care (1) Best Standard of Care + CARDIO (1) Best available care (1) Best available treatment (1) Best standard of care (1) Best supportive care" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy (1) Bevacizumab (1) BioMedomics COVID-19 IgM-IgG Rapid Test (1) Biocontainment Device For Aerosol Generating Procedures (Biobox) (1) Biological (1) Biological Sample Collection (1) Biological collection (patients co infected HIV Sras-CoV-2) (1) Biological sample and clinical data collection (1) Biological samples specific to research (1) Biological sampling (1) Biological test (1) Biological/Vaccine: Angiotensin peptide (1-7) derived plasma (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group (1) Biological: COVID-19 convalescent plasma (1) Biological: mRNA-1273: 100 mcg (1) Biological: mRNA-1273: 50 mcg (1) Biological: oral polio vaccine (1) Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT) (1) Biomarkers expression (1) Biosensor (1) Biosensors (1) Biospecimen collection (1) Bivalirudin Injection (1) Blink and Masseter Inhibitory Reflex (1) Blood Collection (1) Blood D-dimer assay (1) Blood Sample (1) Blood Test (1) Blood Transfusion (1) Blood and derivatives. (1) Blood collection (1) Blood collection on admission and longitudinally (1) Blood collection on their first consultation and 10 to 14 days later (1) Blood donation from convalescent donor (1) Blood for anti-drug antibody (ADA) (1) Blood for pharmacokinetic samples (1) Blood for research purposes (1) Blood group determination (1) Blood plasma (1) Blood sample and data record (1) Blood sample collection (1) Blood sample for serological test (1) Blood sample for serology to measure past infection with SARS-CoV-2 (1) Blood sample for whole genome sequencing (1) Blood samples (collection of 5 mL of blood in a dry tube) (1) Blood samples collection (1) Blood tests sputum, nasal lavage and brushing (1) Bloodwork (1) Body Project (BP) (1) Bolus placebo (1) Bolus vitamin D3 (1) Bone Marrow Harvest (1) Bone conduction headphones (1) Bovine Lactoferrin (1) Bovine Lipid Extract Surfactant (1) Brain Health Education (BHE) (1) Brain MRI (1) Brain MRI scan (1) Brainstem Responses Assessment Sedation Score (BRASS) (1) Brazilian Green Propolis Extract (EPP-AF) (1) Breastfeeding Support Provided to Mothers Through WhatsApp Messaging Application (1) Breath Test & Cheek Swab (1) Breath sample (1) Breath test (1) Brequinar (1) Brexanolone (1) Bridge therapy (1) Brief Behavioral Activation Treatment (1) Brief Behavioral Activation with Mental Imagery (1) Brief Psychiatric Rating Scale (1) Brief Skills for Safer Living (1) Brief cognitive behavioral therapy (1) Brief educational video (1) Brief informational infographic (1) Bromhexine 8 MG (1) Bromhexine Hydrochloride (1) Bromhexine Hydrochloride Tablets (1) Bromhexine Oral Tablet and/or hydroxychloroquine tablet (1) Bromhexine and Spironolactone (1) Broncho-Vaxom® (1) Bronchoalveolar Lavage (BAL) (1) Budesonide (1) Budesonide Nasal (1) Budesonide dry powder inhaler (1) Buprenorphine Sublingual Product (1) Burnout (1) Buspirone + PAP therapy (1) Butterfly (1) C-reactive protein (1) C21 (1) C2Rx (1) C3+ Holter Monitor (1) CAG length <22 (1) CAG length >=22 (1) CAM2038 (1) CAP-1002 Allogeneic Cardiosphere-Derived Cells (1) CAPABLE Transitions (1) CAStem (1) CBT-OSA (1) CCP (1) CCTP (1) CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc (1) CD24Fc (1) CD55 (1) CDX-0159 (1) CERC-002 (1) CETA Short Session (CSS) (1) CFTR Modulators (1) CFZ533 (1) CGB-S-100 (1) CHEST CT SCAN (1) CHLORPROMAZINE (CPZ) (1) CHMI (1) CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) (1) CIG Axial (1) CIG Tilted (1) CK0802 (1) CLBS119 (1) CLIA of IgG and IgM against SARS-Cov-2 (1) CME (active control) (1) CMR with T1 and T2 mapping (1) CNS magnetic resonance imaging (MRI) imaging (1) COM-COVID anonimous survey (1) COMPASS (1) CONTROL GROUP (1) CONVALESCENT PLASMA (1) COPAN swabbing and blood sample collection (1) COSH Self-help smoking cessation booklet (1) COVI-GUARD (1) COVICU (1) COVID 19 Convalescent Plasma (1) COVID 19 Diagnostic Test (1) COVID 19 Self-Questionnaire (1) COVID 19 diagnostic test by PCR (1) COVID 19 impact (1) COVID 19 serology (1) COVID positive via testing (1) COVID visitation restrictions (1) COVID-19 Androgen Sensitivity Test (CoVAST) (1) COVID-19 Antibody testing (1) COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support (1) COVID-19 Breastfeeding Support (1) COVID-19 Convalescent Plasma (CCP) (1) COVID-19 Convalscent Plasma (1) COVID-19 FACILITY (1) COVID-19 IgG / IgM rapid test (whole blood, serum, plasma) (1) COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA) (1) COVID-19 PCR (1) COVID-19 PCR Swab (1) COVID-19 PCR and Serology (1) COVID-19 PCR and serology testing (1) COVID-19 Pandemic (1) COVID-19 Pneumonia (1) COVID-19 Specific T Cell derived exosomes (CSTC-Exo) (1) COVID-19 Swab (1) COVID-19 and Intensive Care (1) COVID-19 antibodies testing (1) COVID-19 antibody point of care test kit (1) COVID-19 barrier box (1) COVID-19 convalescent hyperimmune plasma (1) COVID-19 convalescent plasma (CCP) plus standard of care (SOC) (1) COVID-19 diagnostic PCR (1) COVID-19 diagnostic test (1) COVID-19 e-package: Psychological wellbeing for healthcare workers (1) COVID-19 experience surveys (1) COVID-19 exposure (1) COVID-19 infection (1) COVID-19 infection status (1) COVID-19 positive via testing (1) COVID-19 related health warning leaflet (1) COVID-19 standard care (1) COVID-19 survey (1) COVID-19 swap test PCR (1) COVID-19 test, polymerase chain reaction for SARS-CoV-2 (1) COVID-19 treatment (1) COVID-19 treatments (1) COVID-19+ observational (1) COVID-surgRES questionaire (1) COVID19 (1) COVID19 convalescent plasma infusion (1) COVID19 vaccine (1) COVIDSeq Test (1) COVSurf Drug Delivery System (1) CPAP (1) CPAP treatment (1) CPI-006 (1) CRI management (1) CSL324 (1) CT of the chest (1) CT score (1) CT-P59 (1) CT-V (1) CT-imaging (1) CT-scan (1) CT-scan with minimal invasive autopsy (1) CTUS examination (1) CUROSURF® (poractant alfa) (1) CVnCoV (Dose level confirmed in Part 1) (1) CVnCoV 6 μg (1) CVnCoV 8 μg (1) CVnCoV 8 μg (4 μg double dose) (1) CVnCoV Vaccine (1) CYNK-001 (1) CYP 450 Substrates (1) CYP-001 (1) Cabotegravir 200 mg/mL (1) Cabotegravir 400 mg/mL (1) Cabotegravir Injectable Suspension (CAB LA) (1) Cabotegravir extended release suspension for injection (long-acting) (1) Cabotegravir sodium (Oral Lead In) (1) Caffeine 200 mg (1) Calcium Channel Blockers (1) Calm Meditation App (1) Cambridge Validated Viral Detection Method (1) Camidanlumab Tesirine (1) Camostat (1) Camostat Mesylate (1) Canakinumab 150 MG/ML [Ilaris] (1) Canakinumab Injection 300mg (1) Canakinumab Injection 600mg (1) Candesartan (1) Cannabidivarin (1) Cannabis, Medical (1) Capillary and salivary sampling (1) Caption AI (1) Cardiac surgery (1) Cardiopulmonary resuscitation (1) Caring Contacts (1) Carotid Artery Reactivity Testing (1) Carrimycin (1) Case fatality rate (1) Cash transfer (1) Ceftaroline (1) Ceftriaxone (1) Cell therapy protocol 1 (1) Cell therapy protocol 2 (1) Cellectra 2000 Electroporation (1) Cellular response (1) Cenicriviroc (1) Cenicriviroc (CVC) (1) Cenobamate (1) Centricyte 1000 (1) Centrum Adult (under 50) multivitamin (1) Ceralasertib (1) Cerebral compliance and hemodynamics monitoring (1) Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies (1) Certified cloth face mask plus preventive information (1) ChAdOx1 nCoV-19 (Abs 260) (1) ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost (1) ChAdOx1 nCoV-19 (qPCR) (1) ChAdOx1 nCoV-19 0.5mL boost (1) ChAdOx1 nCoV-19 full boost (1) ChAdOx1 nCoV-19 half boost (1) ChAdOx1 nCoV-19 plus 5x10^10vp boost (qPCR) (1) ChAdOx1 nCoV-19 single dose (1) ChAdOx1 nCoV-19 two dose (1) ChAdox1 n-CoV-19 (Abs 260) vaccine low dose (1) Change in knowledge, motivation, skills, resources (1) Change in preference to surgery under COVID-19 pandemic. (1) Chat-based instant messaging support (1) Chat-based support (1) Chest MRI (1) Chest computed tomography (CT) (1) Chest physiotherapy using a non-invasive oscillating device (1) Chinese Herbal Medicine (1) Chinese medicine treatment (1) Chlorhexidine Gluconate (1) Chloroquine Diphosphate (1) Chloroquine Phosphate Tablets (1) Chloroquine analog (GNS651) (1) Chloroquine diphosphate (1) Chlorpromazine (1) Choice of Assignment: Active Choice (1) Choice of Assignment: Enhanced Active Choice (1) Choice of Assignment: Opt-in (1) Choices and judgements (1) Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument (1) Ciclesonide Inhalation Aerosol (1) Ciclesonide Metered Dose Inhaler [Alvesco] (1) Cimetidine (1) Cisplatin (1) Clarithromycin (1) Clazakizumab 12.5 mg (1) Clazakizumab 25 mg (1) Clevudine (1) Clinical diagnosis of COVID-19 by a health care professional (1) Clinical examination (1) Clinical interview (1) Clinical, laboratory and imaging characteristics of pneumonia (1) Clinolipid (1) CloSYS mouthwash (1) Clofazimine (1) Clopidogrel 75mg (1) Closed-loop control of oxygen supplementation by O2matic (1) Cloth Face Mask (1) Clungene rapid test cassette (1) Co-mestring (co-coping) (1) CoYoT1 Care (1) Coala Heart Monitor (1) Cobicistat (1) Cognitive Behavioural Group Therapy for Perinatal Anxiety (1) Cognitive Stimulation (1) Cognitive Training (1) Cognitive and behavioral intervention. (1) Cognitive behavioral therapy (CBT) (1) Cognitive testing (1) Cohort (1) Colchicine 0.5 MG (1) Colchicine 1 MG Oral Tablet (1) Colchicine plus symptomatic treatment (paracetamol) (1) ColdZyme® mouth spray (1) Coldamaris lozenges (1) Colgate Peroxyl mouthwash (1) Colgate Total mouthwash (1) Colgate periogard mouthwash (1) Collagen-Polyvinylpyrrolidone (1) Collection of Biological Samples (1) Collection of blood samples in order to create a biocollection (1) Collection of breath sample (1) Collection of odour samples (1) Collection of samples (1) Colorectal resection (1) Combination (1) Combination of Lopinavir /Ritonavir and Interferon beta-1b (1) Combination of oral polio vaccine and NA-831 (1) Combined ART/hydroxychloroquine (1) Combined use of a respiratory broad panel multiplex PCR and procalcitonin (1) Communication type (1) Community Referral as appropriate (1) Community based combination HIV prevention package (1) Community interest message (1) Community-driven messages to promote COVID-19 testing (1) Comparable Placebo (1) Comparable Placebo of Oral Polio Vaccine and Placebo of drug (1) Comparable Placebo of drug (1) Compassion focused intervention (1) Complement dosage (1) Complete thrombophilic profile testing by multiplex PCR (1) Completion of post telemedicine encounter survey (1) Completion of pre-pandemic survey (1) Completion of survey after peak of pandemic (1) Complex diagnostic panel (1) Comprehensive treatment (1) Computer Based Response Training Weight Loss Intervention (1) Computer task questionnaires (1) Computerized Talking Touchscreen (1) Conestat alfa (1) Confinement and Communication During the COVID-19 Pandemic (1) Conjunctival swab and nasopharyngeal swab (1) Connected devices measurements (1) Connor-Davidson Resilience Scale 10 items (CD-RISC 10) (1) Contain COVID Anxiety SSI (1) Continuation of ACEi/ARB (1) Continuation of ARB/ACEI (1) Continuation of anti-TNF treatment (1) Continuous Positive Airway Pressure (1) Continuous renal replacement therapy (1) Control (albumin 5%) (1) Control Blend (1) Control Group (pharmacotherapy and/or psychotherapy, n=10) (1) Control Intervention (1) Control Period (1) Control arm (1) Control for aerosol generating procedures (1) Control message (1) Control swab (1) Control-EDI (1) Convalescent Immune Plasma (1) Convalescent Plasma 1 Unit (1) Convalescent Plasma 2 Units (1) Convalescent Plasma as Therapy for Covid-19 patients (1) Convalescent Plasma from COVID-19 donors (1) Convalescent Plasma of patients with COVID-19 (1) Convalescent SARS COVID-19 plasma (1) Convalescent Serum (1) Convalescent anti-SARS-CoV-2 MBT Plasma (1) Convalescent anti-SARS-CoV-2 plasma (1) Convalescent plasma (CP) (1) Convalescent plasma transfusion (1) Convalesscent Plasma (1) Conventional N95 respirator (1) Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) (1) Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules (1) Conventional therapy first (1) Cooking Training (1) Coping strategies video (1) Cord Tissue Mesenchymal Stromal Cells (1) Cordio App (1) Core Warming (1) CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test (1) Coronary artery calcium score and cardiac computed tomographic angiography (1) Coronavirus Disease 2019 (1) Corticosteroid injection (1) Cospherunate/Azythromycine (1) Cospherunate/Phytomedicine/Azythromycien (1) Counter Attitudinal Therapy (1) Couples' Intervention (1) CovX (1) Covax-19™ (1) Covid ICU containment measures (1) Covid-19 + patients (1) Covid-19 Antibody testing (IgG and IgM) (1) Covid-19 Rapid Test Kit (RAPG-COV-019) (1) Covid-19 Standard of Care (1) Covid-19 presto test (1) Covid-19 swab PCR test (1) Covid19 (1) Covidfree@home (1) Crest Pro-Health Multi-Protection mouthwash (1) Crisis intervention therapy (1) Crisis management coaching (1) Crizanlizumab (1) Cross Sectional study using scientifically validated psychometric Scales (1) Cross-sectional observational study (1) Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms (1) Cross-sectional study investigating the association of NPIs with mental health (1) Curently used therapy for COVID-19 non-critical patients (1) Current care per UCLA treating physicians (1) Customized questionnaire (1) Cyclosporin A (1) CytoSorb (1) CytoSorb 300 mL device (1) CytoSorb-Therapy (1) Cytochrome P450 (CYP) Substrates (1) Cytokine Adsorption (1) Cytokines dosage (1) Cytokines measurement (1) D-dimer,CBC.ESR,CRP, (1) DAS181 COVID-19 (1) DAS181 OL (1) DASS-21 instrument (depression and anxiety) (1) DAXI for injection Dose HIGH DOSE (1) DAXI for injection dose LOW DOSE (1) DAXI for injection dose MEDIUM DOSE (1) DB-001 (1) DFV890 (1) DIG Axial (1) DIG Tilted (1) DPPFit (1) DRV (1) DUR-928 (1) DWJ1248 (1) Dabigatran etexilate (1) Dabigatran etexilate + BI 1323495 (1) Daclatasvir 120 mg (1) Daclatasvir 60 mg (1) Daily Coping Toolkit (1) Daily Monitoring (1) Daily Vitamin D3 (1) Daily placebo (1) Danoprevir+Ritonavir (1) Dapagliflozin (1) Dapagliflozin 10 MG (1) Dapagliflozin 10 mg (1) Darunavir and Cobicistat (1) Darunavir/Cobicistat (1) Darvadstrocel (1) Data Collection: Clinical Care Assessments (1) Data collection and clinical testing of subjects (1) Data collection and rhinopharyngeal swab (1) Data collection from blood draw (1) Data collection from lumbar puncture (1) Data collection from medical files (1) Data collection up to 1 year (1) Data monitoring for 48h within the first 12 hours of admission for COVID-19 (1) Data registry (1) Data research, database analysis (1) Ddrops® products, 50,000 IU, Oral (1) Decidual Stromal Cells (DSC) (1) Decitabine (1) Deep Breathing training (1) Deep Venous Disease Diagnostic (1) Defibrotide (1) Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days (1) Defibrotide Injection (1) Degarelix (1) Delayed diagnostics Anyplex TMII RV16 Detection (1) Delivery of iStride™ device gait treatment using telemedicine (1) DeltaRex-G (1) Dental pulp mesenchymal stem cells (1) Depression, Anxiety and Stress Scale (1) Descartes 30 (1) Description of groups caracteristics (1) Desferal 500 MG Injection (1) Desidustat (1) Detection of anti-COVID-19 antibody level (1) Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus. (1) Device used to record voice for screening (1) Dexamethasone (high dose) (1) Dexamethasone and Hydroxychloroquine (1) Dexcom G6 (1) Dexmedetomidine Injectable Product (1) Dexmethylphenidate (1) DiaNose (1) Diabetes type 2 (1) Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta (1) Diagnostic Laboratory Biomarker Analysis (1) Diagnostic Test: serology test for COVID-19 (1) Diagnostic examination for venous thromboembolism (1) Diagnostic mammography (1) Diagnostic test (1) Diagnostic test Covid-19 (1) Diagnostic test for SARS-Cov2 for patients and health staff (1) Diagnostic test for detection of SARS-CoV-2 (1) Dialectical Behavioral Therapy (DBT) Skills (1) Dialyzable Leukocyte Extract (1) Diet tracking and survey (1) Dietary Intervention (1) Dietary Supplement containing resistant starch (1) Dietary advice (1) Dietary advice and advice on timing (1) Dietary counselling on Food Groups according to IYC Feeding practices, WHO (1) Dietary intake, body composition, lifestyle, and CVD risk factors (1) Differences in triage (1) Difficulties lived by disabled children's parents in the period of COVID-19 pandemic (1) Diffusing capacity of carbon monoxide (1) DigiVis visual acuity app (1) Digital Health Online Platform (1) Digital cardiac Counseling (1) Digital intervention (1) Digoxin (1) Digoxin 0.25 mg (1) Diphenhydramine (1) Dipyridamole (1) Dipyridamole 100 Milligram(mg) (1) Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care (1) Direct laryngoscope (1) Direct laryngoscopy (1) Discontinuation of ACEi/ARB (1) Discontinuation of ARB/ACEI (1) Discontinuation of anti-TNF treatment (1) Discussion Board for Social Support +Basic Feedback (1) Discussion Board for Social Support+Personalized Feedback (1) Distilled water (1) Disulfiram (1) Docetaxel (1) Dociparastat sodium (1) Doctella telehealth monitoring (1) Doctor Spot (1) Dolutegravir (1) Doppler Echo (1) Dornase Alfa (1) Dornase Alfa Inhalation Solution (1) Dose Finding Phase (MTD) (1) Dose of Tinzaparin or Dalteparin (1) Double-Blind NT-I7 (1) Double-Blind Placebo (1) Double-Trunk Mask (1) Doxycycline Hcl (1) Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment (1) Drug: GS-5734 - 1.00 mg/kg (1) Drug: GS-5734 - 2.00 mg/kg (1) Drug: Isotretinoin plus Tamoxifen (1) Drug: NA-831 (1) Drug: NA-831 - 0.10 mg/kg (1) Drug: NA-831 - 0.20 mg/kg (1) Drugs and supportive care (1) Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) (1) Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg) (1) DuACT (1) Duodenal biopsy (1) Dupilumab (SAR231893/REGN668) (1) Duplex ultrasound and Computed Tomography Angiography (1) During COVID-19 Pandemic (1) Durvalumab (1) Dutasteride (1) DynamX Bioadaptor (1) Dynamic 3D bone motion capture (1) E-cigarette ad exposure (1) EC-18 (1) ECCO2R (1) ECG-Holter (1) ECMO Implantation (1) EEG (1) EG-HPCP-03a (1) EG-HPCP-03a Placebo (1) EHR-based Clinician Jumpstart (1) EIT-Group (1) ELISA (1) ELISA and Rapid test to detect antibodies against COVID-19 (1) ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB. (1) ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY (1) ELMO PROJECT AT COVID-19: STUDY IN HUMANS (1) EMPOWER (1) ENT exam (1) EP (1) EPDS (Edinburgh Postnatal Depression Scale) (1) ESOGER (1) ESPRIMO (1) ESPRIT™ BTK Device (1) EU-approved RoActemra (1) EUROIMMUN assay (1) EXN407 (1) EXO 1 inhalation (1) EXO 2 inhalation (1) EarSats Pulse Oximeter Probe (1) Early Aggressive Therapy or Traditional Therapy (1) Echo-Doppler (1) Economic benefit message (1) Economic freedom message (1) Edinburgh Postnatal Depression Scale (EDPS) (1) Edoxaban Tablets (1) Education sessions (1) Educational Program on Air Pollution as a Health Risk Reduction Strategy (1) Educational meetings and visual prompts (1) Educational outreach (1) Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors (1) Effortful Control Camp (1) Eicosapentaenoic acid gastro-resistant capsules (1) Ejaculated semen sample (1) Elective Cancer Surgery (1) Electric pad for human external pain therapy (1) Electrical Impedance Tomography (EIT) (1) Electrocardiogram, telemetry, echocardiogram, laboratory values (1) Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care (1) Electroencephalogram with EKG lead (1) Electronic Health Record Review (1) Electronic Survey questionnaire (1) Electronic survey (1) Elisa-test for IgM and IgG to SARS-CoV-2 (1) Emapalumab (1) Embarrassment message (1) Emergency Laparotomy (1) Emergency Ventilator Splitter (1) Emergency surgery (1) Emotion- and Relationship-Focused Therapeutic Interview (1) Emotional Freedom Technique (1) Emotional Support Plan (1) Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet (1) Emtricitabine/tenofovir disoproxil (1) Enbrel (1) End tidal breath sample (1) Endoscopic intervention (1) Endoscopic management according to standard of care (1) Enhanced Chronic Disease Self-management program (1) Enhanced Go NAPSACC (1) Enhanced hygiene measures (1) Enhanced linkage (1) Enhanced supervised fitness training (1) Enoxaparin 1 mg/kg (1) Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml (1) Enoxaparin Higher Dose (1) Enoxaparin Prefilled Syringe [Lovenox] (1) Enoxaparin Prophylactic Dose (1) Enoxaparin sodium (1) Enoxaparin/Lovenox Intermediate Dose (1) Enriched Survey Feedback (1) Ensifentrine Dose 1 (1) Environmental Decontamination (1) Environmental exposure and clinical features (1) Enzalutamide (1) Enzalutamide Pill (1) EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) (1) Equipment with smartwatch throughout hospital stay on the general ward (1) Ergoferon (1) Escin (1) Esflurbiprofen hydrogel patch 165 mg (EFHP) (1) Esomeprazole 20mg (1) Essential Oil Blend (1) Essential oils (1) Estradiol patch (1) Estrogen Therapy (1) Ethanol with Asprin (1) Etoposide (1) Evaluate HACOR score effectivity in this patients (1) Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer (1) Evaluation of clinical, instrumental and laboratory diagnostics tests (1) Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2) (1) Examinations for the research: (1) Examine the impact of COVID-19 during pregnancy (1) Exebacase (1) Exercise Group (1) Exercise Intervention (1) Exercise Testing and Training (1) Exercise Training Only (1) Exercise and Cognitive Training (1) Exercise brochure (1) Exercise capacity (1) Exercise physiology (1) Exercise program (1) Exercise training (1) Exercise training group (1) Experiences in Close Relationship Scale questionnaire (ECR-S) (1) Experimental 1 (1) Experimental 2 (1) Experimental Group (1) Experimental drug (1) Experimental: Questionnaire without precaution information (1) Experts consensus (1) Expiratory training device (1) Exposed to the novel coronavirus disease 2019 (1) Exposure (not intervention) - SARS-CoV-2 infection (1) Exposure Therapy (1) Exposure to the Dutch measures due to the Covid-19 pandemic. (1) Exposure to the SARS-CoV-2 (1) Exposure to the SARS-CoV-2 and its consequences (1) Exposure: Covid-19 infection (1) Expression of receptors and activating proteases (1) Extended sampling and procedures (1) Extra blood sample (1) Extracorporeal Membrane Oxygenation (1) Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (1) Extracorporeal left hemicolectomy anastomosis (1) Extracorporeal membrane oxygenation (1) Extravascular Lung Water Index (1) Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol (1) EyeQue Insight (1) F-652 (1) F-FMISO PET/CT Scan (1) FAVICOVIR 200 mg Film Tablet (1) FAVIR 200 MG FT (1) FAVIRA 200 MG Film Tablet (1) FBT (1) FBT+Variety (1) FEIBA (1) FFP2 (1) FITSTART+ PBI (1) FLOW intervention (1) FLT3 Ligand (CDX-301) (1) FMD (1) FNC dummy tablet+Standard of Care (1) FNC+Standard of Care (1) FT516 (1) FTC/TAF (1) Face mask sampling (1) Face-to-face medical visits (1) Facial fractures reduction or osteosynthesis (1) Facial mask (1) Family Nurture Intervention (FNI) (1) FamilyChildCare (provisional name of app) (1) Farmalarm (1) Favipiravir (3200 mg + 1200 mg) (1) Favipiravir (3200 mg + 1200 mg) combined with Azithromycin (1) Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine (1) Favipiravir (3600 mg + 1600 mg) (1) Favipiravir + Currently used therapy (1) Favipiravir + Standard of Care (1) Favipiravir Combined With Tocilizumab (1) Favipiravir and Hydroxychloroquine (1) Favipiravir plus Nitazoxanide (1) Favipiravir tablets (1) Fecal Microbiota Therapy (FMT) (1) Feeling Good Digital App (1) Fenofibrate (1) Fiberoptic Bronchoscopy (FOB) (1) Fibrin generation markers assays (1) Fidaxomicin (1) File Scanning (1) File scanning (1) FilmArray PCR on respiratory samples (1) FilmArray Pneumonia (1) Filtration Test (1) Fingerstick (1) Fingolimod 0.5 mg (1) Fit test (1) Five-days oseltamivir (1) Fixed Anchoring Strategy (1) Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) (1) Fixed-duration Hydrocortisone (1) Fixed-duration higher dose Hydrocortisone (1) Flexitouch Plus with Cellular Connectivity (FT-CC) (1) Flow controlled ventilation (Evone-ventilator) (1) Flow cytometry (1) Flucelvax (1) Fluoxetine (1) Flurbiprofen 100 mg (1) Fluvirin (1) Fluvoxamine (1) Fluzone High Dose (1) Focus Group Interviews (1) Focused/Targeted Message (1) Folfirinox (1) Folic Acid (1) Follow-up at 14 days (1) Fondapariniux (1) Fondaparinux (1) Food Ads (1) Formulation without Active Drug (1) Fosfomycin disodium (1) Fourth Trimester Mobile Tool (1) Freestyle Libre 14 day CGM system (1) Fremanezumab-Vfrm (1) Froben 100 mg comprimidos revestidos (1) Functional MRI (1) Furosemide Injection Solution for subcutaneous administration (80 mg) (1) Furosemide Injection, USP (1) Fuzheng Huayu Tablet (1) GAD-7 (7-item Generalized Anxiety Disorder) (1) GAD-7 (General Anxiety Disorder) scale (1) GAD-7 General anxiety disorder scale (1) GAMUNEX-C (1) GC4419 (1) GC5131 (1) GENUS device (Active Settings) (1) GENUS device (Sham Settings) (1) GLS-1200 (1) GM-CSF (1) GNX102 (1) GO2 PEEP MOUTHPIECE (1) GPs reports of potential patient safety incidents, non-COVID-19 related (1) GRAd-COV2 (1) GSK3494245 (1) GSK3640254 200 mg (1) GSK3640254 Oral tablet (1) GSK3739937 (1) GSK3882347 (1) GX-19 (1) Gait Retraining (1) Galidesivir (1) Gam-COVID-Vac Lyo (1) Gamification (1) Ganovo+ritonavir+/-Interferon nebulization (1) Garadacimab, Factor XIIa Antagonist Monoclonal Antibody (1) Gargle/Mouthwash (1) Gas exchange measurement (1) Gas exchanges at different PEEP (1) Gastrointestinal endoscopy (1) General Communication Message (1) General Parenting Advice (1) General Public cohort (1) General health education (1) General health through IM Apps (1) Generalized Anxiety Disorder-7 (GAD 7) (1) Generalized Anxiety Disorder-7 (GAD-7) (1) Generic Response Training Control Intervention (1) Gepotidacin (1) Gimsilumab (1) Global Longitudinal Strain (1) Glucose tablets (1) Glycaemic levels (1) Glycine (1) Goal Management Training (GMT) (1) Goal-Oriented Attentional Self-Regulation (GOALS) (1) Graded exercise test (1) Graded exposure therapy (1) Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed (1) Group 2: control group with enoxaparin 40mg/d (1) Group A HCQ (1) Group A: oropharygeal spray and immunostimulant (1) Group B Control (1) Group B: Placebo oropharyngeal spray + Active principle immunostimulant (1) Group C:Active principle oropharyngeal spray + Placebo taken PO (1) Group CBT (1) Group D:Placebo oropharyngeal spray + Placebo taken PO (1) Group Exercise Classes (1) Group Lifestyle Balance (1) Group Lifestyle Balance™ (1) Group Social ABCs (1) Group1 (1) Growth Hormone (1) Growth Mindset (1) Guanfacine hydrochloride (SPD503) (1) Guided online support program (1) Guilt message (1) HADS (1) HADS questionnaire (1) HB-adMSC (1) HCQ & AZ (1) HCQ & AZ vs HCQ+SIR (1) HCQ+AZT (1) HFNO (1) HIIT (intervention) (1) HIT-exercise (1) HLCM051 (1) HLX70 (1) HOME-CoV rule implementation (1) HOPE intervention (1) Halo Oral Spray (1) Halo Placebo (1) Hand sanitizer and hand washing (1) Haptic stimulation (1) Health Care Worker Survey (1) Health Enhancement Program (1) Health Questionnaire (1) Health warning leaflet (1) Health-related quality of life (1) Healthy Minds Program Foundations Training (1) Healthy Weight Program (HW) (1) Healthy lifestyle advise (1) Heated Vest (1) Helmet CPAP (1) Helmet Continuous Positive Airway Pressure (CPAP) (1) Helmet non-invasive ventilation (1) Helmet non-invasive ventilation (NIV) (1) Hemanext One (1) Hemodynamics changes at different PEEP (1) Heparin Infusion (1) Heparin SC (1) Heparin sodium (1) Hepatitis A vaccine (1) Hesperidin and Diosmin mixture (1) Hidroxicloroquina (1) Hidroxicloroquine (1) High Dose of KBP-COVID-19 (1) High Flow Nasal Oxygen (HFNO) (1) High Intensity Interval Training group (1) High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT) (1) High PEEP with end inspiratory pause (1) High PEEP without end inspiratory pause (1) High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) High dose Interferon-beta 1a (1) High dose radiation 100 cGy (1) High flow nasal cannula HFNC (1) High nitrite/NDMA meals (1) High-Concentration Essential Oil (1) High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma (1) High-Titer COVID-19 Convalescent Plasma (HT-CCP) (1) High-flow nasal cannula (1) High-intensity training (1) High-titer Convalescent COVID-19 Plasma (CCP1) (1) Home Health Agency Care (1) Home Pulse Oximetry Monitoring (1) Home Sleep Apnea Testing or In-hospital Polysomnography (1) Home exercise (1) Home exercise program (1) Home sample collection of concerning mole with physician supervision (1) Home visiting (1) Home-based exercise (1) Home-use Test and Follow-up Questionnaire (1) Honey (1) Hormones (1) Hospital admission (1) Hospital anxiety and depression scale (1) Hospitalized Patients for COVID-19 Infection (1) Huaier Granule (1) Human Amniotic Fluid (1) Human Biological samples (1) Human Coach first, then Virtual Assistant (1) Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs) (1) Human biological samples (1) Human milk donors (1) Human umbilical cord derived CD362 enriched MSCs (1) Human umbilical cord mesenchymal stem cells + best supportive care (1) Humanistic Care (1) Humor/Salience (1) Hydrogen Oxygen Generator with Nebulizer (1) Hydroxychloroquin with Azithromycin (1) Hydroxychloroquine (placebo) (1) Hydroxychloroquine + Azithromycin (1) Hydroxychloroquine + azithromycin + / - tocilizumab (1) Hydroxychloroquine + lopinavir/ritonavir (1) Hydroxychloroquine + placebo (1) Hydroxychloroquine , Sofosbuvir, daclatasvir (1) Hydroxychloroquine - Daily Dosing (1) Hydroxychloroquine - Daily dosing (1) Hydroxychloroquine Only Product in Oral Dose Form (1) Hydroxychloroquine Oral Product (1) Hydroxychloroquine Pill (1) Hydroxychloroquine Pre-Exposure Prophylaxis (1) Hydroxychloroquine SAR321068 (1) Hydroxychloroquine Sulfate (HCQ) (1) Hydroxychloroquine Sulfate + Azithromycin (1) Hydroxychloroquine Sulfate + Azythromycin (1) Hydroxychloroquine Sulfate 200 milligram (mg) Tab (1) Hydroxychloroquine Sulfate 400 mg twice a day (1) Hydroxychloroquine Sulfate 600 mg once a day (1) Hydroxychloroquine Sulfate 600 mg twice a day (1) Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets (1) Hydroxychloroquine and azithromycin treatment (1) Hydroxychloroquine and azithromycin treatment arm. (1) Hydroxychloroquine as post exposure prophylaxis (1) Hydroxychloroquine combined with Azithromycin (1) Hydroxychloroquine in combination of Azithromycin (1) Hydroxychloroquine plus Nitazoxanide (1) Hydroxychloroquine plus standard preventive measures (1) Hydroxychloroquine sulfate (1) Hydroxychloroquine sulfate &Azithromycin (1) Hydroxychloroquine, Azithromycin (1) Hydroxychloroquine, Clindamycin (1) Hydroxychloroquine, Clindamycin, Primaquine - high dose. (1) Hydroxychloroquine, Clindamycin, Primaquine - low dose. (1) Hydroxychloroquine, Doxycycline (1) Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) (1) Hydroxychloroquine/Azithromycine (1) Hydroxychloroquine/Chloroquine (1) Hydroxycloroquine and Azythromycine (1) Hyperbaric Chamber (1) Hyperbaric Oxygen (1) Hyperbaric Oxygen Therapy (1) Hyperbaric oxygen (1) Hyperbaric oxygen therapy (1) Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device) (1) Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) (1) Hyperimmune plasma (1) Hypertension (1) Hypocaloric, low carbohydrate diet (1) Hypocaloric, moderate low fat diet (1) IC14 (1) IC14, a monoclonal antibody against CD14 (1) ICU Recovery + Physical Therapy (1) ICU treatment (1) ID NOW vs. Accula (1) IER-R (posttraumatic stress) (1) IGV-001 Cell Immunotherapy (1) IIEF-5 questionnaire (1) IMM-101 (1) IN01 vaccine (1) INC424 / Ruxolitinib (1) INM005 (1) INOpulse (1) IO-202 Dose Escalation (1) IO-202 Dose Expansion (1) ION-827359 (1) IP-10 in CDS protocol (1) IPSS questionnaire (1) ISIS 721744 (1) IV Deployment Of cSVF In Sterile Normal Saline IV Solution (1) IV Dexamethasone (1) IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care. (1) IVIG (1) IW-3718 (1) Ibudilast (1) Ibuprofen (1) Icatibant (1) Icosapent ethyl (IPE) (1) Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus (1) IgG (1) IgG SARS CoV 2 antibodies (1) IgG SARS CoV2 (1) IgG antibodies immunoassay (1) IgG test (1) IgIV (1) IgM and IgG diagnostic kits to SARS-CoV-2 (1) Iloprost (1) Imaging (1) Imaging by thoracic scanner (1) Imaging of the lungs (1) Imatinib Mesylate (1) Imatinib tablets (1) Immune response study (1) Immunfluorescence (1) Immunofluorescence Imaging (1) Immunofree tablets and Reginmune capsule (1) Immunoglobulin (1) Immunoglobulin of cured patients (1) Immunoglubulins (1) Immunological profiling (1) Immunosuppressive (1) Impact Event Score (1) Impact of COVID-19 questionnaire (1) Impact of Event Scale-Revised (1) Implementation Facilitation (IF) (1) In-Person Default (1) In-person in clinic follow-up visit (1) In-person instruction (1) Inactivated SARS-CoV-2 vaccine (Vero cell) (1) Inactivated convalescent plasma (1) IncobotulinumtoxinA 100 UNT Injection [Xeomin] (1) Increasing Willingness and Uptake of COVID-19 Testing and Vaccination (1) Independent Living Program for Affordable Housing. (1) Individualised Ayurveda (1) Individualized-Chinese herbal medicine (1) Indomethacin (1) Infant Mental Health-Home Visiting (1) Infectious Disease and Cardiology Clinical Consultations (1) Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration (1) Infliximab (1) Information (1) Information and referral condition (1) Information leaflet (1) Information-only intervention (1) Informed consent (1) Infusion IV of Mesenchymal Stem cells (1) Infusion placebo (1) Inhaled Hypertonic ibuprofen (1) Inhaled ILOPROST (1) Inhaled Supplemental Oxygen (1) Inhaled beclomethasone (1) Inhaled budesonide (1) Inhaled budesonide and formoterol (1) Inhaled nitric oxide (iNO) (1) Inhaled nitric oxide gas (1) Inhaled placebo (1) Inhaled sedation (1) Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs (1) Injection into olfactory cleft (1) Inspiratory Muscle Training (1) Inspiratory training device (1) Insulin (1) Insulin regimen (1) Interactive workshops LiPAT intervention group (1) Interferon alfa (1) Interferon-Alpha2B (1) Interferon-Beta (1) Interferon-ß-1a (1) Interferon-β 1a (1) Interferon-β1a (1) Interleukin 6 (IL6) Antagonist (1) Interleukin 6 (IL6) Antagonist and corticosteroids (1) Interleukin assessment in semen (1) Interleukin-1 receptor antagonist (1) Interleukin-6 Gene-174C detection (1) Intermediate dose thromboprophylaxis (1) Intermittent prone positioning instructions (1) Internet-based Cognitive Behavioral Therapy (1) Internet-based guided self-help based on CBT principles (1) Internet-based self-help (1) Internet-based self-help after 3 weeks (1) Internet-connected computer tablet (1) Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic (1) Interpersonal Therapy (1) Intervention App (1) Intervention group CoronaCope (1) Intervention group_rehabilitation program (1) Intervention program (1) Intervention-EDI and health coaching (1) Interview by psychologists (1) Interviews only. (1) Intracorporeal left hemicolectomy anastomosis (1) Intralipid (1) Intramuscular Vaccine (1) Intranasal heparin sodium (porcine) (1) Intraosseous access (1) Intravenous Immune Globulin (1) Intravenous Immunoglobulin (1) Intravenous Infusions of Stem Cells (1) Intravenous access (1) Intravenous drug (1) Intravenous saline injection (Placebo) (1) Intravenous sedation (1) Intubation Box (1) Invasive mechanical ventilation (1) Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours (1) Investigation of smell and taste disorders (1) Ion Mobility Spectrometry (IMS) (1) Iota-Carrageenan (1) Isoflurane Inhalant Product (1) Isoniazid, Rifampicin, Pyrazinamide and Ethambutol (1) Isoprinosine (1) Isoquercetin (IQC-950AN) (1) Isotonic saline (1) Isotonic saline 0.9% (1) Isotretinoin Only Product in Oral Dose Form (1) Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment (1) Itolizumab IV infusion (1) Ivermectin (IVM) (1) Ivermectin + Doxycycline (1) Ivermectin + Doxycycline + Placebo (1) Ivermectin + Placebo (1) Ivermectin 3mg Tab (1) Ivermectin 5 MG/ML (1) Ivermectin 6 MG Oral Tablet (2 tablets) (1) Ivermectin Injectable Solution (1) Ivermectin Tablets (1) Ivermectin nasal (1) Ivermectin oral (1) Ivermectin plus Nitazoxanide (1) Ivermectin wth chloroquine (1) Ixazomib Placebo (1) JNJ-53718678 (1) JNJ-53718678 125 mg (1) JNJ-53718678 2.5 mg/kg (1) JNJ-53718678 250 mg (1) JNJ-53718678 3 mg/kg (1) JNJ-53718678 4.5 mg/kg (1) JNJ-66525433 (1) JS016 (anti-SARS-CoV-2 monoclonal antibody) (1) Janus Kinase Inhibitor (ruxolitinib) (1) KELEA Excellerated Water (1) KIR phenotype evaluation (1) KOH 10 % (1) Kamada Anti-SARS-CoV-2 (1) Kaplan Meier analysis (1) Ketamine (1) Ketamine Hydrochloride (1) Ketamine Injectable Product (1) Ketotifen 1 MG (1) Kevzara sc (1) Knowledge, Attitude, Practice, Awareness, Preference (1) Kundalini Yoga and Anxiety Reduction Training (1) L-citrulline (1) LAU-7b (1) LB1148 (1) LDAEP (1) LEAF-4L6715 (1) LEAF-4L7520 (1) LIIT.CI ACT (1) LIIT.CI CFT (1) LIVE (1) LMWH (1) LRX712 (1) LSALT peptide (1) LY3127804 (1) LY3473329 (1) LYMPHOCYTE MONOCYTE RATIO (1) Laboratory Analyses (1) Laboratory Biomarker Analysis (1) Laboratory tests (1) Lactobaciltus rhamnosus GG (1) Lactobaciltus rhamnosus GG Placebo (1) Lactoferrin (1) Lactoferrin (Apolactoferrin) (1) Lambda 180 mcg S.C (1) Late dexamethazone (1) Late-Dexamethasone (1) Lateral Position (left and right lateral decubitus) (1) Lazertinib (1) Leadership Training (1) Learning running subcuticular sutures on the Gamified Educational Network (1) Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5. (1) Let It Out (LIO)-C (1) Leukapheresis (1) Levamisole (1) Levamisole Pill + Budesonide+Formoterol inhaler (1) Levamisole and Isoprinosine (1) Levamisole and isoprinosine (1) Levilimab (1) Lianhua Qingwen (1) Liberase Enzyme (Roche) (1) Licorice extract (1) LifeSignals Biosensor 1AX* (1) Lifestyle App (1) Lifestyle change promotion program (1) Lifestyle intervention (1) Limbix Spark (1) Linagliptin (1) Linagliptin 5 MG (1) Linagliptin tablet (1) Liquid Alpha1-Proteinase Inhibitor (Human) (1) Liquid Model (1) Liquid Peanut Extract (1) Listerine Mouthwash Product (1) Live Long Walk Strong rehabilitation program (1) Liver function tests ,serum ferritin and PCR for COVID-19 . (1) Liver injury (1) Local Bone Autograft (1) Local standard of care (1) Lock-down and social distancing (1) Lopinavir (1) Lopinavir / Ritonavir Pill (1) Lopinavir / Ritonavir plus Ribavirin (1) Lopinavir / ritonavir tablets combined with Xiyanping injection (1) Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride (1) Lopinavir 200Mg/Ritonavir 50Mg FT Reference (1) Lopinavir 200Mg/Ritonavir 50Mg FT Test (1) Lopinavir 200Mg/Ritonavir 50Mg Tab (1) Lopinavir and Ritonavir Tablets (1) Lopinavir and ritonavir (1) Lopinavir-Ritonavir Drug Combination (1) Lopinavir/ Ritonavir (1) Lopinavir/ Ritonavir Oral Tablet (1) Lopinavir/ Ritonavir Placebo (1) Lopinavir/Ritonavir + hydoxychloroquine (1) Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet (1) Lopinavir/Ritonavir 400 mg/100 mg (1) Lopinavir/ritonavir treatment (1) Losmapimod oral tablet (1) Loss Frame and Fear Appeals (1) Lovenox 40 MG in 0.4 mL Prefilled Syringe (1) Low Dose (10 mg) Control (1) Low Dose of KBP-COVID-19 (1) Low Molecular Weight Heparin (1) Low PEEP - FiO2 high (1) Low PEEP - FiO2 low (1) Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) Low dose CT (1) Low dose Interferon-beta 1a (1) Low dose Low molecular weight heparin or Placebo (1) Low dose radiation 35 cGy (1) Low dose radiation therapy (1) Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis (1) Low fat "standard care" control breakfast (1) Low flow ECMO driving by CVVH machine (1) Low nitrite/NDMA meals (1) Low or upper respiratory tract sample (1) Low-Carb High-Fat breakfast (1) Low-Carbohydrate Diet (1) Low-Concentration Essential Oil (1) Low-dose Chest CT (1) Low-dose radiotherapy (1) Lower-dose prophylactic anticoagulation (1) Lucinactant (1) Lung CT (1) Lung CT scan analysis in COVID-19 patients (1) Lung Cancer Screening Decision Tool (1) Lung Function Test (1) Lung Function tests (1) Lung Low Dose Radiation (1) Lung Ultrasound (1) Lung impedance technique (1) Lung ultrasound use in patients hospitalized with COVID (1) M201-A Injection (1) MAGEC Spine Rod (1) MANAGEMENT OF COVID-19 (1) MAS825 (1) MCC IMS (1) MCN (Methylene blue, vitamin C, N-acetyl cysteine) (1) MEDI7219 (1) MELT-100 (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg (1) MFS (1) MGA012 (1) MGC018 (1) MK-5475 (1) MLS Laser (1) MMR vaccine (1) MPT0B640 (1) MR or M-M-R II ® vaccine (1) MR-Pro-ADM (1) MRI (1) MRI (heart, brain, lungs, kidney) (1) MRx-4DP0004 (1) MSB11456 (1) MSC (1) MSC Treatment (1) MSCT (1) MSCs (1) MSCs-derived exosomes (1) MSTT1041A (1) MSTT1041A-matched Placebo (1) MVA-BN-Filo (1) MVA-MERS-S_DF1 - High Dose (1) MVA-MERS-S_DF1 - Low Dose (1) MVC-COV1901 (1) MW33 injection (1) MW33 injection placebo (1) Machine learning model (1) Macrolide administered for 3-5 days (1) Macrolide administered for up to 14 days (1) Magnetic Resonance Imaging (1) Magnetic Resonance Spectroscopy (MRS). (1) Maintenance or reduction of immunosuppression (1) MakAir (1) Male Sexual Health Questionnaire (MSHQ) (1) Maltodextrin (1) Mannitol (1) Manremyc (1) Maraviroc (1) Maraviroc + Currently used therapy (1) Maraviroc 300 mg (1) Maraviroc+Favipiravir+CT (1) Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) (1) Masimo, LidCO (1) Masked Saline Placebo (1) Maslach Burnout Inventory (MBI) (1) Massive parallel sequencing of host genome (1) Matched Placebo Hydroxychloroquine (1) Matched placebo (1) Matching Placebo (1) Maternal stress (1) Maximal effort test (1) McGrath videolaryngoscope (1) Measles-Mumps-Rubella Vaccine (1) Mechanical Trombectomy (1) Mechanical ventilation with the automated BVM compressor (1) Med-South Weight Loss Intervention (1) Media Intervention (1) Medical Mask (1) Medical Ozone procedure (1) Medical Record Review - Inpatient Treatment (1) Medical records-based recommendation (1) Medical/surgical mask (1) Medically Tailored Meals (1) Medication Review (1) Meditation Therapy (1) Meditation and Anxiety Reduction Training (1) Meditation app usage (1) Mediterranean diet, no caloric restriction (1) Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) Medtronic Interstim II Model 3058 Neurostimulator (1) Mefloquine (1) Mefloquine + azithromycin + / - tocilizumab (1) Melatonin 2mg (1) Melphalan (1) MenACWY (1) MenACWY boost (1) MenACWY single dose (1) MenACWY two dose (1) MenACWY vaccine (1) MenCare+/Bandebereho fathers'/couples' group education (1) Mental Health questionnaire (1) Meplazumab for Injection (1) Merimepodib (1) Mesenchymal Stem Cell (1) Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords (1) Mesenchymal Stromal Cells infusion (1) Mesenchymal Stromal Stem Cells - KI-MSC-PL-205 (1) Mesenchymal cells (1) Mesenchymal stem cell (1) Mesenchymal stem cell therapy (1) Mesenchymal stem cells (1) Mesenchymal stromal cell-based therapy (1) Messaging (1) Metacognitive therapy and work-focused interventions (1) Metformin (1) Metformin XR (1) MethylPREDNISolone 80 Mg/mL Injectable Suspension (1) Methylene Blue 5 MG/ML (1) Methylprednisolone Injectable Product (1) Metoprolol 100 mg (1) Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) (1) Microcrystalline Cellulose, NF (1) Microscopy of defined brain regions on autopsy specimens (1) Midazolam 5 mg (2.5 mL) (1) Midazolam injection (1) Milk of magnesia (1) MindRhythm Harmony (1) Mindful Self-Compassion (1) Mindfullness based cognitive program (1) Mindfulness + Compassion Intervention (MC) (1) Mindfulness Alone (MO) Intervention (1) Mindfulness Based Intervention (1) Mindfulness Rounds (1) Mindfulness based intervention (1) Mindfulness exercises (1) Mindfulness intervention (1) Mindfulness program (1) Mindfulness session(s) (1) Mindfulness training (MT) Connect (1) Mindfulness-Based Cognitive Therapy (1) Mindfulness-based "STOP touching your face" practice (1) Minimal Attention Control Intervention (1) MinnRAP Peer Support Program (1) Minocycline (1) Mobile Enhanced Prevention Support (1) Mobile Mental Health App - 1 (1) Mobile Mental Health App - 10 (1) Mobile Mental Health App - 2 (1) Mobile Mental Health App - 3 (1) Mobile Mental Health App - 4 (1) Mobile Mental Health App - 5 (1) Mobile Mental Health App - 6 (1) Mobile Mental Health App - 7 (1) Mobile Mental Health App - 8 (1) Mobile Mental Health App - 9 (1) Model Building (1) Model validation (1) Moderate-intensity continuous training (1) Modified Rankin score (1) Monalizumab (1) Monitoring Visit - Baseline (1) Monitoring Visit - Week 4 (1) Monitoring Visit - Week 8 (1) Monitoring for aggravation (1) Monitoring physiological data with the Hexoskin smart shirt (1) Montelukast 10 mg (1) Montelukast 10mg (1) Montelukast Oral Granules (1) Montmorrillonite (1) Morning Bright Light Therapy (1) Mother Provides MOM (1) Moxibustion plus Cupping (1) Moxifloxacin or Levofloxacin (1) Mucodentol (1) Multi Modal Balance Training (1) Multi-tasking Training (1) MultiStem (1) Multicapillary column coupled ion mobility spectrometry (1) Multifrequency Bioimpedance Spectroscopy (1) Multiple Doses of Anti-SARS-CoV-2 convalescent plasma (1) Multivitamin (1) Mupirocin (1) Muscle Relaxation Therapy (1) Muscle ultrasound (1) MuscleSound Ultrasound (1) Muse headband with Myndlift app (1) Music Therapy (1) MySafeRx Inspire Flex (1) MySafeRx Inspire Plus (1) N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I (1) N-803 (1) N-95 Respirator (1) N95 Respirator (1) N95 respirator (1) NA (no intervention) (1) NA-831 (1) NA-831 and Atazanavir (1) NA-831and Dexamethasone (1) NBT-NM108 (1) NETosis markers (1) NG Biotech (1) NG test (1) NHANES smell and taste tests (1) NICU Acquires MOM (1) NIO® (Intraosseous access) (1) NIVOLUMAB (1) NK Cells (1) NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells (1) NK-1R antagonist (1) NO gas (1) NO intervention planned due to the observational study design - only a diagnostic testing (1) NO intervention planned due to the observational study design only a diagnostic testing (1) NO-Immunosuppressive (1) NOX66 (1) NP-120 (Ifenprodil) (1) NT-I7 (1) NaCl (1) NaCl 0.9% (1) NaCl Solution (1) Nafamostat Mesylate (1) Naltrexone (1) Naltrexone 380 MG (1) Narrative Exposure Therapy (1) Nasal Dexamethasone (1) Nasal Irrigation (1) Nasal Swab (1) Nasal lavage (1) Naso pharyngeal swab (1) NasoVAX (1) Nasopharyngeal (NP) swab (1) Nasopharyngeal Swab (1) Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR (1) Nasopharyngeal swab and main laboratory (1) Nasopharyngeal swabs (1) Nasopharyngeal, oropharyngeal, or saliva swab (1) Natural Honey (1) Nebulised heparin (1) Nebulised unfractionated heparin (UFH) (1) Nebulized Platelet Lysate (1) Nebulized Sterile Saline (1) Nebulized administration of RLF-100 or Placebo (1) Negative COVID Test Result - Hypothetical Scenario (1) Negative Ion Generator (1) Nemolizumab (1) NestaCell® (1) Neural network diagnosis algorithm (1) Neuromuscular Electrical Stimulation (1) Neuromuscular evaluation (1) Neutral writing control (1) Neutralizing antibodies (1) New QIAstat-Dx fully automatic multiple PCR detection platform (1) New screening strategy (1) Newsfeed function (1) Next generation Sequencing (NGS) analysis (1) Niclosamide (1) Niclosamide suspension (1) Nicotinamide riboside (1) Nigella sativa (1) Nil intervention (1) Nintedanib 150 MG (1) Nintedanib 150 MG [Ofev] (1) Nitazoxanide 500 MG (1) Nitazoxanide 500Mg Oral Tablet (1) Nitazoxanide Tablets (1) Nitazoxanide and atazanavir/ritonavir (1) Nitazoxanide with ivermectin (1) Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation (1) Nitric Oxide delivered via LungFit™ system (1) Nitric Oxide-Continuous and Sessions (1) Nitric Oxide-Releasing Drug (1) Nitric Oxide-Sessions (1) Nivolumab Injection (1) No Intervention - Observational Study (1) No Personal protective equipment (PPE) (1) No Racial Inequality Highlighting (1) No Treatment (1) No intervention (survey study for medical doctors). (1) No intervention - exposure is to COVID-19 (1) No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups (1) No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests (1) No intervention, observational (1) No interventions (1) No interventions planned (1) No interverntion (1) No research related technology based social interactions (1) No special intervention (1) Non Extracorporeal Membrane Oxygenation (1) Non Intervention (1) Non applicable (1) Non interventional study (1) Non invasive visual acuity testing (1) Non-ACEI/ARB (1) Non-Anchoring Strategy Control (1) Non-Heated Vest (1) Non-Interventional (1) Non-Mindfulness intervention (1) Non-contact ECG (1) Non-contact MCE system (1) Non-convalescent Plasma (control plasma) (1) Non-convalescent fresh frozen plasma (Standard plasma) (1) Non-enhanced CT scan of the chest (1) Non-food Ads (1) Non-hospitalization procedures (1) Non-interventional (1) Non-interventional study (1) Non-invasive cardiac imaging (1) Non-invasive red LLLT treatment to chest of patient. (1) Non-invasive ventilatory support (1) None - NA (1) Normal (9%) Saline (1) Normal Saline 0.9% (1) Normal Saline Infusion + standard of care (1) Normal saline 0.9% (1) Normal saline solution (NSS), Placebo - Phase 1 (1) Normal saline solution (NSS), Placebo - Phase 2 (1) Normal saline solution (NSS), Placebo, Day 189 - Phase 2 (1) Normal saline solution (NSS), Placebo, Day 21 - Phase 1 (1) Normal saline solution (NSS), Placebo, Day 21 - Phase 2 (1) Normobaric oxygen therapy (1) Norovirus Bivalent (GI.1 / GII.4) Vaccine(high) (1) Norovirus Bivalent (GI.1 / GII.4) Vaccine(low) (1) Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle) (1) Not bravery message (1) Novel laser inferometry test for CORONA virus (1) NuSepin® 0.1 mg (1) NuSepin® 0.2 mg (1) Nudge (1) Nursing care to reduce anxiety, fear and loneliness (1) Nutrition (1) Nutrition Consult and Protein Supplementation (1) Nutrition support (1) Nutritional assessment (1) Nutritional counseling (1) Nutritional education (1) Nutritional support system (NSS) (1) Nuvastatic (1) NİCaS (1) ONC201 (1) OP-101 (1) OT Guided Cognitive Interventions (1) Obesity (1) Observation of Virtual Actions (1) Observation of Virtual Actions (step 4) (1) Observation of behavior and COVID-19 infection will be conducted. (1) Observation of patients with known, suspected, or at risk for COVID-19 infection (1) Observation only (1) Observational (registry) (1) Observational Study (1) Observational cohort study on the natural history of hospitalized SARS-COV-2 patients. (1) Observational measurement of biometric data. No change to health care provided. (1) Observational only (1) Observational study (1) Observational study only (1) Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples (1) Obvio-19 app (1) Octagam (1) Octagam 10% (1) Odd/Even birth year intervention groups (1) Office FU (1) Olaparib Oral Tablet [Lynparza] (1) Olfaction testing (1) Olfactometry (1) Olfactory retraining (1) Omega 3/Nigella Sativa Oil (1) Omega 3/Nigella Sativa Oil/Anise seed capsule (1) Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice (1) Omega 3/Nigella Sativa Oil/Indian Costus (1) Omega 3/Nigella Sativa Oil/Quinine pills (1) Omega-3 Fatty Acid Supplement (1) Omeprazole 20mg (1) Omeprazole 40 mg (1) Omnibiotic AAD (1) On-Line Survey (1) On-line exercise and education (1) On-site exercise and education (1) OnabotulinumtoxinA 100 UNT [Botox] (1) One COVID-19 vaccine candidate (TMV-083) administration - High dose (1) Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop (1) Online Intervention Mental Health COVID-19 (1) Online Questionnaire (1) Online Questionnaires (1) Online Survey about Dietary and Lifestyle Habits (1) Online bibliotherapy programme (1) Online cognitive behavioral therapy (CBT) (1) Online instruction (1) Online support Group (1) Only Standard Treatment (1) Ophthalmologic exam (1) Opt-in Recruitment Email (1) Opt-out Recruitment Email (1) Optical Coherence Tomography (OCT) (1) Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East (1) Oral (1) Oral 25-Hydroxyvitamin D3 (1) Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions (1) Oral fluid swab (1) Oral supplement enriched in antioxidants (1) Oral-B Mouth Sore mouthwash (1) Oropharyngeal Swab (1) Orthopaedic Surgical Procedures (1) Oseltamivir 75mg (1) Other (1) Others(No intervention) (1) Otilimab (1) Outpatient MRI (1) Oxidative Stress ELISA Kit (1) Oxycodone and Midazolam (1) Oxycodone, Paroxetine, and Quetiapine (1) Oxygen Hood (1) Oxygen Therapy (1) Oxygen gas (1) Oxygen supply (1) Oxygen-ozone therapy, probiotic supplementation and Standard of care (1) Oxytocin (1) Ozanimod (1) Ozone auto-hemotherapy (1) P2Et (Caesalpinia spinosa extract) (1) PACE-Life (1) PARTNER-MH (1) PB1046 (1) PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test) (1) PCR for COVID-19 (1) PCR, lung ultrasound (1) PD-1 blocking antibody+standard treatment (1) PDS-08 (1) PEAR-008 (1) PEEP trial (1) PEP flute (1) PET-CT of 18F-FDG (1) PET/CT Scan (1) PF-06939999 dose escalation (1) PF-06939999 in combination with docetaxel (1) PF-06939999 monotherapy (1) PF-07104091 + palbociclib (1) PF-07104091 + palbociclib + letrozole (1) PF-07104091 monotherapy (1) PF-07304814 (1) PH-combination therapy (1) PH-monotherapy (1) PH94B (1) PHQ-9 (9-item Patient Health Questionnaire) (1) PHQ-9 (Patient Health Questionnaire) Depression Scale (1) PHQ-9 Depression Scale (1) PHR160 Spray (1) PLACEBO GROUP (1) PLN-74809 (1) PLX-PAD (1) PP-MI Intervention (1) PRO-SERO-COV (1) PROTECTIVE VENTILATION (1) PRV-015 (1) PSC-04 (1) PSG (1) PSQI (1) PSS (Perceived Stress Scale) (1) PT-PCR test for SARS-CoV-2 (1) PT-Pal (1) PTC299 (1) PTI-125, 100 mg tablet (1) PTSD (1) PWV (1) Pacebo: Calcium citrate (1) Pacing + mindfulness (1) Pacritinib (1) Palliative care assessment (1) Pamrevlumab (1) Pandemic control measures (1) Paraclinical examination (1) Paramedic Coaching (1) Parents and Infants Engaged (1) Part 1 - TL-895 (1) Part 2 - Placebo (1) Part 2 - TL-895 (1) Partially HLA-matched SARS-CoVSTs (1) Partner-assisted intervention (1) Passed infection of SARS-CoV-2 (1) Pathogen-specific aAPC (1) Pathways for Parents after Incarceration (1) Patient Characteristics (1) Patient Education (1) Patient Health Questionnaire (PHQ-9) (1) Patient Health Questionnaire-9 (PHQ-9) (1) Patient Navigation Program (1) Patient Status Engine (1) Patient management suffering of coronavirus infection (1) Patient sampling (1) Patient with SAR-CoV-2 infection (1) Patient-centred advice on Telephone Consultation in TB Patients: (1) Patient-only intervention (1) Patients admitted to Intensive Care Unit with SARS-CoV2 (1) Patients received standard of care treatment during hospitalization (1) Patients with the treatment agains COVID19 (1) Pectin (1) Peer Education on Exercise for Recovery (1) Peer Resilience Champion (1) Peginterferon Lambda-1a (1) Peginterferon lambda alfa-1a subcutaneous injection (1) Pegylated Interferon-α2b (1) Pegylated interferon lambda (1) Pembrolizumab (MK-3475) (1) Percutaneous Coronary Revascularization for STEMI (1) Percutaneous Transluminal Angioplasty (PTA) Device (1) Performance of WHEELS-I in promoting DASH/SRD adoption (1) Performing Virtual Actions (1) Performing of lung ultrasound (1) Performing routine care (clinical and paraclinical tests) (1) Peripheral Blood (1) Peripheral blood sampling (1) Personal Exercise Intervention (1) Personal Protective Testing Booth (1) Personal behaviours (1) Personal freedom message (1) Personal protective equipment (1) Personal protective equipment (PPE) (1) Personal protective equipment from biological hazard (1) Personalized Anchoring Strategy (1) Personalized health education (1) Philips Lumify Ultrasound System (1) Phlebotomy (1) Phone Administration of Questionnaires (1) Phone-call screening and management by a medical student/general practitioner tandem (1) Phosphate buffered saline Placebo (1) Photobiomodulation (1) Phsyiotherapy (1) Physical Exam (1) Physical Exercises (1) Physical Therapy (1) Physical Therapy Exercise (1) Physical exercise (1) Physiological saline solution (1) Physiological serum (1) Physiology (1) Physiotherapy - Manual Therapy (1) Piclidenoson (1) Pilot a rapid SARS-CoV-2 testing strategy (1) Pioglitazone (1) Pioglitazone 30 mg (1) Piperacillin-tazobactam (1) Piperacillin/tazobactam (1) Placebo (0.9% normal saline) (1) Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE) (1) Placebo (Methylcellulose) capsule (1) Placebo (PB0) (1) Placebo (PBO) (1) Placebo (Plasma-Lyte 148) (1) Placebo (carrier control) (1) Placebo (for Zonisamide) (1) Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) (1) Placebo 0.10 mg + 1.00 mg/kg (1) Placebo 0.20 mg + 2.00 mg/kg (1) Placebo 0.9% NaCl solution (1) Placebo 250 cc 24 hours continuous infusion for 15 days (1) Placebo Atazanavir (1) Placebo Daclatasvir 120 (1) Placebo Daclatasvir 60 mg (1) Placebo EC-18 (1) Placebo Glycerin SLIT (1) Placebo Group (1) Placebo Infusion (1) Placebo LSF (1) Placebo PBMT/sMF (1) Placebo Saline (1) Placebo Sofosbuvir/Daclatasvir 120 (1) Placebo Sofusbuvir + Daclatasvir 60 mg (1) Placebo Starch (1) Placebo Subcutaneous Solution (1) Placebo Tablet (1) Placebo Vaccine (1) Placebo capsules (1) Placebo comparator: DW-NI (1) Placebo comparator: DW-NS (1) Placebo control (non-behavioral infographic) (1) Placebo for Azithromycin (1) Placebo for Hydroxychloroquine (1) Placebo for Risankizumab IV (1) Placebo for Risankizumab SC (1) Placebo for Upadacitinib (1) Placebo inhalation (1) Placebo injection (1) Placebo matching to gepotidacin (1) Placebo mouthwash (water) (1) Placebo of Hydroxychloroquine (1) Placebo of LPV/r Tablets (1) Placebo of excipient(s) will be administered (1) Placebo on a 0- and 14-day schedule (1) Placebo oral (1) Placebo pMDI (1) Placebo plus standard preventive measures (1) Placebo solution (1) Placebo tablet (1) Placebo to Match RDV (1) Placebo videos (1) Placebo- 0.10 mg/kg (1) Placebo- 0.20 mg/kg (1) Placebo- 1.00 mg/kg (1) Placebo- 2.00 mg/kg (1) Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine (1) Placebo/Control (1) Placebo: Emtricitabine/tenofovir disoproxil Placebo (1) Placebo: Hydroxychloroquine (1) Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells (1) Plant Polyphenol (1) Plaquenil 200Mg Tablet (1) Plasma Donation (1) Plasma exchange (1) Plasma expansion with Ringer's Acetate (1) Plasma from COVID-19 convalescent patient (1) Plasma from a volunteer donor (1) Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19 (1) Pleth variability index (1) Plethysmography & DLCO (1) Plitidepsin 1.5 mg/day (1) Plitidepsin 2.0 mg/day (1) Plitidepsin 2.5 mg/day (1) Pneumococcal vaccine (1) Point of care ultrasound (1) Point-of-Care Ultrasonography (POCUS) (1) Point-of-care test for SARS-CoV-2 (1) Polymorphism of the HSD3B1 (1) Polyoxidonium (1) Positive COVID Test Result - Hypothetical Scenario (1) Positive Emotion Skills Course (1) Positive Minds Strong Bodies Enhanced (1) Positive Peer Journaling (PPJ) (1) Positive feedback (1) Post COVID-19 Functional Satus Scale (1) Post Traumatic Stress Disorder questionnaire (PTSD-8) (1) Post-mortem tissue collection (1) Postpartum women under investigation for Coronavirus or diagnosed with COVID-19 (1) Postural Positioning (1) Povidine iodine nasal swabs (1) Povidone-Iodine (PVP-I) (1) Povidone-Iodine 0.4% NI (1) Povidone-Iodine 0.5% (1) Povidone-Iodine 0.5% NI (1) Povidone-Iodine 0.5% NS (1) Povidone-Iodine 0.6% NI (1) Povidone-Iodine 0.6% NS (1) Povidone-Iodine 2% (1) Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP (1) Povidone-iodine (1) Powered Air purifying respirator (1) Pozelimab (1) PrEP (1) Prasugrel Hydrochloride 10 MG Oral Tablet (1) Pravastatin 40 mg (1) Pre-operative breast magnetic resonance imaging (1) Prediction Market (1) Predictive factors for clinical response in patients with COVID-19. (1) Predictors adverse evolution (1) Predictors of health care provide (1) Prednisolone (1) Prednisone tablet (1) Pregnant women under investigation for Coronavirus or diagnosed with COVID-19 (1) Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein (1) Premier Biotech COVID-19 IgG/IgM Rapid test Cassette (1) Presatovir placebo (1) Prescription Opioid Management App (1) Presence of specific anti-SARS-CoV-2 antibodies (1) PreserVision AREDS formulation gel tabs (1) Prevalence of COVID-19 (1) Prevenar 7 and Prevenar 13 (1) Preventive information (1) Previfenon® (1) Primary care (1) Primary care professionals reports of potential patient safety incidents, non-COVID-19 related (1) Pro BNP , Vitamin D (1) Probiorinse (1) Probiotic and LC-PUFA (1) Probiotics (1) Problem-solving and relationship improvement intervention. (1) Progesterone 100 MG (1) Prognostic score (1) Progressive cycling exercise test to exhaustion (1) Project ECHO (1) Project Health (1) Prolastin (1) Prolectin-M; a (1-6)-alpha-D-Mannopyranose class (1) Prolonged Exposure (PE) (1) Promotion of flour (1) Prone (1) Prone Positioning (PP) (1) Prone decubitus (1) Prone position ventilation (1) Prone positioning (PP) (1) Prophylactic/Intermediate Dose Enoxaparin (1) Propofol (1) Propranolol Hydrochloride (1) Proprietary extract of Nerium oleander (1) Prosocial acts (1) Prospective Chart Review (1) Prospective oberservational registry (1) Prospective observation (1) Prospective study across two time-points examining the impact of viral mitigation protocols on mental health (1) Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout (1) Protocolised mechanical ventilation strategy (1) Proton Therapy (1) Prototype BMS-986165 (1) Prototype swab (1) Provision of flour (1) Proxalutamide (1) Psilocybin (1) Psychiatric counseling (1) Psycho-Social Questionnaire (1) Psychoeducation and Safety (1) Psychoeducational intervention (1) Psychological and Behaviour Change Support (1) Psychological and physical rehabilitation based humanistic care (1) Psychological stress and adaptation at work score (PSAS) (1) Psychological treatment (1) Psychosocial stimulation and healthy eating education (1) Public Health England Gold Standard (1) Public space exposure (1) Pulmonary Physiotherapy Techniques (1) Pulmonary Rehabilitation (1) Pulmonary Vascular Permeability Index (1) Pulmonary and Motor Rehabilitation (1) Pulmonary function test (1) Pulmonary function testing (1) Pulmonary function tests (1) Pulmonary ultrasound (1) Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) (1) Pulse CO-Oximetry Hemoglobin measurement transcutaneous (1) Pulse Oximeter (1) Pulse oximetry (1) Pyridostigmine Bromide (1) Pyronaridine-Artesunate (1) Pyronaridine-artesunate (1) Q-NRG Metobolic Cart Device (1) Q16 testing (1) QFR (1) QazCovid-in® - COVID-19 inactivated vaccine (1) QuadraMune(TM) (1) Quadrivalent RIV with 2018-2019 NH H3 strain (1) Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant (1) Quadrivalent RIV with H3 strain 1 (1) Quadrivalent RIV with H3 strain 1 and adjuvant (1) Quadrivalent RIV with H3 strain 2 (1) Quadrivalent RIV with H3 strain 2 and adjuvant (1) Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19) (1) Quality of Life (1) Quality of life promotion (1) Quantitative IgG Test (1) Quantitative analysis of SARS-CoV-2 antibodies (1) Quantitative analysis of anti-SARS-CoV-2-antibodies (1) Quantitative and qualitative assessments of mental health (1) Quantra System (1) Quercetin (1) Quercetin Prophylaxis (1) Quercetin Treatment (1) Questionaire (1) Questionnaire and interview (1) Questionnaire by phone call (1) Questionnaire for evaluation of confinement on deviant sexual fantasies (1) Questionnaire forms (1) Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index (1) Questionnaire with precaution information (1) Questionnaire, phone call (1) Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too. (1) Questionnaire-based observational study (1) Questionnaires for specific phobia (1) Questionnaires on psychological quality of life (1) Questionnaires, spirometry (1) Questionnary (1) Quetiapine (1) Quick Defense (1) Quinquina-Stevia/Azythromycin (1) RAAS inhibitor [continued standard of care] (1) RAPA-501-Allo off-the-shelf Therapy of COVID-19 (1) RAPID-3 (1) RBA-2 (1) RBT-9 (90 mg) (1) RDV (1) RECHARGE (1) REGN10933 + REGN10987 (1) REGN10933+REGN10987 (1) REGN3048 (1) REGN3051 (1) RESP301, a Nitric Oxide generating solution (1) RIA-device (Remote Investigation and Assessment) (1) RISE (1) RO6953958 (1) RO7234292 (RG6042) (1) RPH-104 80 mg (1) RS blend (1) RSV LID/ΔM2-2/1030s (1) RSV Mobile Application (1) RSVPreF3 formulation 2 (1) RSVPreF3 formulation 3 (1) RT PCR SARS-CoV-2 (1) RT-PCR Covid-19 (1) RT-PCR SARS-Cov2 (1) RT-PCR and antibody testing (1) RTB101 (1) RTLS data (1) RUC-4 Compound (1) RUTI® vaccine (1) Racial Inequality Highlighted (1) Radiological Detection (1) Radspherin (1) Ramelteon 8mg (1) Ramipril 2.5 MG Oral Capsule (1) Random Donor Plasma (1) Randomized to Delayed Cord Clamping at birth (1) Randomized to Umbilical Cord Milking at birth (1) Ranitidine (1) Rapamycin (1) Rapid Onsite COVID-19 Detection (1) Rapid detection test (1) Rapid diagnostics using Anyplex TMII RV16 Detection (1) Rapid molecular test (1) Rarefaction (1) Rayaldee 30Mcg Extended-Release (ER) Capsule (1) Razuprotafib (1) Razuprotafib Subcutaneous Solution (1) ReWalk 6.0 (1) Reading a Book (1) Real cTBS to the vmPFC (1) Real iTBS to the dlPFC (1) Real-time chat-based support through IM Apps (1) Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) (1) Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid (1) Recombinant Human Interferon α2b Spray (1) Recombinant Interferon Alfa-2b (1) Recombinant S protein SARS vaccine (1) Recombinant human alkaline phosphatase (1) Recombinant human angiotensin-converting enzyme 2 (rhACE2) (1) Recombinant human interferon α1β (1) Recombinant human plasma gelsolin (Rhu-pGSN) (1) Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (1) Recombinase aided amplification (RAA) assay (1) Reconsolidation of Traumatic Memories (RTM) (1) Reduced Dose Bevacizumab (1) Reference Treatment- BMS-986165-01 (1) Reference: Favipiravir 200 mg (Avigan) (1) Referral card (1) Regadenoson myocardial perfusion imaging stress test (1) Registery Data Collection (1) Regular Inpatient Medical Care (1) Regular messages through Instant Messaging (IM) (1) Rehabilitation (1) Rehabilitation exercise protocol (1) Reinforcement learning message delivery (1) Relamorelin 10 μg (1) Relation between frailty and clinical outcomes in elderly patients with COVID-19. (1) Relaxation (1) Relaxation Breathing (1) Relaxation Therapy (1) Remain COVID Free SSI (1) Remdesivir (RDV) (1) Remote Caregiver Training (1) Remote Cognitive Behavioral Therapy for Insomnia (1) Remote Intensive Group Behavioral Treatment (IGBT) (1) Remote Photoplethysmography (rPPG) vital sign acquisition (1) Remote consultation (1) Remote controlled exercise (1) Remote pulmonary rehabilitation (1) Removal of dead space filter (1) Renin-angiotensin system inhibitors (1) Replenish protein group (1) Reporting of anosmia, ageusia and other clinical symptoms (1) Repository Corticotropin Injection (1) ResCure™ (1) Resilience Program (1) Resolute Onyx (1) Respiratory Exercise Training (1) Respiratory Mechanics (1) Respiratory filter in-line placed with the standard mouthpiece (1) Respiratory mechanics measurement (1) Respiratory physiotherapy (1) Respiratory rehabilitation (1) Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening (1) Response and Attention Training (1) Responsive training with no video feedback (1) Responsive training with video feedback (1) Resveratrol (1) Resveratrol Placebo (1) Retrospective case-control analysis (1) Retrospective data collection (1) Reverse transcription polymerase chain reaction (1) Reverse-transcription polymerase chain reaction (RT-PCR) (1) RhACE2 APN01 (1) Riboflavin Placebo (1) Rifaximin Novel Formulation (1) Rilpivirine Injectable Suspension (RPV LA) (1) Rilpivirine extended release suspension for injection (long-acting) (1) Ringer solution (1) Rintatolimod (1) Risankizumab (1) Risankizumab IV (1) Risankizumab SC (1) Risk factors (1) Risk of MERS infection (1) Risk reduction (1) Ritonavir (1) Ritonavir+Oseltamivir (1) Ritonavir/lopinavir (1) Rituximab (1) Rivaroxaban 2.5 MG (1) Rivaroxaban 2.5 Mg Oral Tablet (1) Rivaroxaban placebo tablets (1) RoActemra iv (1) RoActemra sc (1) Robot Assisted Percutaneous Cardiovascular Intervention (1) Robotic therapy (1) Rosuvastatin (Inhibitor arm) (1) Rosuvastatin (Placebo arm) (1) Rosuvastatin + BAY1817080 (1) Rosuvastatin + BI 1323495 (1) Routine Oral Care and Analgesia (1) Routine care (no SARS-CoVSTs) (1) Routine standard of care (1) Rt PCR (1) Ruconest (1) Ruxolitinib 5 MG (1) Ruxolitinib administration (1) Ruxolitinib plus simvastatin (1) SAB-301 (1) SAMBA II (Diagnostic for the Real World) (1) SAR443122 (1) SARILUMAB (1) SARS-CoV (1) SARS-CoV 2 RNA PCR Semen (1) SARS-CoV 2 RNA PCR Urine (1) SARS-CoV-2 Ab (1) SARS-CoV-2 IgG Antibody Testing Kit (1) SARS-CoV-2 PCR (1) SARS-CoV-2 S1/S2 IgG (1) SARS-CoV-2 Specific T Cells (1) SARS-CoV-2 antibody based IVIG therapy (1) SARS-CoV-2 antibody immunoassays (1) SARS-CoV-2 antibody test (1) SARS-CoV-2 antibody testing (1) SARS-CoV-2 convalescent plasma treatment (1) SARS-CoV-2 non-immune Plasma (1) SARS-CoV-2 plasma (1) SARS-CoV-2 questionnaire survey (1) SARS-CoV-2 rS - Phase 1 (1) SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 (1) SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2 (1) SARS-CoV-2 rS/Matrix-M1 Adjuvant (1) SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics (1) SARS-CoV-2 vaccine (inactivated) (1) SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (1) SARS-CoV-2 vaccine formulation 1 with adjuvant 2 (1) SARS-CoV-2 vaccine formulation 2 with adjuvant 1 (1) SARS-CoV-2 vaccine formulation 2 with adjuvant 2 (1) SARS-CoV-2 vaccine formulation 2 without adjuvant (1) SARS-CoV-2 viral composition (1) SARS-CoV-2-test (1) SARS-CoV2 Autoantibody detection (1) SARS-CoV2 Infection (1) SARS-CoV2 serum antibody testing (1) SARS-Cov-2 infection (1) SARSCoV2 Convalescent Plasma (1) SBI-101 (1) SBRT (1) SCB-2019 (1) SCB-2019 with AS03 adjuvant (1) SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant (1) SCD (1) SCH Intervention (1) SCTA01 (1) SECRET questionnaire (1) SEL-212A (1) SEL-212B (1) SF12, EQ-5D-5L and work status standardized quantitative assessments (1) SHG (1) SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted) (1) SKILLZ-Girl Enhanced football curriculum (1) SLEDD with a L-MOD (1) SMBI digital app (1) SMS message support (1) SMS messages (1) SMS-based support (1) SNDX-6352 (1) SNG001 (1) SNO (1) SOC (1) SOC + IFX-1 (1) SOC + Intravenous Famotidine (1) SOC plus 15mg/kg EB05 IV (1) SOC plus Placebo IV (1) SOC: Temozolomide (1) SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales (1) SPIN-CHAT Program (1) SPIRIT-in person (1) SPIRIT-remote (1) SSE educational intervention (1) ST-2427 (1) STC-19 score (1) STI-5656 (1) STP + COVID-19 Convalescent Plasma (CP) (1) STP + Standard Plasma (SP) (1) Saline Control (1) Saline Nasal Irrigation (1) Saline Placebo (1) Saline containing 1% Human serum albumin(solution without UC-MSCs) (1) Saline oral/nasal rinse (1) Saline placebo (1) Saline with Baby Shampoo Nasal Irrigation (1) Saline-sodium citrate (SSC) buffer (1) Saliva (1) Saliva and NPS test (1) Saliva specimen (1) Saliva-based testing (1) Sample Collection/Performance Evaluation (A) (1) Sample Collection/Performance Evaluation (B) (1) Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine) (1) Sampling of tissue (1) Sampling salivary (1) Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] (1) Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA] (1) Sarilumab Prefilled Syringe (1) Sarilumab SAR153191 (1) Sars-Cov-2 serology (1) Sars-Cov2 serology (1) Satisfaction evaluation (1) Scanning Chest X-rays and performing AI algorithms on images (1) Schirmer Test I (1) Screening breast magnetic resonance imaging (1) Screening digital breast tomosynthesis (1) Screening digital mammography (1) Screening test for covid ( RT PCR and CT Chest) (1) Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] (1) Sedentary behaviour (1) Self Study (1) Self-Compassion for Chronic Pain Virtual Group Treatment Program (1) Self-Help Therapy (1) Self-System Therapy (1) Self-acupressure (1) Self-administered questionnaires (1) Self-focused acts (1) Self-guided exercises (1) Self-help booklet (1) Self-help guided by a lay provider (1) Self-interest message (1) Self-management booklet (SWitCh: Stay well during COVID-19) (1) Self-prone position recommendation (1) Self-questionnary (1) Selitrectinib (BAY2731954) (1) Semen Qualitative Analysis (1) Semi-directive interview (1) Sensbiosys (1) Sensitivity Intervention (1) Sensitivity and Couples' Intervention (1) SensiumVitals wearable sensor (1) Sequencing (1) Seraph®-100 Microbind® Affinity Blood Filter (1) Serelogy testing, RT PCR (1) Serial seroconversion measurements in hospital employees during the COVID-19 pandemic (1) Serologic SARS-CoV-2 screening (1) Serologic assays for antibodies to SARS-CoV-2 (1) Serologic immunoassays to SARS-CoV-2 antibodies (1) Serologic testing (1) Serological Assay or IgG for SARS-CoV-2 (1) Serological analyses to be lead on a pre-existing biobank (1) Serological screening for IgG and IgM antibodies against COVID-19 (1) Serological test for COVID-19. (1) Serological testing (1) Serological tests will be applied on patients blood sampling (1) Serology (1) Serology Test (1) Serology for Covid-19 (1) Serology test follow-up (1) Serology test for COVID-19 (1) Seroprevalence of SARS-CoV-2 infection in patients with HIV infection (1) Serum SARs COV 2 IGg screening in health care workers (1) Serum test (1) Serum testing (1) Serum tube collection (1) Serum zinc, vitamin d vitamin b12 levels . (1) Setanaxib (1) Sevoflurane inhalant product (1) Sham Attention Training (1) Sham Device Treatment (1) Sham Stimulation (1) Sham cTBS to the vmPFC (1) Sham iTBS to the dlPFC (1) Sham intervention (1) Shared Decision Making (1) Shock-dependent hydrocortisone (1) Sildenafil (1) Sildenafil citrate tablets (1) Silymarin (1) Simha Kriya (1) Simple cognitive task intervention (1) Simplified Geriatric Evaluation (1) Simulation Airway Coaching (1) Simulation of Repurposed Drugs for COVID-19 (1) Simultaneous EGD and colonoscopy (1) Singing for Lung Health group attendance (1) Single fraction whole lung radiotherapy (1) Single high dose vitamin D (1) Sirolimus 1 MG/ML (1) Sirukumab (1) Sitagliptin (1) Six-minute walk test (6MWT) (1) Six-month ARV dispensing (1) Sleep App (1) Sleep Education (1) Sleepio (1) Slef questionnaires fulfilment (1) Small Gift (1) Smartphone application LiPAT (1) Snorkel-based improvised personal protective equipment (1) Social ABCs (1) Social Communication and Emotional Skill Development (SCESD) module (1) Social Distancing Advertisements (1) Social comparison Intervention (1) Social media & news consumption (1) Socialization (1) Sodium Bicarbonate (1) Sodium Chloride 9mg/mL (1) Sodium Nitrite (1) Sodium bicarbonate (1) Sofosbuvir (1) Sofosbuvir + Daclatasvir 120 mg (1) Sofosbuvir 400 MG plus Daclatasvir 200mg (1) Sofosbuvir and Ledipasvir (1) Sofosbuvir plus Ledipasvir (1) Sofosbuvir/Daclatasvir (1) Sofosbuvir/daclatasvir (1) Software Messaging (1) Sofusa DoseConnect (1) Sofusbuvir + Daclastavir 60 mg (1) Solaraze (1) Solcera (1) Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA (1) Spartan COVID-19 System (1) Spartan Cube Point-of Care Covid-19 test (1) Specific anti-SARS-CoV-2 antibodies (1) Specimen Collection (1) Spectrila® (1) Spironolactone 100mg (1) Sputum and blood sampling (1) Sputum collection (1) Sputum sample (1) St. George's Respiratory Questionnaire (SGRQ) (1) Staff Wellbeing Centres (1) Stakeholder of TIP-OA Program (1) Stamaril (live attenuated yellow fever vaccine) (1) Standar medical treatmen (1) Standar of care (1) Standard (specific) therapy for COVID-19 (1) Standard 12-lead ECG, NT-proBNP, echocardiography (1) Standard COVID-19 therapies (1) Standard Care Therapy (1) Standard Dissemination Practice (1) Standard Donor Plasma (1) Standard Dose Bevacizumab (1) Standard Mask (1) Standard Of Care (SOC) (1) Standard Of Care (SOC) + Placebo (1) Standard Plasma (FFP) (1) Standard Public Health measures (1) Standard SII SBCC (1) Standard Therapy (1) Standard Therapy Protocol (STP) (1) Standard Treatment (1) Standard Ventilation Strategy (1) Standard administration of oxygen flow (1) Standard care delivered in the isolation hospitals. (1) Standard care therapy (1) Standard charity resources (1) Standard communication email (1) Standard diagnosis test (1) Standard interface (1) Standard medical care (1) Standard mouthpiece (1) Standard of Care (Intravenous access) (1) Standard of Care (SOC) + ANG-3777 (1) Standard of Care (SOC) and Colchicine+Rosuvastatin (1) Standard of Care (SOC): Radiation Therapy (1) Standard of Care (SoC) (1) Standard of Care Treatment (1) Standard of Care Triple IS (1) Standard of Care thromboprophylaxis (1) Standard of care (Paracetamol) (1) Standard of care (SOC) plus placebo (1) Standard of care for SARS-CoV-2 infection (1) Standard of care management (1) Standard of care therapies (1) Standard of care therapy (1) Standard of care. (1) Standard oxygen therapy (1) Standard protein group (1) Standard screening strategy (1) Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment (1) Standard supportive care (1) Standard therapeutic protocol (1) Standard therapy (1) Standard therapy for AUD (1) Standard therapy for AUD plus Chess-based cognitive treatment (1) Standard therapy for COVID-19 according to the stablished hospital protocols. (1) Standard therapy for TUD (1) Standard therapy of COVID-19 (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation (1) Standard therapy recommended by the Ministry of Health of the Russian Federation. (1) Standard treatment according to the Clinical protocols (1) Standard treatment for COVID-19 (1) Standard-of-care (1) Standard-of-care treatment (1) Standard-titer Convalescent COVID-19 plasma (CCP2) (1) Standardised questionnaires (1) Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) (1) Standards of Care (1) State-trait anxiety inventory scale (1) Statins (Cardiovascular Agents) (1) Stem Cell Educator-Treated Mononuclear Cells Apheresis (1) Stem Cell Product (1) Stereotactic Radiotherapy (1) Sterile Normal Saline for Intravenous Use (1) Sterile Water for Injection (1) Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection (1) Stool collection (1) Stool collection or fecal swab (1) Streptokinase (1) Stress and emotion management (1) Study A (1) Study Arm (1) Study B (1) Study C (1) Study D (1) Study Group (1) Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2 (1) Suboxone (1) Sudarshan Kriya Yoga (SKY) (1) Sulfonatoporphyrin(TPPS) plus Sunlight exposure. (1) Sulodexide (1) Supine Positioning (1) Supine position (1) Supplement Drink (1) Support treatment (1) Supported Adopted Intervention 1 (1) Supported Adopted Intervention 2 (1) Supported Adopted Intervention 3 (1) Supraflex Cruz 60 Micron (1) Suramin (1) Surge capacity (1) Surgery (1) Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail (1) Surgical Management (1) Surgical Management + Treatment (1) Surgical facial mask (1) Surgical mask (1) Surgical procedures performed under general anesthesia (1) Surveillance card (1) Survey Group (1) Survey administration (1) Survey and Questionnaire (1) Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later (1) Surveys (1) Susceptibility to infection (1) Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors (1) Sustained attention (1) Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) (1) SyB V-1901 (1) Symptom Survey (1) Symptom and Exposure Surveys (1) Symptomatic drugs (1) Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations) (1) Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) (1) Symptoms entered into the CovidX application (1) Symptoms questionnare (1) Systemic indirect endovenous ozone therapy (1) T-cell receptor (TCR) repertoire (1) T3 solution for injection (1) T89 (1) TAK-018 (1) TAK-018 Placebo (1) TAK-671 (1) TAK-671 Placebo (1) TAK-906 Maleate (1) TAK-906 Maleate Placebo (1) TAK-981 (1) TAPE-Software (1) TAVR or SAVR (1) TBD Compound 1 (1) TBD Compound 2 (1) TBD Compound 3 (1) TCC-COVID mHealth solution (1) TCM prescriptions (1) TD139 (1) TDCS (1) TDR (1) TEM-tPA (1) TERA Intervention (1) TERN-101 (1) TGplPTH1-34 in fibrin (1) TJ003234 (1) TLRs activation measurement (1) TMS (1) TNKase (1) TOF protocol (1) TRIIM Treatment (1) TRV027 (1) TXA127 (1) TY027 (1) Table Setting Training (1) Tacrolimus (1) Tafenoquine Oral Tablet (1) Take Control (1) Taking biological samples (1) Taking blood samples for analyzing progesterone levels (1) Talabostat Mesylate plus Pembrolizumab (1) Tap water (1) Taste and olfactory function evaluation (1) Taste test (1) Team Intervention (1) Tear Collection (1) Tears swab (1) Technology based social interactions (1) Technology-assisted Index (1) Tele-Pulmonary rehabilitation (1) Tele-Yoga Therapy (1) Tele-delivered psychological intervention (1) Tele-interventions related to diabetes management and mental well-being (1) Tele-medicine platform (1) Tele-yoga therapy (1) Teleconsultation either by phone or by computer consultation (1) Telehealth CBT (1) Telehealth Consultation (1) Telehealth coaching sessions (1) Telehealth monitoring (1) Telehealth phone calls (1) Telemedicine FU (1) Telemedicine follow-up visit (1) Telemedicine to remote outpatient visit in bariatric patient (1) Telephone Coaching (1) Telephone follow-up (1) Telephone interview (1) Telephone survey (1) Telephonic interview during the Italian lockdown. (1) Telephonic medical visit (1) Telerehabilitation-Based (1) Telesimulation (1) Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg (1) Telmisartan 20 mg/amlodipine 2.5 mg . (1) Telmisartan 20 mg/indapamide 1.25 mg (1) Telmisartan 40Mg Oral Tablet (1) Telmisartan 40mg (1) Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care. (1) Temporarily holding the RAAS inhibitor [intervention] (1) Temsirolimus (1) Ten-days oseltamivir (1) Tenecteplase (1) Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE) (1) Test PCR (1) Test for SARS-CoV-2 (1) Test: Favipiravir 200 mg (LOQULAR) (1) Tested for SARS-CoV-2 (regardless of the result) (1) Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals (1) Testing for SARS-CoV-2 (1) Testing of SARS-CoV-2 antibodies (1) Testing procedure for Binding antibodies (1) Tests (1) Tetrandrine (1) Text message (1) Tezacaftor/Ivacaftor + Ivacaftor (1) Thalidomide (1) The CRAFT program (adapted due to COVID-19) (1) The DryShield (1) The MBSR program (adapted due to COVID-19) (1) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: (1) The PREPARE program (1) The Vie Scope laryngoscope (1) The control group will not receive hydroxychloroquine (1) The demographic, clinical, laboratory, and instrumental data (1) The high-volume evacuator (1) The saliva ejector (1) The standard Macintosh laryngoscope (1) The standard of care (1) The usual treatment (1) Therapeutic Anticoagulation (1) Therapeutic Exercise and Education (1) Therapeutic Plasma Exchange (TPE) (1) Therapeutic Plasma exchange (1) Therapeutic plasma exchange (TPE) (1) Therapist Guided E-Therapy (1) Therapist-guided one-session online exposure therapy according to (Öst, 1989) (1) Therapy Intervention (1) There is no intervention (1) There is no intervention in this study (1) Thermography (1) Thiazide or Thiazide-like diuretics (1) This is an online survey with no intervention. (1) Thoracic CT Scan (1) Thorax CT (1) Thoraxic computed tomography (1) Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28 (1) Three doses of placebo at the schedule of day 0, 14, 28(high-dose group) (1) Throat swab and/or nasopharyngeal swab (1) Throat swab sample for measuring current infection with SARS-CoV-2 (1) Thrombin Generation Assay (TGA) (1) Thrombin generation test assay (1) Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) (1) Thromboprophylaxis (1) Thymosin+standard treatment (1) Tigerase® and best available care (1) Tildrakizumab (1) Tinzaparin or unfractionated heparin (1) Tirofiban Injection (1) Tissue plasminogen activator (1) Titanium blood test (1) To assess for development of IgG antibodies against SARS-CoV2 (1) Tociliuzumab (1) Tocilizumab +/- ruxolitinib (stages 2b/3) (1) Tocilizumab 180 MG/ML (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA] (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses) (1) Tocilizumab Injection [Actemra] (1) Tocilizumab Prefilled Syringe (1) Tocilizumab and Ruxolitinib (Advanced stage 3) (1) Tomeka® (1) Toraymyxin PMX-20R (PMX Cartridge) (1) Toremifene (1) Tracheal intubation and cardiopulmonary resuscitation (1) Tracheostomy with aerosol box in COVID-19 positive patients (1) Tracheotomy (1) Tradipitant (1) Traditional Chinese Medicine Prescription (1) Traditional antirheumatic drugs (1) Training clinicians in basic critical care and the management of severe COVID-19 cases (1) Training for Awareness, Resilience, and Action (TARA) (1) Training of youth, community health assistants and community health workers. (1) Training session adressing information and health literacy (1) Training video on anxiety, fear and loneliness in the COVID-19 environment. (1) Tramadol (1) Tranexamic acid (1) Tranexamic acid tablets (1) Transcranial Electrical Stimulation (1) Transcutaneous Auricular Vagus Nerve Stimulation (1) Transfusion of COVID-19 convalescent plasma (1) Transfusion of SARS-CoV-2 Convalescent Plasma. (1) Transfusion of standard Plasma. (1) Transitional Online Peer Support Group (n=20) (1) Transparent, reusable respirator (1) Transplant patient (1) Transpulmonary pressure measurements (1) Transpulmonary thermodilution (1) Trauma-informed yoga video recording (1) Treadmill electrocardiographic stress test (1) Treamid (1) Treatment (1) Treatment As Usual (1) Treatment and prophylaxis (1) Treatment as usual (1) Treatment as usual vitamin D (1) Treatment for COVID-19 (1) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : (1) Treatment with Dexmedetomidine (1) Tremelimumab (1) Trimethoprim Sulfamethoxazole (TMP/SMX) (1) Trivia Training (1) Trust in science message (1) Tuberculin test (1) Two COVID-19 vaccine candidate (TMV-083) administrations - High dose (1) Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose (1) Two dose MenACWY vaccine (1) Two dose MenACWY vaccine 4-12 weeks (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (1) Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 (1) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule (1) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule (1) Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 (1) Two doses of placebo at the emergency vaccination schedule (1) Two doses of placebo at the routine vaccination schedule (1) Two doses of placebo at the schedule of day 0, 28(high-dose group) (1) Two doses of placebo at the schedule of day 0, 28(middle-dose group) (1) Tympanic Temperature (1) UB-612 (1) UCMSCs (1) UCPVax + Nivolumab (1) ULTRAPROTECTIVE VENTILATION (1) UNIKINON (Chloroquine phosphate) 200mg tablets (1) UTTR1147A (1) UTTR1147A-matched Placebo (1) Ulinastatin (1) Ultimaster Tansei 80 Micron (1) Ultra Brief Online Mindfulness-based Intervention (1) Ultra-Low-dose radiotherapy (1) Ultrasound lung imaging as part of FAST+ evaluation (1) Ultrasound of the lower limbs (1) Umbilical Cord Lining Stem Cells (ULSC) (1) Umbilical Cord Mesenchymal Stem Cells (1) Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. (1) Umbilical cord Wharton's jelly-derived human (1) Umbilical cord derived mesenchymal stem cells (1) Umifenovir (1) Unavailable COVID Test Result - Hypothetical Scenario (1) Unfractionated Heparin IV (1) Unfractionated heparin SC (1) Unfractionated heparin nebulized (1) Unified Protocol for COVID-19 Parenting Stress (UP-COVID) (1) Uniform random message delivery (1) Universal Screening Arm (1) Unsupervised exercise (1) Unsupervised physical activities (1) Upadacitinib (1) Upadacitinib (ABT-494) (1) Urinary Incontinence (1) Urine Test (1) Urine collection (1) Urine sample (1) Use of Doctorgram Mobile Application (1) Use of Doctorgram Patient Kit (1) Use of Remote Pulse Oximeter (1) Use of mobile application (1) Use of social media during COVID-19 (1) Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures (1) Usual Care Only (1) Usual Care plus Customized Referrals (1) Usual antibiotic treatment (1) Usual care positioning with no instructions (1) V-SARS (1) V/Q SPECT-CT (1) V/Q Vest (1) V591 (1) VC (1) VCPM (1) VESTA respirator (1) VIB4920 (1) VIB7734 (1) VIP4SCI (1) VIR-7831 (1) VITROS Anti-SARS-CoV-2 IgG test (1) VRC-MALMAB0100-00-AB (1) VRC-SRSDNA015-00-VP (1) VXA-CoV2-1 (1) Vaccine (1) Vaginal fluid Covid-19 PCR test (1) Valproate (1) Valsartan (Diovan) (1) Values Clarification and Attitudes Transformation (VCAT) Workshop (1) Vancomycin (1) Vancomycin with Taper/Pulse (1) Vascular surgery (1) Vehicle + Heparin along with best supportive care (1) Vehicle Control (1) Venepuncture (1) VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) (1) Ventil - a gas flow divider (1) Verapamil (1) Veru-111 (1) VibroLUNG (1) Video (1) Video Chat + Basic Feedback (1) Video Chat +Personalized Feedback (1) Video Dance classes (1) Video Default (1) Video Visit (1) Video based aerobic exercise (1) Video based exercise (1) Video-Based (1) Video-Based intervention (1) Videofluoroscopic Swallowing Study (VFSS) (1) Vie Scope laryngoscopy (1) Vielight RX Plus (1) Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic (1) Viral Specific T-cells (VSTs) (1) Virtual ACT Workshop for Emotional Eating (1) Virtual Assistant first, then Human Coach (1) Virtual Care and Remote Automated Monitoring (1) Virtual Care at Home (1) Virtual Group Exercise (1) Virtual Group Intervention (1) Virtual Peer Support Platform (1) Virtual Reality (1) Virtual Reality Behavioral Activation (1) Virtual Reality Goggles (1) Virtual Reality Pain Neuroscience Education (1) Virtual reality therapy first (1) Virtual-Care Cognitive Behavioural Therapy (1) Viruxal Oral and Nasal Spray (1) Vit D (1) VitalConnect Vital Sign Patch (1) Vitamin B12 (1) Vitamin C tablets (1) Vitamin D 1000 IU (1) Vitamin D3 or Placebo (1) Vitamins (1) Viusid and Asbrip (1) VivaDiag™ COVID-19 lgM/IgG Rapid Test (1) ViviGen® Cellular Bone Matrix (1) Volatile Organic Compounds analysis (1) Volunteer of TIP-OA Program (1) Voraxaze (1) WALC-R (1) WFI 5% glucose (1) WFI water nebulization (1) WHO recommendations (waiting condition) (1) WHOQOL-BREF (1) WHOQOL-BREF survey (1) WJ-MSCs (1) WW (1) Wait list time (1) Waiting list (1) Waiting list where participants wait for delayed treatment (1) Waitlist (1) Walk Test (1) Water Without an Elevated Level of KELEA (1) Wearable Activity Trackers, Exercise Prescription and Virtual Care (1) Wearable Medical Device (Empatica E4) (1) Wearing surgical face mask sprayed with hypertonic saline (1) Web + text smoking cessation intervention (1) Web Based Survey (1) Web application users (1) Web-based REDCap survey (1) Web-based psychosocial peer-to-peer support (1) Web-based self-report questionnaires (1) WebEx Physical Activity Program (1) Weekly Assessment (1) Weight Counseling (1) Weight Loss (1) Wellness (1) Wharton's jelly derived Mesenchymal stem cells. (1) White Sender in Acknowledgement (1) White Sender in Informational Videos (1) Whole Exome Sequencing (1) Whole Genome Analysis (1) Whole exome sequencing (1) Withings ScanWatch (1) Without haptic stimulation (1) Woebot Substance Use Disorder (1) Women receiving extra remembering by healthcare (1) Workshops control group LiPAT (1) Wrist-worn feedback physical activity monitor (1) Written Information (1) Written Summary of Rounds (1) XAV-19 (1) XC221 (1) XCEL-UMC-BETA (1) XPro1595 (1) XatJove Anoia Aplication (1) Xiyanping injection (1) YH25448 (1) Yin Hu Qing Wen Granula(low does) (1) YinHu QingWen Decoction (1) YinHu QingWen Decoction(low dose) (1) Yinhu Qingwen Granula (1) Yoga group (1) Zanubrutinib (1) Zaritt Burden Interview (1) Zavegepant (BHV-3500) (1) Zilucoplan® (1) Zinc (Placebo) (1) Zinc Citrate (1) Zinc Gluconate (1) Zinc Picolinate (1) Zinc Picolinate Placebo (1) Zinc Sulfate (1) Zinc gluconate (1) Zithromax Oral Product (1) Zofin (1) Zolpidem + PAP therapy (1) Zonisamide (1) [14C]-GSK3640254 intravenous infusion (1) [14C]-GSK3640254 powder (1) [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL) (1) [TIMP-2]*[IGFBP-7] (1) a specifically designed self-administered questionnaire (1) a survey (1) acetylsalicylic acid (1) actigraphy (1) acute kidney injury (1) additional blood tubes (1) aerosol box (1) aerosolized DNase (1) after-each-case room disinfection (1) airway management during sedation or general anesthesia (1) all treatment about COVID-2019 (1) allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) (1) allogeneic mesenchymal stem cell (1) alpha one antitrypsin inhalation (1) alveolar recruitment (1) amlodipine 5 mg/indapamide 2.5 mg (1) amoxicillin/clavulanate (1) anti-CD40 antibody (CDX-1140) (1) anti-SARS-CoV-2 human convalescent plasma (1) anti-SARS-CoV-2 plasma (1) antidiabetic treatment (1) antithymocyte globulin (rabbit) (1) appendectomy (1) artus Influenza A/B RT-PCR Test (1) assessment of the sequelae after hospitalization for Sars-COV-2 (1) attendance by ambulance crew (1) auscultation by using traditional stethoscope and electronic stethoscope under full PPE (1) autologous adipose-derived stem cells (1) autopsy (1) avdoralimab (1) azithromycin (1) azoximer bromide (1) bacTRL-Spike (1) behavioral lifestyle intervention (1) belatacept (1) bidirectional oxygenation mouthpiece (1) biochemical analysis (1) biological assays in particular on the lipid metabolism (1) biological samples collection (1) biological samples day of delivery (1) biological samples, questionnaires and interviews (1) biopsies of subcutaneous adipose tissue (1) blastocyst-stage embryo transfer (1) blood sample for seroepidemiological investigation (1) blood sampling for biobank (1) blood test for SARS-COV2 serology (1) bromelain (1) bronchoscopy examination (1) canakinumab (1) captopril 25mg (1) care as usual (1) care modalities (1) carotid-femoral pulse-wave velocity (1) cellulose-containing placebo capsules (1) chest radiography (1) chest x-ray (1) chiropractic team (1) chlorine dioxide 3000 ppm (1) chloroquine (1) cholecalciferol 200,000 IU (1) cholecalciferol 50,000 IU (1) chronic pain team (1) cleavage-stage embryo transfer (1) collection of biological samples (1) collection of swabs (1) community health worker support (1) comparison of sample collection methods (1) complication (1) computerized cognitive training (CCT) (1) congenital malformation (1) conjunctival RT PCR (1) conjunctival swab (1) consultation (1) control (1) convalescent plasma application to SARS-CoV-2 infected patients (1) convalescent plasma from recovered COVID 19 donor (1) conventional management of patients (1) conventional oxygen (1) corticosteroid nasal irrigation (1) covid-19 positive pregnant women (1) current IPAC-UHN PPE (1) daily room disinfection (1) daily syndromic surveillance (1) dapansutrile capsules (1) data record (1) decisions of limitations and stop processing (1) demographic and clinical data obtained from hospital's electronic medical record. (1) diagnostic (1) diagnostic tests for COVID-19 infection (1) dialysis (1) digoxin (1) double gloves (1) draw blood (1) e-Psychotherapy (1) e-ink screen (1) echocardiogram 2D (1) eculizumab (1) efgartigimod IV (1) efgartigimod PH20 SC (1) electrolytes (1) ensoETM device (1) enzalutamide (1) enzalutamide Placebo (1) epidemiological and demographic characteristics (1) evaluation of skin microvascular flow and reactivity (1) everolimus (1) exchange blood transfusion from normal donor (1) exercise brochure (1) exposure (1) fMRI (1) faecal sample collector (1) famotidine (1) favipiravir (1) favipiravir tablets+chloroquine phosphatetablets tablets (1) favorable outcome (1) feces samples (COVI-BIOME ancillary study) (1) fingertip tests for POC assays (1) fsfi survey (1) further processing of health data (1) gammaCore® (Vagus nerve stimulation) (1) gammaCore® Sapphire (non-invasive vagus nerve stimulator) (1) global survey (1) high flow nasal cannula (HFNC) (1) high flow nasal cannula device (1) high-titer anti-Sars-CoV-2 plasma (1) home care monitoring (1) home spirometry (1) hormones (1) hospitalized children with Covid19 (1) human cord tissue mesenchymal stromal cells (1) hydrocortisone (1) hydroxychloroquine + azithromycin (1) hydroxychloroquine in combination with camostat mesylate (1) hydroxychloroquine placebo (1) hydroxychloroquine sulfate 200 MG (1) hyper immunoglobulins containing anti-Corona VS2 immunoglobulin (1) hyperbaric oxygen therapy (HBOT) (1) hyperimmune plasma (1) hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint (1) iAMP test (1) iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System (1) identify SARS-CoV-2 infection by serology (1) imPulse™ Una e-stethoscope (1) imaging, blood tests (1) immunoSEQ Dx (1) impliminting Online Distance Learning (1) in-hospital mortality rate (1) indirect calorimetry (1) inhalable hydroxychloroquine (HCQ) (1) inhaled hydroxychloroquine (1) inhaled type I interferon (1) interleuken 6 level measurment (1) intermediate dose Enoxaparin/ unfractionated heparin (1) intradermal injection of BCG Vaccine (1) intravenous immunoglobulin therapy (1) intubation (1) iota carrageenan (1) ioveraº (1) ioveraº sham (1) it is a survey (1) laboratory biomarkers (1) labs (1) lanadelumab (1) less-frequency hemodialysis (1) leucovorin (1) life questionnaires (1) lifestyle modification (1) liposomal lactoferrin (1) lopinavir/ritonavir (1) lopinavir/ritonavir group (1) lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate (1) lulizumab pegol (1) lung mechanics at different PEEP (1) lung ultrasound (1) lung ultrasound (LUS) (1) mHealth Assessments (1) mMRC (Modified Medical Research Council) Dyspnea Scale (1) mRNA in urine test (1) management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia (1) mavrilimumab (1) measurement of circulating sFlt1 concentration (1) mechanical ventilation (1) mechanical ventilator settings and position (1) media multi-task (1) media package (1) melatonin (1) meplazumab for injection (1) mesenchymal stem cells (1) metenkefalin + tridecactide (1) methylprednisolone (1) methylprednisolone therapy (1) mindfulness, emotion didactics, interpersonal skills, experiential learning (1) miniprobe Alveoflex (1) mobile internet survey on self-test (1) modification of the planned therapeutic management (1) modified IPAC-UHN PPE (1) molecular testing for virus RNA using RT-PCR (1) mometasone furoate nasal spray (1) monthly serologic IgM/G test (1) morning Yoga-based breathing support (1) mortality (1) mouthrinse with bêta-cyclodextrin and citrox (1) mouthrinse without bêta-cyclodextrin and citrox (1) multipeptide cocktail (1) muscle ultrasound (1) mycophenolate mofetil (1) mycophenolate mofetil (MMF) (1) mycophenolic acid (1) nCapp, a cell phone-based auto-diagnosis system (1) nangibotide (1) nasal pharyngeal (NP) swab samples (1) nasopharyngeal Covid 19 RT-PCR (1) nebulised recombinant tissue-Plasminogen Activator (rt-PA) (1) nebulization (1) newborns from covid 19 positive mothers (1) no intervention-mechanistic study (1) no intervention. observational cohort study (1) no interventional study (1) non (1) non applicable (1) non e-cigarette TV commercials (1) non interventional (1) non-RAS blocking antihypertensives (1) non-contact magnetically-controlled capsule endoscopy (1) non-interventional (1) none - observational (1) none, this study is observational (1) nosocomial infection/hospital acquired infection (1) not applicable (observational study) (1) nutritional intervention (1) oSOC (1) observation (1) observation of covid 19 pneumonia (1) olfactory and gustatory tests (1) olfactory device (1) online KKH Sports Singapore Program with Usual Care (1) online mindfulness group (1) online questionnaires (1) online survey (1) oral co-trimoxazole (1) oral polio vaccine + information (1) oropharyngeal swabs (1) oxygen treatment (1) oxyhydrogen (1) pathogen reduced SARS-CoV-2 convalescent plasma (1) patients COVID 19 (1) patients receiving nasal high flow (1) performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection (1) peripheral blood draw (1) phone call (1) photobiomodulation and photodynamic therapy (1) pirfenidone (1) placebo (hartmann plus albumine) (1) placebo capsules (1) placebo for clazakizumab (1) placebo for risankizumab IV (1) placebo rinse (1) placebo+rHuPH20 (1) plasma from convalescent patients with COVID-19 (1) plasma hyperimmune (1) plasma therapy using convalescent plasma with antibody against SARS-CoV-2 (1) poractant alfa (1) positive psychological intervention (1) prayer (1) pre-operative screening (1) pre_dinner Yoga-based breathing support (1) pre_lunch Yoga-based breathing support (1) predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables? (1) prednisolone (1) proper diet (1) prophylactic heparin (1) prophylactic lactoferrin daily (1) psycho-education video (1) psychological and sociological interviews (1) psychological assessment (1) pulmonary anomalies 4 months after documented COVID-19 pneumonia (1) pulmonary ultrasound (1) qRT-PCR and serology (1) quality of life questionnaires (1) quality of live assessment (1) quesionnair (1) questionaire to husband and wife (1) questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality (1) questionnaire and optional interview (1) questionnaire filling (1) quetionnary (1) rapid salivary test (1) rapid serological test (1) reSET-O (1) realtime PCR (1) recombinant human interferon Alpha-1b (1) recovered covid 19 patients plasma (1) rectal swab (1) regular care (1) remdesivir (1) research specific blood sample (1) respiratory function rehabilitation training (1) retrospective metagenomics on clinical samples collected during hospitalization (1) rhDNase I (1) rhPTH(1-84) (1) risankizumab (1) risk factors (1) rosuvastatin (1) saint george respiratory questionnaire (1) saliva collection (1) saliva sample (1) samling of oropharynx and nasopharynx (1) self-administered structured questionnaire (1) serological test (1) serology test (1) sertraline (1) serum chemistry analysis (1) serum inflammatory biomarkers (1) severe covid-19 pneumonia with ET (1) sham TMS (1) smell household Items (1) sodium chloride 0.9% (1) sofosbuvir (1) spirometry (1) standard chemotherapy (1) standard concomitant therapy (1) standard medical treatment (1) standard newborn and infant care (1) standard operating procedures (1) standard procedure (1) standard prophylactic dose Enoxaparin/ unfractionated heparin (1) standard protocol (1) standard treatment (1) standard western medicine treatment (1) standardized Lung Ultrasound (LUS) examination (1) stem cells (1) stress and anxiety questionnaire (1) supportive and symptomatic treatment (1) surveys and questionnaires (1) sweat samples (COVIDOG ancillary study) (1) systemic treatment (1) tacrolimus (1) telehealth applications (1) telephone consult (1) telmisartan 40 mg/amlodipine 5 mg (1) telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg (1) telmisartan 40 mg/indapamide 2.5 mg (1) thalidomide (1) theraputic heparin (1) this study is non- interventional (1) thoracic CT-scan (1) thoracic computed tomography scan (1) thoracic lung ultrasound (1) thromboprofylaxis protocol (1) thromboprophylaxis with low-molecular-weight heparin or fondaparinux (1) thymosin alpha 1 (1) topical steroids and cyclosporin-A (1) tracheostomy (1) transparent sheet (1) trimethoprim/sulfamethoxazole (1) turkish physicians (1) unfractionated heparin (1) urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic (1) use and exposure to disinfectants during the coronavirus pandemic (1) vaccine BCG (1) vaccine candidate MVA-MERS-S (1) vadadustat (1) venipuncture in peripheral vein (1) ventilatory support with oxygen therapy (1) vitamin D (1) vitamin d (1) von Willebrand factor (Recombinant) (1) vv-ECMO (1) washed microbiota transplantation (1) web based survey (1) wedged insole (1) zinc (1) zinc gluconate and ascorbic acid (1) ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF. (1) γ-Globulin (1) Оxygen therapy (1)

    Hydroxychloroquine

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (206)


    Name (Synonyms) Correlation
    drug364 Azithromycin Wiki 0.36
    drug2557 Placebo oral tablet Wiki 0.20
    drug3408 Telmisartan Wiki 0.17
    Name (Synonyms) Correlation
    drug3674 Vitamin C Wiki 0.17
    drug1683 Interferon Beta-1A Wiki 0.15
    drug1773 KB109 + Self Supportive Care (SSC) Wiki 0.14
    drug1863 Lopinavir-Ritonavir Wiki 0.14
    drug3063 Self Supportive Care (SSC) Alone Wiki 0.14
    drug1853 Lopinavir / Ritonavir Wiki 0.13
    drug1872 Lopinavir/ritonavir Wiki 0.13
    drug2505 Placebo Wiki 0.12
    drug1684 Interferon Beta-1B Wiki 0.12
    drug3749 Zinc Wiki 0.11
    drug3676 Vitamin D Wiki 0.11
    drug3 (Standard of Care) SoC Wiki 0.10
    drug1575 Hyperbaric oxygen therapy Wiki 0.10
    drug3428 Testing procedure for Binding antibodies Wiki 0.10
    drug1297 Favipiravir (3200 mg + 1200 mg) Wiki 0.10
    drug2503 Piperacillin-tazobactam Wiki 0.10
    drug1854 Lopinavir / Ritonavir Pill Wiki 0.10
    drug1525 Hydroxychloroquine + azithromycin + / - tocilizumab Wiki 0.10
    drug3842 congenital malformation Wiki 0.10
    drug2471 Personal Protective Testing Booth Wiki 0.10
    drug3757 Zithromax Oral Product Wiki 0.10
    drug137 AZD7442 Wiki 0.10
    drug739 Ceftriaxone Wiki 0.10
    drug1634 Immunoglobulin Wiki 0.10
    drug2496 Physiology Wiki 0.10
    drug827 Cognitive testing Wiki 0.10
    drug429 BVA-100 Wiki 0.10
    drug2519 Placebo Administration Wiki 0.10
    drug1313 Fibrin generation markers assays Wiki 0.10
    drug4158 unfractionated heparin Wiki 0.10
    drug1185 Emtricitabine/tenofovir disoproxil Wiki 0.10
    drug3755 Zinc Sulfate Wiki 0.10
    drug322 Association of diltiazem and niclosamide Wiki 0.10
    drug3122 Shock-dependent hydrocortisone Wiki 0.10
    drug3472 Thrombin generation test assay Wiki 0.10
    drug2028 Mesenchymal stromal cell-based therapy Wiki 0.10
    drug131 AWARD advice Wiki 0.10
    drug3617 VIB7734 Wiki 0.10
    drug2815 Razuprotafib Subcutaneous Solution Wiki 0.10
    drug1327 Fixed-duration Hydrocortisone Wiki 0.10
    drug2748 Questionnaire with precaution information Wiki 0.10
    drug4166 ventilatory support with oxygen therapy Wiki 0.10
    drug501 Blink and Masseter Inhibitory Reflex Wiki 0.10
    drug3681 Vitamins Wiki 0.10
    drug3533 Treatment as usual vitamin D Wiki 0.10
    drug4042 plasma from convalescent patients with COVID-19 Wiki 0.10
    drug3750 Zinc (Placebo) Wiki 0.10
    drug2331 Online instruction Wiki 0.10
    drug4082 remdesivir Wiki 0.10
    drug1955 Macrolide administered for up to 14 days Wiki 0.10
    drug4063 qRT-PCR and serology Wiki 0.10
    drug1300 Favipiravir (3600 mg + 1600 mg) Wiki 0.10
    drug1692 Interferon-β1a Wiki 0.10
    drug2571 Placebo: Hydroxychloroquine Wiki 0.10
    drug226 Amoxicillin-clavulanate Wiki 0.10
    drug1324 Five-days oseltamivir Wiki 0.10
    drug2261 Normobaric oxygen therapy Wiki 0.10
    drug1453 Health warning leaflet Wiki 0.10
    drug1522 Hydroxychloroquine (placebo) Wiki 0.10
    drug132 AWARD plus COVID-specific advice Wiki 0.10
    drug3702 Walk Test Wiki 0.10
    drug1526 Hydroxychloroquine + lopinavir/ritonavir Wiki 0.10
    drug2512 Placebo (carrier control) Wiki 0.10
    drug1645 In-person instruction Wiki 0.10
    drug1860 Lopinavir 200Mg/Ritonavir 50Mg Tab Wiki 0.10
    drug2474 Personal protective equipment Wiki 0.10
    drug1963 Mannitol Wiki 0.10
    drug2096 Moxifloxacin or Levofloxacin Wiki 0.10
    drug1556 Hydroxychloroquine combined with Azithromycin Wiki 0.10
    drug1298 Favipiravir (3200 mg + 1200 mg) combined with Azithromycin Wiki 0.10
    drug615 COSH Self-help smoking cessation booklet Wiki 0.10
    drug1032 Dexamethasone and Hydroxychloroquine Wiki 0.10
    drug3770 additional blood tubes Wiki 0.10
    drug343 Auditory Evoked Potentials (AEP) Wiki 0.10
    drug1040 Diagnostic Laboratory Biomarker Analysis Wiki 0.10
    drug3446 The standard of care Wiki 0.10
    drug2305 Olfaction testing Wiki 0.10
    drug2682 Protocolised mechanical ventilation strategy Wiki 0.10
    drug738 Ceftaroline Wiki 0.10
    drug2840 Referral card Wiki 0.10
    drug1250 Experts consensus Wiki 0.10
    drug531 Bloodwork Wiki 0.10
    drug2537 Placebo capsules Wiki 0.10
    drug3245 Standard supportive care Wiki 0.10
    drug3701 Waitlist Wiki 0.10
    drug1248 Experimental drug Wiki 0.10
    drug2180 Neutralizing antibodies Wiki 0.10
    drug2534 Placebo Subcutaneous Solution Wiki 0.10
    drug1242 Exercise training Wiki 0.10
    drug3965 metenkefalin + tridecactide Wiki 0.10
    drug1789 LAU-7b Wiki 0.10
    drug2470 Personal Exercise Intervention Wiki 0.10
    drug3826 cellulose-containing placebo capsules Wiki 0.10
    drug3880 exchange blood transfusion from normal donor Wiki 0.10
    drug550 Brexanolone Wiki 0.10
    drug2005 Mefloquine + azithromycin + / - tocilizumab Wiki 0.10
    drug1937 MRI (heart, brain, lungs, kidney) Wiki 0.10
    drug2019 Mesenchymal Stem Cell Wiki 0.10
    drug2550 Placebo of Hydroxychloroquine Wiki 0.10
    drug2216 No intervention (survey study for medical doctors). Wiki 0.10
    drug887 Control arm Wiki 0.10
    drug1954 Macrolide administered for 3-5 days Wiki 0.10
    drug4086 retrospective metagenomics on clinical samples collected during hospitalization Wiki 0.10
    drug2036 Methylene Blue 5 MG/ML Wiki 0.10
    drug2570 Placebo: Emtricitabine/tenofovir disoproxil Placebo Wiki 0.10
    drug2107 Muscle ultrasound Wiki 0.10
    drug2790 RTB101 Wiki 0.10
    drug4 - Synthetic anti-malarial drugs Wiki 0.10
    drug2769 REGN10933+REGN10987 Wiki 0.10
    drug2004 Mefloquine Wiki 0.10
    drug2353 Other Wiki 0.10
    drug3673 Vitamin B12 Wiki 0.10
    drug588 CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc Wiki 0.10
    drug2195 Nitazoxanide 500 MG Wiki 0.10
    drug1170 Electronic Health Record Review Wiki 0.10
    drug2551 Placebo of LPV/r Tablets Wiki 0.10
    drug2097 Mucodentol Wiki 0.10
    drug3441 The control group will not receive hydroxychloroquine Wiki 0.10
    drug1554 Hydroxychloroquine and azithromycin treatment arm. Wiki 0.10
    drug3418 Ten-days oseltamivir Wiki 0.10
    drug1561 Hydroxychloroquine sulfate &Azithromycin Wiki 0.10
    drug1290 Facial mask Wiki 0.10
    drug2347 Oral supplement enriched in antioxidants Wiki 0.10
    drug3575 Umbilical Cord Lining Stem Cells (ULSC) Wiki 0.10
    drug1213 Equipment with smartwatch throughout hospital stay on the general ward Wiki 0.10
    drug2120 NA (no intervention) Wiki 0.10
    drug126 AVIGAN Wiki 0.10
    drug1014 Defibrotide Wiki 0.10
    drug1299 Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine Wiki 0.10
    drug2535 Placebo Tablet Wiki 0.10
    drug926 Corticosteroid injection Wiki 0.10
    drug3572 Ultra-Low-dose radiotherapy Wiki 0.10
    drug1654 Indomethacin Wiki 0.10
    drug666 COVID-19 related health warning leaflet Wiki 0.10
    drug1328 Fixed-duration higher dose Hydrocortisone Wiki 0.10
    drug3751 Zinc Citrate Wiki 0.10
    drug1161 Effortful Control Camp Wiki 0.10
    drug3137 Single high dose vitamin D Wiki 0.10
    drug1023 Descartes 30 Wiki 0.10
    drug2504 Piperacillin/tazobactam Wiki 0.10
    drug1249 Experimental: Questionnaire without precaution information Wiki 0.10
    drug1927 MFS Wiki 0.10
    drug703 CYP-001 Wiki 0.10
    drug1432 HB-adMSC Wiki 0.10
    drug1278 FFP2 Wiki 0.10
    drug3662 Virtual Group Intervention Wiki 0.10
    drug1862 Lopinavir and ritonavir Wiki 0.10
    drug3001 SMS-based support Wiki 0.10
    drug768 Chat-based support Wiki 0.10
    drug1805 Laboratory Analyses Wiki 0.10
    drug3046 Sarilumab Wiki 0.09
    drug432 Bacille Calmette-Guérin (BCG) Wiki 0.07
    drug2927 Routine care for COVID-19 patients Wiki 0.07
    drug779 Chloroquine Sulfate Wiki 0.07
    drug3181 Spirometry Wiki 0.07
    drug2944 SARS-CoV-2 Wiki 0.07
    drug900 Convalescent Plasma Transfusion Wiki 0.07
    drug1895 Low molecular weight heparin Wiki 0.07
    drug2029 Mesenchymal stromal cells Wiki 0.07
    drug3233 Standard of care (SOC) Wiki 0.07
    drug925 Corticosteroid Wiki 0.07
    drug1524 Hydroxychloroquine + azithromycin Wiki 0.07
    drug3133 Simvastatin Wiki 0.07
    drug3496 Tofacitinib Wiki 0.07
    drug3453 Therapeutic anticoagulation Wiki 0.07
    drug1627 Imatinib Wiki 0.07
    drug3688 Vonoprazan Wiki 0.07
    drug1312 Fiberoptic Endoscopic Evaluation of Swallowing Wiki 0.07
    drug2521 Placebo Comparator Wiki 0.07
    drug2796 Radiation therapy Wiki 0.07
    drug1582 Hypothermia Wiki 0.07
    drug2176 Neuromuscular Blocking Agents Wiki 0.07
    drug1296 Favipiravir Wiki 0.07
    drug908 Convalescent plasma Wiki 0.07
    drug3485 Tocilizumab Wiki 0.07
    drug3231 Standard of care Wiki 0.07
    drug1745 Ivermectin Wiki 0.06
    drug498 Biospecimen Collection Wiki 0.06
    drug2210 No Intervention Wiki 0.06
    drug2556 Placebo oral capsule Wiki 0.06
    drug154 Acalabrutinib Wiki 0.05
    drug4113 standard care Wiki 0.05
    drug2044 Midazolam Wiki 0.04
    drug1913 Lung ultrasound Wiki 0.04
    drug1093 Doxycycline Wiki 0.04
    drug464 Best Practice Wiki 0.04
    drug2855 Remdesivir Wiki 0.04
    drug798 Clazakizumab Wiki 0.04
    drug3815 blood sampling Wiki 0.04
    drug3678 Vitamin D3 Wiki 0.04
    drug3257 Standard treatment Wiki 0.04
    drug963 DAS181 Wiki 0.04
    drug441 Baricitinib Wiki 0.04
    drug776 Chloroquine Wiki 0.04
    drug717 Camostat Mesilate Wiki 0.04
    drug2742 Questionnaire Administration Wiki 0.04
    drug2351 Oseltamivir Wiki 0.04
    drug2752 Questionnaires Wiki 0.04
    drug229 Anakinra Wiki 0.04
    drug518 Blood sample Wiki 0.03
    drug2037 Methylprednisolone Wiki 0.03
    drug1196 Enoxaparin Wiki 0.03
    drug2572 Placebos Wiki 0.02

    Correlated MeSH Terms (36)


    Name (Synonyms) Correlation
    D003141 Communicable Diseases NIH 0.26
    D007239 Infection NIH 0.24
    D055371 Acute Lung Injury NIH 0.18
    Name (Synonyms) Correlation
    D012127 Respiratory Distress Syndrome, Newborn NIH 0.17
    D045169 Severe Acute Respiratory Syndrome NIH 0.16
    D012128 Respiratory Distress Syndrome, Adult NIH 0.16
    D018352 Coronavirus Infections NIH 0.15
    D018450 Disease Progression NIH 0.07
    D009101 Multiple Myeloma NIH 0.07
    D011020 Pneumonia, Pneumocystis NIH 0.07
    D007035 Hypothermia NIH 0.07
    D054219 Neoplasms, Plasma Cell NIH 0.07
    D013577 Syndrome NIH 0.07
    D011014 Pneumonia NIH 0.06
    D012141 Respiratory Tract Infections NIH 0.05
    D003680 Deglutition Disorders NIH 0.05
    D004211 Disseminated Intravascular Coagulation NIH 0.05
    D011024 Pneumonia, Viral NIH 0.05
    D014777 Virus Diseases NIH 0.04
    D011665 Pulmonary Valve Insufficiency NIH 0.04
    D007676 Kidney Failure, Chronic NIH 0.04
    D018357 Respiratory Syncytial Virus Infections NIH 0.04
    D014808 Vitamin D Deficiency NIH 0.04
    D001930 Brain Injuries, NIH 0.03
    D001172 Arthritis, Rheumatoid NIH 0.03
    D007674 Kidney Diseases NIH 0.03
    D017563 Lung Diseases, Interstitial NIH 0.03
    D020141 Hemostatic Disorders NIH 0.03
    D001778 Blood Coagulation Disorders NIH 0.03
    D001168 Arthritis NIH 0.03
    D007251 Influenza, Human NIH 0.03
    D055370 Lung Injury NIH 0.02
    D002318 Cardiovascular Diseases NIH 0.02
    D014947 Wounds and Injuries NIH 0.02
    D001008 Anxiety Disorders NIH 0.02
    D016638 Critical Illness NIH 0.01

    Correlated HPO Terms (12)


    Name (Synonyms) Correlation
    HP:0006775 Multiple myeloma HPO 0.07
    HP:0002090 Pneumonia HPO 0.06
    HP:0005521 Disseminated intravascular coagulation HPO 0.05
    Name (Synonyms) Correlation
    HP:0002015 Dysphagia HPO 0.05
    HP:0010444 Pulmonary insufficiency HPO 0.04
    HP:0001370 Rheumatoid arthritis HPO 0.04
    HP:0000077 Abnormality of the kidney HPO 0.03
    HP:0006515 Interstitial pneumonitis HPO 0.03
    HP:0001369 Arthritis HPO 0.03
    HP:0001928 Abnormality of coagulation HPO 0.03
    HP:0011947 Respiratory tract infection HPO 0.02
    HP:0001626 Abnormality of the cardiovascular system HPO 0.02

    Clinical Trials

    Navigate: Correlations   HPO

    There are 99 clinical trials


    1 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

    REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.

    NCT02735707
    Conditions
    1. Community-acquired Pneumonia, Influenza, COVID-19
    Interventions
    1. Drug: Fixed-duration Hydrocortisone
    2. Drug: Shock-dependent hydrocortisone
    3. Drug: Ceftriaxone
    4. Drug: Moxifloxacin or Levofloxacin
    5. Drug: Piperacillin-tazobactam
    6. Drug: Ceftaroline
    7. Drug: Amoxicillin-clavulanate
    8. Drug: Macrolide administered for 3-5 days
    9. Drug: Macrolide administered for up to 14 days
    10. Drug: Five-days oseltamivir
    11. Drug: Ten-days oseltamivir
    12. Drug: Lopinavir/ritonavir
    13. Drug: Hydroxychloroquine
    14. Drug: Hydroxychloroquine + lopinavir/ritonavir
    15. Drug: Interferon-β1a
    16. Drug: Anakinra
    17. Drug: Fixed-duration higher dose Hydrocortisone
    18. Drug: Tocilizumab
    19. Drug: Sarilumab
    20. Drug: Vitamin C
    21. Drug: Therapeutic anticoagulation
    22. Drug: Simvastatin
    23. Drug: Convalescent plasma
    24. Other: Protocolised mechanical ventilation strategy
    MeSH:Pneumonia
    HPO:Pneumonia

    Primary Outcomes

    Measure: All-cause mortality

    Time: Day 90

    Description: Primary end-point for patients with suspected or proven COVID-19 pandemic infection

    Measure: Days alive and not receiving organ support in ICU

    Time: Day 21

    Secondary Outcomes

    Measure: ICU Mortality

    Time: Day 90

    Measure: ICU length of stay

    Time: Day 90

    Measure: Hospital length of stay

    Time: Day 90

    Measure: Ventilator free days

    Time: Day 28

    Measure: Organ failure free days

    Time: Day 28

    Measure: All-cause mortality

    Time: 6 months

    Description: EQ5D-5L and WHODAS 2.0 (not completed in all regions)

    Measure: Health-related Quality of life assessment

    Time: 6 months

    Measure: Proportion of intubated patients who receive a tracheostomy

    Time: Day 28

    Description: Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital

    Measure: Destination at time of hospital discharge

    Time: Free text Day 90

    Measure: Readmission to the index ICU during the index hospitalization

    Time: Day 90

    Measure: World Health Organisation 8-point ordinal scale outcome

    Time: Hospital discharge

    Other Outcomes

    Description: Antibiotic Domain specific outcome

    Measure: Occurrence of multi-resistant organism colonisation/infection

    Time: Day 90, censored at hospital discharge

    Description: Antibiotic Domain specific outcome

    Measure: Occurrence clostridium difficile

    Time: Day 90, censored at hospital discharge

    Description: Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.

    Measure: Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death

    Time: Day 90, censored at hospital discharge

    Description: Antiviral Domain specific outcome. Only required at selected sites.

    Measure: Change from baseline influenza virus levels in upper and lower respiratory tract specimens

    Time: Day 3, up to Day 7

    Description: COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint

    Measure: Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing)

    Time: Day 90, censored at hospital discharge
    2 Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19

    The study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.

    NCT04261517
    Conditions
    1. Pneumonia, Pneumocystis
    2. Coronavirus
    3. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    MeSH:Pneumonia, Pneumocystis Pneumonia
    HPO:Pneumonia

    Primary Outcomes

    Measure: The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3

    Time: 3 days after randomization

    Measure: The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5

    Time: 5 days after randomization

    Measure: The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7

    Time: 7 days after randomization

    Measure: The mortality rate of subjects at weeks 2

    Time: 14 days after randomization

    Secondary Outcomes

    Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time: 14 days after randomization

    Description: The diagnosis of critical illness case was based on the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4) made by National Health Commission of the People's Republic of China.

    Measure: The critical illness rate of subjects at weeks 2

    Time: 14 days after randomization
    3 Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial

    Study Objective: 1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus. 2. To test if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.

    NCT04308668
    Conditions
    1. Corona Virus Infection
    2. Acute Respiratory Distress Syndrome
    3. SARS-CoV Infection
    4. Coronavirus
    5. Coronavirus Infections
    Interventions
    1. Drug: Hydroxychloroquine
    2. Other: Placebo
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

    Primary Outcomes

    Description: Number of participants at 14 days post enrollment with active COVID19 disease.

    Measure: Incidence of COVID19 Disease among those who are asymptomatic at baseline

    Time: 14 days

    Description: Repeated Measure mixed regression model of change in: Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)

    Measure: Overall change in disease severity over 14 days among those who are symptomatic at baseline

    Time: 14 days

    Secondary Outcomes

    Description: Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease.

    Measure: Incidence of Hospitalization

    Time: 14 days

    Description: Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease.

    Measure: Incidence of Death

    Time: 90 days

    Description: Outcome reported as the number of participants in each arm who have confirmed SARS-CoV-2 infection.

    Measure: Incidence of Confirmed SARS-CoV-2 Detection

    Time: 14 days

    Description: Outcome reported as the number of participants in each arm who self-report symptoms compatible with COVID19 infection.

    Measure: Incidence of Symptoms Compatible with COVID19 (possible disease)

    Time: 90 days

    Description: Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason.

    Measure: Incidence of All-Cause Study Medicine Discontinuation or Withdrawal

    Time: 14 days

    Description: Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)

    Measure: Overall symptom severity at 5 and 14 days

    Time: 5 and 14 days

    Description: Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the percent of participants who fall into each category per arm.

    Measure: Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry

    Time: 14 days
    4 Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)

    Double blinded randomized clinical trial designed to evaluate the security and efficacy of hydroxychloroquine as treatment for COVID-19 severe respiratory disease. The investigators hypothesize that a 400mg per day dose of hydroxychloroquine for 10 days will reduce all-cause hospital mortality in patients with severe respiratory COVID-19 disease.

    NCT04315896
    Conditions
    1. COVID-19
    2. Severe Acute Respiratory Syndrome
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections

    Primary Outcomes

    Description: incidence of all-cause mortality

    Measure: All-cause hospital mortality

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days

    Secondary Outcomes

    Description: Days from ER admission to hospital discharge

    Measure: Length of hospital stay

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days

    Description: need of invasive or non invasive mechanical ventilation

    Measure: Need of mechanical ventilation

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days

    Description: 28 minus days without invasive ventilation support in patients with invasive mechanical ventilation at randomization

    Measure: Ventilator free days

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days

    Description: Adverse Reactions

    Measure: Grade 3-4 adverse reaction

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days
    5 Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults

    This study is a multi-centre, adaptive, randomized, open clinical trial of the safety and efficacy of treatments for COVID-19 in hospitalized adults. The study is a multi-centre/country trial that will be conducted in various sites in Europe with Inserm as sponsor. Adults (≥18 year-old) hospitalized for COVID-19 with SpO2 ≤ 94% on room air OR acute respiratory failure requiring supplemental oxygen or ventilatory support will be randomized between 4 treatment arms, each to be given in addition to the usual standard of care (SoC) in the participating hospital: SoC alone versus SoC + Remdesivir versus SoC + Lopinavir/Ritonavir versus SoC (this treatment arm has been ceased since June 29, 2020) + Lopinavir/Ritonavir plus interferon ß-1a versus SoC (this treatment arm has been ceased since June 29, 2020) + Hydroxychloroquine (this treatment arm has been ceased since May 24, 2020). Randomization will be stratified by European region and severity of illness at enrollment (moderate disease: patients NOT requiring non-invasive ventilation NOR high flow oxygen devices NOR invasive mechanical ventilation NOR ECMO and severe disease: patients requiring non-invasive ventilation OR high flow oxygen devices OR invasive mechanical ventilation OR ECMO). The interim trial results will be monitored by a Data Monitoring Committee, and if at any stage evidence emerges that any one treatment arm is definitely inferior then it will be centrally decided that that arm will be discontinued. Conversely, if good evidence emerges while the trial is continuing that some other treatment(s) should also be being evaluated then it will be centrally decided that one or more extra arms will be added while the trial is in progress. The primary objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19, the primary endpoint is the subject clinical status (on a 7-point ordinal scale) at day 15.

    NCT04315948
    Conditions
    1. Corona Virus Infection
    Interventions
    1. Drug: Remdesivir
    2. Drug: Lopinavir/ritonavir
    3. Drug: Interferon Beta-1A
    4. Drug: Hydroxychloroquine
    5. Other: Standard of care
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Not hospitalized, no limitations on activities Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death.

    Measure: Percentage of subjects reporting each severity rating on a 7-point ordinal scale

    Time: Day 15

    Secondary Outcomes

    Description: Time to an improvement of one category from admission on an ordinal scale. Time to an improvement of two categories from admission on an ordinal scale. Time to discharge (categories 1 or 2 of ordinal scale) from admission. Subject clinical status on an ordinal scale at days 3, 5, 8, 11, and 29. Mean change in the ranking on an ordinal scale from baseline to days 3, 5, 8, 11, 15 and 29 from baseline.

    Measure: Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale

    Time: Days 3, 5, 8, 11, 15 and 29

    Description: • Change from baseline to days 3, 5, 8, 11, 15, and 29 in NEWS.

    Measure: The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.

    Time: Days 3, 5, 8, 11, 15 and 29

    Measure: Number of oxygenation free days in the first 28 days

    Time: 29 days

    Measure: Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.

    Time: 29 days

    Measure: Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.

    Time: 29 days

    Measure: Ventilator free days in the first 28 days

    Time: 29 days

    Measure: Incidence of new mechanical ventilation use during the trial.

    Time: 29 days

    Description: • Duration of hospitalization (days).

    Measure: Hospitalization

    Time: 29 days

    Description: Rate of mortality

    Measure: Mortality

    Time: In hospital, Day 28, Day 90

    Measure: Cumulative incidence of serious adverse events (SAEs)

    Time: 29 days

    Measure: Cumulative incidence of Grade 3 and 4 adverse events (AEs)

    Time: 29 days

    Measure: Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)

    Time: 29 days

    Measure: Changes from baseline in blood white cell count

    Time: 29 days

    Measure: Changes from baseline in haemoglobin

    Time: 29 days

    Measure: Changes from baseline in platelets

    Time: 29 days

    Measure: Changes from baseline in creatinine

    Time: 29 days

    Measure: Changes from baseline in blood electrolytes (including kaliemia)

    Time: 29 days

    Measure: Changes from baseline in prothrombine time

    Time: 29 days

    Measure: Changes from baseline in international normalized ratio (INR)

    Time: 29 days

    Measure: Changes from baseline in glucose

    Time: 29 days

    Measure: Changes from baseline in total bilirubin

    Time: 29 days

    Measure: Changes from baseline in alanine aminotransferase (ALT)

    Time: 29 days

    Measure: Changes from baseline in aspartate aminotransferase (AST)

    Time: 29 days

    Other Outcomes

    Measure: Percent of subjects with SARS-CoV-2 detectable in nasopharyngeal sample

    Time: Days 3, 5, 8, 11, 15, 29

    Measure: Quantitative SARS-CoV-2 virus in nasopharyngeal sample

    Time: Days 3, 5, 8, 11, 15, 29

    Measure: Quantitative SARS-CoV-2 virus in blood

    Time: Days 3, 5, 8 and 11

    Description: On Day 1, plasma concentration 4 hours after the first administration (peak), and before the second administration (trough at H12) On Days 3, 5, 8 and 11, trough plasma concentration (before dose administration) while hospitalized

    Measure: Plasma concentration of lopinavir

    Time: Days 1, 3, 5, 8 and 11

    Description: On Day 1, plasma concentration 4 hours after the first administration (peak), and before the second administration (trough at H12) On Days 3, 5, 8 and 11, trough plasma concentration (before dose administration) while hospitalized

    Measure: Plasma concentration of hydroxychloroquine

    Time: Days 1, 3, 5, 8 and 11
    6 Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial)

    Triple blinded, phase III randomized controlled trial with parallel groups (200mg of hydroxychloroquine per day vs. placebo) aiming to prove hydroxychloroquine's security and efficacy as prophylaxis treatment for healthcare personnel exposed to COVID-19 patients.

    NCT04318015
    Conditions
    1. COVID-19
    2. Severe Acute Respiratory Syndrome
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Severe Acute Respiratory Syndrome Corona Coronavirus Infections

    Primary Outcomes

    Description: Symptomatic infection rate by COVID-19 defined as cough, dyspnea, fever, myalgia, arthralgias or rhinorrhea along with a positive COVID-19 real-time polymerase chain reaction test.

    Measure: Symptomatic COVID-19 infection rate

    Time: From date of randomization until the appearance of symptoms or study completion 60 days after treatment start

    Secondary Outcomes

    Description: Symptomatic infection rate by other non-COVID-19 viral etiologies defined as cough, dyspnea, fever, myalgia, arthralgias or rhinorrhea along with a positive viral real time polymerase chain reaction test.

    Measure: Symptomatic non-COVID viral infection rate

    Time: From date of randomization until the appearance of symptoms or study completion 60 days after treatment start

    Description: Number of days absent from labor due to COVID-19 symptomatic infection

    Measure: Days of labor absenteeism

    Time: From date of randomization until study completion 60 days after treatment start

    Description: Absenteeism from labor rate due to COVID-19 symptomatic infection

    Measure: Rate of labor absenteeism

    Time: From date of randomization until study completion 60 days after treatment start

    Description: Rate of severe respiratory COVID-19 disease in healthcare personnel

    Measure: Rate of severe respiratory COVID-19 disease in healthcare personnel

    Time: From date of randomization until the appearance of symptoms or study completion 60 days after treatment start
    7 Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial

    The purpose of this study is to test the hypothesis that post-exposure prophylaxis with hydroxychloroquine will reduce the symptomatic secondary attack rate among household contacts of known or suspected COVID-19 patients.

    NCT04318444
    Conditions
    1. COVID-19
    2. Corona Virus Infection
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: This is defined as either 1. COVID-19 infection confirmed within 14 days of enrollment, following self-report of COVID-19 symptoms to the research study; OR, 2. COVID-19 infection confirmed within 14 days of enrollment, with self-report of COVID-19 symptoms to a treating physician.

    Measure: Number of participants with symptomatic, lab-confirmed COVID-19.

    Time: Date of enrollment to 14 days post-enrollment date
    8 Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients

    The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized infectious disease of the respiratory tract. Around 20% of those infected have severe pneumonia and currently there is no specific or effective therapy to treat this disease. Therapeutic options using malaria drugs chloroquine and hydroxychloroquine have shown promising results in vitro and in vivo test. But those efforts have not involved large, carefully-conducted controlled studies that would provide the global medical community the proof that these drugs work on a significant scale. In this way, the present study will evaluate the effectiveness and safety of the use of hydroxychloroquine combined with azithromycin compared to hydroxychloroquine monotherapy in patients hospitalized with pneumonia by SARS-CoV2 virus.

    NCT04321278
    Conditions
    1. Coronavirus Infections
    2. Pneumonia, Viral
    Interventions
    1. Drug: Hydroxychloroquine + azithromycin
    2. Drug: Hydroxychloroquine
    MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia
    HPO:Pneumonia

    Primary Outcomes

    Description: Evaluation of the clinical status of patients on the 15th day after randomization defined by the Ordinal Scale of 6 points (score ranges from 1 to 6, with 6 being the worst score)

    Measure: Evaluation of the clinical status

    Time: 15 days after randomization

    Secondary Outcomes

    Description: All-cause mortality rates at 29 days after randomization

    Measure: All-cause mortality

    Time: 29 days after randomization

    Description: Evaluation of the clinical status of patients on the 7th and 29th day after randomization defined by the Ordinal Scale of 6 points (score ranges from 1 to 6, with 6 being the worst score)

    Measure: Evaluation of the clinical status

    Time: 7 and 29 days after randomization

    Description: Number of days free from mechanical ventilation at 29 days after randomization

    Measure: Number of days free from mechanical ventilation

    Time: 29 days after randomization

    Description: Number of days that the patient was on mechanical ventilation after randomization

    Measure: Duration of mechanical ventilation

    Time: 29 days after randomization

    Description: Length of hospital stay on survivors

    Measure: Duration of hospitalization

    Time: 29 days after randomization

    Description: Presence of other secondary infections

    Measure: Other secondary infections

    Time: 29 days after randomization

    Description: Time from treatment start to death

    Measure: Time from treatment start to death

    Time: 29 days after randomization

    Description: Morbimortality, daily life activities, mental health, and quality of life

    Measure: Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life

    Time: 3, 6, 9 and 12 months

    Description: Leucocyte transcriptome

    Measure: Assess whether the tested therapies may be affected by leucocyte phenotype

    Time: Baseline

    Other Outcomes

    Description: Occurrence of QT interval prolongation

    Measure: QT interval prolongation

    Time: 29 days after randomization

    Description: Occurrence of gastrointestinal intolerance

    Measure: Gastrointestinal intolerance

    Time: 29 days after randomization

    Description: Occurrence of laboratory hematimetric parameters, creatinine and bilirubin

    Measure: Laboratory abnormalities

    Time: 29 days after randomization

    Description: Occurrence of adverse events related to the use of the investigational products

    Measure: Adverse events

    Time: 29 days after randomization
    9 The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients

    The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients diagnosed with COVID-19. This trial will follow the core WHO protocol but has additional efficacy, safety and explorative endpoints.

    NCT04321616
    Conditions
    1. SARS-CoV Infection
    2. COVID 19
    3. Acute Respiratory Distress Syndrome ARDS
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Remdesivir
    3. Other: (Standard of Care) SoC
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

    Primary Outcomes

    Description: All cause in-hospital mortality

    Measure: In-hospital mortality

    Time: 3 weeks

    Secondary Outcomes

    Measure: Occurrence and duration of mechanical ventilation

    Time: 3 weeks

    Measure: Occurrence and duration of intensive care unit (ICU) treatment

    Time: 3 weeks

    Measure: Duration of hospital admittance

    Time: 1 month

    Measure: 28 Day mortality

    Time: 3 weeks

    Measure: Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen

    Time: 3 weeks

    Measure: Occurrence of co-infections

    Time: 3 weeks

    Measure: Occurrence of organ dysfunction

    Time: 3 months

    Other Outcomes

    Measure: Inflammatory and anti-inflammatory mediators as assessed in serum and plasma

    Time: Throughout hospitalization

    Measure: Markers of extracellular matrix remodeling

    Time: Throughout hospitalization and 3 months after remission

    Measure: Markers of endothelial activation

    Time: Throughout hospitalization

    Measure: Markers of platelet activation

    Time: Throughout hospitalization
    10 Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19

    This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.

    NCT04322396
    Conditions
    1. Virus Diseases
    2. Infection Viral
    3. Corona Virus Infection
    Interventions
    1. Drug: Azithromycin
    2. Drug: Hydroxychloroquine
    3. Drug: Placebo oral tablet
    4. Drug: Placebo oral tablet
    MeSH:Infection Communicable Diseases Virus Diseases Coronavirus Inf Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Measure: Number of days alive and discharged from hospital within 14 days

    Time: 14 days

    Secondary Outcomes

    Description: The patient will becategorized into one of the following 8 categories depending on status of their hospitalization: Dead (yes/no) Hospitalized and receiving mechanical ventilation or ExtraCorporalMembraneOxygenation (ECMO) (yes/no) Hospitalized and receiving Non-invasive ventilation or "high-flow oxygen device" (yes/no) Hospitalized and given oxygen supplements different from (2) and (3) (yes/no) Hospitalized and without oxygen treatment, but receiving other treatment (both related to COVID-19 or other) (yes/no) Hospitalized for observation (yes/no) Discharged from hospital with restriction of activity level (yes/no) Discharged from hospital without any restrictions of activity level (yes/no) Only one category can be "yes".

    Measure: Categorization of hospitalization status

    Time: 14 days

    Measure: Admitted to intensive care unit, if admitted to ICU then length of stay

    Time: 14 days

    Measure: Have used Non-invasive ventilation (NIV) during hospitalization

    Time: 14 days

    Measure: Mortality

    Time: 30 days

    Measure: Length of hospitalization

    Time: 14 days

    Measure: Days alive and discharged from hospital

    Time: 30 days

    Measure: Mortality

    Time: 90 days

    Measure: Mortality

    Time: 365 days

    Measure: Number of readmissions (all causes)

    Time: 30 days

    Measure: Number of days using non-invasive ventilation (NIV)

    Time: 14 days

    Description: Delta PaO2 measured in arterial puncture

    Measure: Change in patient's oxygen partial pressure

    Time: 4 days

    Description: Delta PaCO2 measured in arterial puncture

    Measure: Change in patient's carbondioxid partial pressure

    Time: 4 days

    Description: pH measured in arterial puncture

    Measure: Level of pH in blood

    Time: 4 days

    Measure: Time for no oxygen supplement (or regular oxygen supplement "LTOT")

    Time: 14 days
    11 Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

    This is a multi-center, randomized controlled, superiority, open label trial. The objective of this trial is to evaluate the efficacy of HCQ in patients with newly diagnosed COVID-19 who have mild to moderate disease or at risk for complications. We aim to demonstrate decrease in progression to severe pneumonia and hospital related complications among patients who are treated with HCQ compared to patients who are not.

    NCT04323631
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Other: The control group will not receive hydroxychloroquine
    MeSH:Infection Disease Progression

    Primary Outcomes

    Description: Number patients developing severe infection or death

    Measure: Number patients developing severe infection or death

    Time: within 28 days
    12 Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study

    A new human coronavirus responsible for pneumonia, SARS-CoV-2, emerged in China in December 2019 and has spread rapidly. COVID-19, the disease caused by this virus, has a very polymorphous clinical presentation, which ranges from upper respiratory tract infections to acute respiratory distress syndrome. It may appear serious straightaway or may evolve in two stages, with a worsening 7 to 10 days after the first clinical signs, potentially linked to a cytokine storm and accompanied by a high risk of thrombosis. The global mortality rate of COVID-19 is between 3% and 4%, with severe forms being more frequent among older patients. Management is symptomatic as no antiviral treatment has demonstrated any clinical benefit in this condition. Hydroxychloroquine is a derivative of chloroquine commonly used in some autoimmune diseases, such as systemic lupus erythematosus. It is active in vitro in cellular models of infection by many viruses such as HIV, hepatitis C or SARS-CoV. However, its interest in viral infections in humans has not been demonstrated. Very recently, a preliminary uncontrolled study evaluated the effect of hydroxychloroquine on viral shedding in subjects with COVID-19. Among 20 patients treated with hydroxychloroquine at a dose of 600 mg per day, the percentage of patients with detectable SARS-CoV-2 RNA in the nasopharynx decreased from 100% at inclusion (start of treatment) to 43% six days later. In comparison, 15 of 16 untreated patients had a positive RT-PCR six days after inclusion. Furthermore, hydroxychloroquine has immunomodulating and anti-inflammatory properties, which could theoretically prevent or limit secondary worsening. The research hypothesis is that treatment with hydroxychloroquine improves prognosis and reduces the risk of death or use for invasive ventilation in patients with COVID-19.

    NCT04325893
    Conditions
    1. Coronavirus
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo
    MeSH:Coronavirus Infections

    Primary Outcomes

    Measure: Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.

    Time: Day 14

    Secondary Outcomes

    Measure: Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.

    Time: Day 28

    Description: WHO Ordinal Scale for Clinical Improvement ranges from 0 to 8, higher score meaning poorer outcome

    Measure: Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14

    Time: Day 14

    Description: WHO Ordinal Scale for Clinical Improvement ranges from 0 to 8, higher score meaning poorer outcome

    Measure: Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.

    Time: Day 28

    Measure: Number of all-cause mortality at day 14

    Time: Day 14

    Measure: Number of all-cause mortality at day 28

    Time: Day 28

    Measure: Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5

    Time: Day 5

    Measure: Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10

    Time: Day 10

    Measure: The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.

    Time: Day 28

    Measure: Number of all-cause mortality at day 28 in patients aged 75 and older

    Time: day 28

    Measure: Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older

    Time: day 28

    Measure: Rate of severe adverse events at day 28

    Time: day 28

    Measure: Number of all-cause mortality at day 14 in patients aged 75 and older

    Time: day 14
    13 Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial

    Since December 2019, the emergence of a new coronavirus named SARS-Cov-2 in the city of Wuhan in China has been responsible for a major epidemic of respiratory infections, including severe pneumonia. Within weeks, COVID-19 became a pandemic. In the absence of specific antiviral treatment, a special attention should be given to prevention. Personal protection equipments may be insufficiently protective, including in healthcare workers, a significant proportion of whom (around 4%) having been infected in the outbreaks described in China and more recently in Italy. Infection in healthcare workers could result from the contact with COVID-19 people in community or with infected colleagues or patients. As it will take at least a year before vaccines against SARS-CoV-2 becomes available, chemoprophylaxis is an option that should be considered in this setting where prevention of SARS-CoV-2 infection in Health Care Workers. The COVIDAXIS trial evaluates a chemoprophylaxis of SARS-CoV-2 infection in Health Care Workers. This trial is divided into two distinct studies that could start independently each with its own randomization process: COVIDAXIS 1 will study Hydroxychloroquine (HCQ) versus placebo; COVIDAXIS 2 will study Lopinavir/ritonavir (LPV/r) versus placebo. Upon randomization healthcare workers (HCWs) involved in the management of suspected or confirmed COVID-19 cases will be assigned to one of the following 2 treatment groups:

    NCT04328285
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo of Hydroxychloroquine
    3. Drug: Lopinavir and ritonavir
    4. Drug: Placebo of LPV/r Tablets
    MeSH:Infection

    Primary Outcomes

    Description: An infection by SARS-CoV-2 is defined by either: a positive specific Reverse Transcription - Polymerase Chain Reaction (RT-PCR) on periodic systematic nasopharyngeal swab during follow-up OR a positive specific RT-PCR on a respiratory sample in case of onset of symptoms consistent with COVID-19 during follow-up OR a seroconversion to SARS-CoV-2 after randomization.

    Measure: Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)

    Time: Up to 2.5 months

    Secondary Outcomes

    Description: Number of adverse events expected or unexpected, related and unrelated to the treatment, notably grades 2, 3 and 4 (moderate, severe and lifethreatening, according to the Adverse National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0) in each arm.

    Measure: Evaluation of the occurrence of adverse events in each arm,

    Time: Up to 2.5 months

    Description: Number of treatment discontinuations in each arm

    Measure: Evaluation of the discontinuation rates of the investigational drug in each arm,

    Time: Up to 2 months

    Description: Treatment adherence rate will be assessed by: measurement of LPV and HCQ plasma concentrations using LC-MS/MS or LC-Fluorimetric detection the count of returned drugs at each visit.

    Measure: Evaluation of the adherence of participants to study drug,

    Time: Up to 2 months

    Description: Number of incident cases of symptomatic SARS-CoV-2 infections among HCWs in each arm. Symptomatic infection is defined as : a positive specific RT-PCR on a respiratory or non respiratory sample OR a thoracic CT scan with imaging abnormalities consistent with COVID-19. These investigations being performed in case of signs/symptoms consistent with COVID-19 during follow-up.

    Measure: Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,

    Time: Up to 2.5 months

    Description: Number of incident cases of asymptomatic SARS-CoV-2 infection among HCWs in each randomization arm. Asymptomatic infection is defined as : a positive specific RT-PCR on periodic systematic nasopharyngeal swab during clinical follow-up without consistent clinical signs/symptoms during follow-up OR as seroconversion to SARS-CoV-2 between start and end of the study in HCWs that did not reported any consistent clinical symptoms during follow-up

    Measure: Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm

    Time: Up to 2.5 months

    Description: Number of incident cases of severe SARS-CoV-2 infections among HCWs in each randomization arm, defined as : a positive specific RT-PCR on a respiratory sample OR a thoracic CT scan with imaging abnormalities consistent with COVID-19 performed in case of onset of symptoms consistent with COVID-19 during follow-up in a participant who need to be hospitalized for respiratory distress. Respiratory distress defined as dyspnea with a respiratory frequency > 30/min, blood oxygen saturation <93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio <300 and/or lung infiltrates >50% (1).

    Measure: Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.

    Time: Up to 2.5 months

    Description: Safety. Electrocardiogram (ECG)

    Measure: corrected QT interval (ms)

    Time: At baseline, at D2 (only for COVIDAXIS 1) and every week up to 2 months.
    14 Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial

    Objective: To determine if pre-exposure prophylaxis with hydroxychloroquine is effective for the prevention of COVID-19 disease.

    NCT04328467
    Conditions
    1. COVID-19
    2. Corona Virus Infection
    3. ARDS
    4. Acute Respiratory Distress Syndrome
    Interventions
    1. Drug: Hydroxychloroquine
    2. Other: Placebo
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

    Primary Outcomes

    Description: Outcome reported as the percent of participants in each arm who are COVID-19-free at the end of study treatment.

    Measure: COVID-19-free survival

    Time: up to 12 weeks

    Secondary Outcomes

    Description: Outcome reported as the percent of participants in each arm who have a confirmed SARS-CoV-2 infection during study treatment.

    Measure: Incidence of confirmed SARS-CoV-2 detection

    Time: up to 12 weeks

    Description: Outcome reported as the percent of participants in each arm who report COVID-19-related symptoms during study treatment.

    Measure: Incidence of possible COVID-19 symptoms

    Time: up to 12 weeks

    Description: Outcome reported as the percent of participants in each arm who discontinue study medication use for any reason during treatment.

    Measure: Incidence of all-cause study medicine discontinuation

    Time: up to 12 weeks

    Description: Participants will self-report COVID-19 status on an ordinal scale as follows: No illness (score=1), Illness with outpatient observation (score=2), Hospitalization (or post-hospital discharge) (score=3), or Hospitalization with ICU stay or death (score=4). Possible scores range from 1-4 with higher scores indicating greater disease severity.

    Measure: Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end

    Time: up to 12 weeks

    Description: Outcome reported as the percent of participants in each arm who are hospitalized or expire due to COVID-19 during study treatment.

    Measure: Incidence of Hospitalization for COVID-19 or death

    Time: up to 12 weeks

    Description: Outcome reported as the percent of participants in each arm who experience medication-related side effects during study treatment.

    Measure: Incidence of study medication-related side effects

    Time: up to 12 weeks
    15 A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.

    Albertans with COVID-19 are at risk of deteriorating and developing severe illness. Those over age 40 or with co-morbid illness, and likely those who are immune suppressed, are at highest risk. This study will include a focus on people with immune-suppressed states. Individuals confirmed to have SARS-CoV-2 infection will be identified using administrative data (positive lab result, age 18 or over, not hospitalized, and not living in SL4 level of care). They will then be contacted by AHS staff, independent of the researchers, to obtain their consent for the researchers to contact them about this trial. The AHS staff member who contacts the individual will enroll consenting individuals into a study database. If they provided an email address an email will automatically be sent to the individual with study information. Those who decline to be contacted will also be informed of the study website so they can choose to review the study information and self-enrol, although they will need to do so quickly to meet study timelines. Enrolled participants will be contacted by a study coordinator. Those without access to the internet will be informed about the study details when they are contacted by a study coordinator. When the study coordinator contacts potential participants the study will be reviewed, and the potential participant will have an opportunity to ask questions. Consent for participation will be obtained by telephone. Telephone consent will be recorded. Participants will then be screened for inclusion and exclusion criteria by telephone interview and review of Alberta Netcare. Alberta Netcare is the province of Alberta's public Electronic Health Record used to store patient information so that it is easily accessible to healthcare professionals for the purpose of care. Information like immunizations, ECG results, diagnostic images and reports, written medical reports (e.g. surgery reports, consultations, hospital admissions), diagnostic lab testing results (e.g. blood tests, urine tests, blood bank info), allergies and intolerances (drug and food allergies, food intolerances), prescription history, and general patient information (e.g. name, birthdate, personal health number, address, phone number). Those who are not eligible for the study will be informed of the reason(s) for ineligibility (generally it will be a safety exclusion and they should be aware of this). Those who are eligible will be randomized to receive HCQ or placebo for a total duration of 5 days. Study drug will be delivered to their residence by courier. Telephone follow-up will occur at day 7 (range 7-10 days) and at day 30 (range 25-35 days).

    NCT04329611
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine

    Primary Outcomes

    Description: The aim of this intervention is to prevent severe COVID-19 disease. This trial aims to confirm that severe COVID-19 disease can be reduced by a relative risk reduction of 50% by the use of hydroxychloroquine.The aim of this intervention is to prevent severe COVID-19 disease. This trial aims to confirm that severe COVID-19 disease can be reduced by a relative risk reduction of 50% by the use of hydroxychloroquine.The aim of this intervention is to prevent severe COVID-19 disease. This trial aims to confirm that severe COVID-19 disease can be reduced by a relative risk reduction of 50% by the use of hydroxychloroquine.

    Measure: Composite of hospitalization, invasive mechanical ventilation or death within 30 days

    Time: Within 30 days of randomization

    Secondary Outcomes

    Description: Mortality within 30 days of randomization

    Measure: mortality

    Time: Within 30 days of randomization

    Description: defined as the number of days from randomization to complete symptom resolution, based on public health follow-up and day 7 and day 30 telephone interview (continuous)

    Measure: Symptom duration

    Time: Within 30 days of randomization

    Description: Disposition of the patient at the Day 30 telephone followup

    Measure: Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased (categorical)

    Time: Within 30 days of randomization
    16 Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial

    This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19.

    NCT04329832
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin

    Primary Outcomes

    Description: Per https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf, this scale reflects a range from uninfected to dead, where 0 is "no clinical or virological evidence of infection", 1 is "no limitation of activities", 2 is "limitation of activities", 3 is "hospitalized, no oxygen therapy", 4 is "oxygen by mask or nasal prongs", 5 is "non-invasive ventilation or high-flow oxygen", 6 is "intubation and mechanical ventilation", 7 is "ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)", and 8 is "death".

    Measure: COVID Ordinal Outcomes Scale at 14 days

    Time: Assessed once on day 14 after enrollment (enrollment is day 0)

    Secondary Outcomes

    Description: Calculated as a worst-rank ordinal (death is counted as -1 days).

    Measure: Hospital-free days at 28 days (number of days patient not in hospital)

    Time: Admission (day 1) to 28 days after admission (day 28)

    Description: Calculated as a worst-rank ordinal (death is counted as -1 days).

    Measure: Ventilator-free days at 28 days (number of days patient not on a ventilator)

    Time: Admission (day 1) to 28 days after admission (day 28)

    Description: Calculated as a worst-rank ordinal (death is counted as -1 days).

    Measure: ICU-free days at 28 days (number of days patient not in an ICU)

    Time: Admission (day 1) to 28 days after admission (day 28)

    Measure: Time to a 1-point decrease in the WHO ordinal recovery score

    Time: Admission (day 1) to 14 days after admission (day 14)
    17 A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)

    This study is an adaptive, randomized, open-label, controlled clinical trial, in collaboration with countries around the world through the World Health Organization. Subjects will be randomized to receive either standard-of-care products or the study medication plus standard of care, while being hospitalized for COVID-19. Participants will be randomized to one of the following groups: 1. Lopinavir/ritonavir 400mg/100mg PO BID for 14 day plus optimized supportive care, OR 2. Hydroxychloroquine 800mg BID for 1 day then 400mg BID for 10 days plus optimized supportive care, OR 3. Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care, OR 4. Optimized support care all or until discharge from hospital, whichever occurs first

    NCT04330690
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Lopinavir/ritonavir
    2. Drug: Hydroxychloroquine
    3. Drug: remdesivir

    Primary Outcomes

    Description: All-cause mortality, assessed at hospital discharge.

    Measure: Efficacy of Interventions as assessed by all-cause mortality

    Time: 29 days

    Secondary Outcomes

    Description: Measure with Ordinal Scale the time it takes for subject improvement

    Measure: Time to improvement of one category from admission

    Time: up to 60 days

    Description: Subject clinical status at days 3, 5, 8, 11, 15, 29, 60 measured using the ordinal scale below: The scale is as below 0: Uninfected, no viral RNA Asymptomatic, viral RNA detected Symptomatic, independent Symptomatic, Assistance Needed Hospitalized: no oxygen therapy Hospitalized, on oxygen Hospitalized, Oxygen by NIV or high-flow Mechanical ventilation, p/f>150 or s/f >200 Mechanical ventilation, p/f<150 or s/f<200 OR vasopressors mechanical ventilation, p/f<150 AND vasopressors, dialysis, or ECMO death

    Measure: Subject clinical status

    Time: up to 60 days

    Description: Mean change in the ranking from baseline to days 3, 5, 8, 11, 15, 29, 60 using the ordinal scale below: The scale is as below 0: Uninfected, no viral RNA Asymptomatic, viral RNA detected Symptomatic, independent Symptomatic, Assistance Needed Hospitalized: no oxygen therapy Hospitalized, on oxygen Hospitalized, Oxygen by NIV or high-flow Mechanical ventilation, p/f>150 or s/f >200 Mechanical ventilation, p/f<150 or s/f<200 OR vasopressors mechanical ventilation, p/f<150 AND vasopressors, dialysis, or ECMO death

    Measure: Change in Subject clinical status

    Time: up to 60 days

    Description: the number of oxygen free days experienced

    Measure: Oxygen free days

    Time: up to 29 days

    Description: if the subject required oxygen during hospitalization

    Measure: Incidence of oxygen use

    Time: up to 29 days

    Description: if the subject required oxygen, for how long was it required

    Measure: Duration of oxygen use

    Time: up to 29 days

    Description: if the subject required mechanical ventilation during hospitalization

    Measure: Incidence of new mechanical ventilation

    Time: up to 29 days

    Description: if the subject required mechanical ventilation, for how long was it required

    Measure: Duration of mechanical ventilation

    Time: up to 29 days

    Description: the length of hospitalization required

    Measure: Duration of hospitalization

    Time: up to 29 days

    Description: Mortality rates calculated at day 15, 29, and 60.

    Measure: Mortality

    Time: up to 60 days

    Description: The safety of the intervention will be evaluated during the trial period as compared to the control arm as assessed by the cumulative incidence of Grade 3 and 4 AEs and SAEs using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Paediatric Adverse Events, version 2.1 (July 2017).

    Measure: Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time: up to 30 days after last dose of drug adminstration

    Other Outcomes

    Description: To evaluate the virologic efficacy of lopinavir/ritonavir, hydroxychloroquine, or remdesivir as compared to the control arm as assessed by the percent of subjects with SARS-CoV-2 detectable in OP sample at days 3, 5, 8, 11, 15, and 29

    Measure: Time to viral clearance of lopinavir/ritonavir as compared to the control arm

    Time: up to 29 days
    18 Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Multicentre, Double-Blinded Randomized Controlled Trial

    The investigators aim to evaluate the efficacy of pre-exposure prophylaxis with hydroxychloroquine in healthcare workers with high-risk of SARS-CoV-2 infection.

    NCT04331834
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebos

    Primary Outcomes

    Description: Confirmed cases of a COVID-19 (defined by a positive PCR for SARS-CoV-2 or symptoms compatible with COVID-19 with seroconversion) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative PCR for SARS-CoV-2 on day 0 and negative serology for SARS-CoV-2 on day 0.

    Measure: Confirmed cases of a COVID-19

    Time: Up to 6 months after start of treatment

    Secondary Outcomes

    Description: SARS-CoV-2 seroconversion in the PrEP group compared to placebo in during 6 months of follow-up in healthcare workers with negative serology at day 0.

    Measure: SARS-CoV-2 seroconversion

    Time: Up to 6 months after start of treatment

    Description: Incidence of clinical and/or laboratory adverse events will be compared in the PrEP group and in the placebo arm.

    Measure: Occurrence of any adverse event related with hydroxychloroquine treatment

    Time: Up to 6 months after start of treatment

    Description: Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers will be estimated by the number of healthcare workers diagnosed with COVID-19 in the placebo group, among the total of healthcare workers included in the non-PrEP group during the study period.

    Measure: Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers

    Time: Up to 6 months after start of treatment

    Measure: Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19

    Time: Up to 6 months after start of treatment

    Description: A repository (biobank) of serum samples obtained from healthcare workers confirmed COVID-19 cases for future research on blood markers to predict SARS-CoV-2 infection.

    Measure: COVID-19 Biobank

    Time: Up to 6 months after start of treatment
    19 Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)

    COVID-19 is a respiratory disease caused by the new coronavirus (SARS-CoV-2) and causes considerable morbidity and mortality. Currently, there is no vaccine or therapeutic agent to prevent and treat a SARS-CoV-2 infection. This clinical trial is designed to evaluate the use of Tocilizumab in combination with hydroxychloroquine and azithromycin for the treatment of hospitalized adult patients with COVID-19.

    NCT04332094
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Tocilizumab
    2. Drug: Hydroxychloroquine
    3. Drug: Azithromycin

    Primary Outcomes

    Measure: In-hospital mortality

    Time: Through hospitalization, an average of 2 weeks

    Measure: Need for mechanical ventilation in the Intensive Care Unit

    Time: Through hospitalization, an average of 2 weeks
    20 Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease

    ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study personnel will all be blinded to study group assignment.

    NCT04332991
    Conditions
    1. Coronavirus
    2. Acute Respiratory Infection
    3. SARS-CoV Infection
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: We will determine the COVID Ordinal Scale for all patients on study day 15 COVID Ordinal Scale defined as: Death Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation) Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)

    Measure: COVID Ordinal Outcomes Scale on Day 15

    Time: assessed on study day 15

    Secondary Outcomes

    Description: Vital status of the patient on day 15 will be determined using any of the following methods: medical record review, phone calls to patient or proxy

    Measure: all-location, all-cause mortality assessed on day 15

    Time: assessed on study day 15

    Description: Vital status of the patient at day 28 will be determined using any of the following methods: medical record review, phone calls to patient or proxy

    Measure: all-location, all-cause mortality assessed on day 29

    Time: assessed on study day 29

    Description: We will determine the COVID Ordinal Scale for all patients on study day 3

    Measure: COVID Ordinal Outcomes Scale on Study Day 3

    Time: assessed on study day 3

    Description: We will determine the COVID Ordinal Scale on study day 8

    Measure: COVID Ordinal Outcomes Scale on Study Day 8

    Time: assessed on study day 8

    Description: We will determine the COVID Ordinal Scale on study day 29

    Measure: COVID Ordinal Outcomes Scale on Study Day 29

    Time: assessed on study day 29

    Description: We will determine the number of patients who are either dead or on ECMO ( extracorporeal membrane oxygenation) between enrollment and day 28

    Measure: Number of patients dead or with receipt of ECMO between enrollment and Day 28

    Time: Enrollment to Day 28

    Description: The number of calendar days between randomization and 28 days later that the patient is alive and without the use of oxygen therapy. Patients who die prior to day 28 are assigned zero oxygen free days.

    Measure: Oxygen-free days through Day 28

    Time: 28 days after randomization

    Description: Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days.

    Measure: Ventilator-free days through Day 28

    Time: 28 days after randomization

    Description: The number of calendar days between randomization and 28 days later that the patient is alive and without the use of vasopressor therapy. Patients who die prior to day 28 are assigned zero vasopressor free days.

    Measure: Vasopressor-free days through Day 28

    Time: 28 days after randomization

    Description: The number of days spent out of the ICU to day 28.

    Measure: ICU-free days to Day 28

    Time: 28 days after randomization

    Description: Defined as 28 days minus the number of days from randomization to discharge home.If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero.

    Measure: Hospital-free days to Day 28

    Time: 28 days after randomization

    Other Outcomes

    Description: We will determine the number of patients that experience seizure between randomization and day 28

    Measure: Number of patients with seizures to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience ventricular arrhythmia between randomization and day 28

    Measure: Number of patients with atrial or ventricular arrhythmia to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience cardiac arrest between randomization and day 28

    Measure: Number of patients with cardiac arrest to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience elevation in aspartate aminotransferase or alanine aminotransferase to twice the local upper limit of normal between randomization and day 28

    Measure: Number of patients with elevation in aspartate aminotransferase or alanine aminotransferase to twice the local upper limit of normal to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience acute pancreatitis between randomization and day 28

    Measure: Number of patients with acute pancreatitis arrest to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience acute kidney injury between randomization and day 28

    Measure: Number of patients with acute kidney injury to day28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience renal replacement therapy between randomization and day 28

    Measure: Number of patients with receipt of renal replacement therapy to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience symptomatic hypoglycemia between randomization and day 28

    Measure: Number of patients with symptomatic hypoglycemia to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience neutropenia, lymphopenia, anemia, or thrombocytopenia between randomization and day 28

    Measure: Number of patients with neutropenia, lymphopenia, anemia, or thrombocytopenia to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience severe dermatologic reaction between randomization and day 28

    Measure: Number of patients with severe dermatologic reaction to day 28

    Time: 28 days after randomization

    Description: Time to recovery, defined as time to reaching level 5, 6, or 7 on the COVID Outcomes Scale, which is the time to the earlier of final liberation from supplemental oxygen or hospital discharge

    Measure: Time to recovery, defined as time to reaching level 5, 6, or 7 on the COVID Outcomes Scale, which is the time to the earlier of final liberation from supplemental oxygen or hospital discharge

    Time: 28 days after randomization
    21 A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures

    In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with COVID-19 will be tested for COVID-19 infection via nasopharyngeal (NP) swab once weekly for 7 weeks. Of those, one hundred eighty (180) will receive weekly doses of hydroxychloroquine for the duration of the study. Subjects who opt not to receive the study drug will form the control group.

    NCT04333225
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    MeSH:Infection

    Primary Outcomes

    Description: Rate of COVID-19 positive conversion on weekly nasopharyngeal (NP) sampling

    Measure: Rate of COVID-19 positive conversion

    Time: 7 weeks

    Secondary Outcomes

    Description: Time-to-first clinical event consisting of a persistent change for any of the following: One positive NP sample Common clinical symptoms of COVID-19 infection including fever, cough, and shortness of breath Less common signs and symptoms of COVID-19 infection including headache, muscle pain, abdominal pain, sputum production, and sore throat

    Measure: Time-to-first clinical event

    Time: 7 weeks

    Other Outcomes

    Description: Time-to-first clinical worsening event consisting of any of the following: Hospitalization for COVID-19 infection Intensive care unit admission for COVID-19 infection All cause death

    Measure: Time-to-first clinical worsening event

    Time: 7 weeks
    22 Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)

    This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19. Eligible participants will be randomly assigned (1:1) to either treatment group (HCQ) or placebo in a double-blind fashion. Course of treatment is 30 days.

    NCT04334148
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: Number of participants with clinical infection with COVID-19 infection(hydroxychloroquine vs placebo)

    Measure: Number of participants with clinical infection with COVID-19 infection

    Time: 30 days

    Secondary Outcomes

    Description: Number of participants with COVID-19 infection shedding (hydroxychloroquine vs placebo)

    Measure: Number of participants with COVID-19 viral shedding

    Time: 30 days

    Description: Safety as measured by number of adverse events (hydroxychloroquine vs placebo)

    Measure: Safety as measured by number of adverse events

    Time: 30 days
    23 Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial

    This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating outpatients with suspected or confirmed COVID-19.

    NCT04334382
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin

    Primary Outcomes

    Description: Admitted to a hospital (not merely kept for emergency room observation)

    Measure: Hospitalization within 14 days of enrollment

    Time: From enrollment to 14 days after enrollment

    Secondary Outcomes

    Measure: Duration of COVID-19-attributable symptoms

    Time: From enrollment to 14 days after enrollment

    Description: Hospital-free days at 28 days (number of days patient not in hospital); calculated as worst-rank ordinal with mortality by day 28 assigned the worst score

    Measure: Hospital-free days at 28 days

    Time: Admission (day 1) to 28 days after admission (day 28)

    Description: Ventilator-free days at 28 days (number of days patient not on a ventilator); calculated as worst-rank ordinal with mortality by day 28 assigned the worst score

    Measure: Ventilator-free days at 28 days

    Time: Admission (day 1) to 28 days after admission (day 28)

    Description: ICU-free days at 28 days, calculated as worst-rank ordinal with mortality by day 28 assigned the worst score

    Measure: ICU-free days at 28 days

    Time: Admission (day 1) to 28 days after admission (day 28)
    24 A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection

    This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).

    NCT04334512
    Conditions
    1. COVID-19
    2. Corona Virus Infection
    3. Coronavirus-19
    4. Sars-CoV2
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin
    3. Dietary Supplement: Vitamin C
    4. Dietary Supplement: Vitamin D
    5. Dietary Supplement: Zinc
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Number of days from COVID-19 diagnosis to recovery via RT-PCR

    Measure: The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy

    Time: 12 weeks

    Description: Reduction and/or progression of symptomatic days, reduction of symptom severity

    Measure: Reduction or Progression of Symptomatic Days

    Time: 12 weeks

    Description: Assess the symptom response to study therapy as measured by the survey in the EDC

    Measure: Assess the safety of Quintuple Therapy

    Time: 12 weeks

    Description: Pulse from baseline to 12 weeks

    Measure: Assess the safety of Quintuple Therapy via pulse

    Time: 12 weeks

    Description: Oxygen saturation from baseline to 12 weeks

    Measure: Assess the safety of Quintuple Therapy via oxygen saturation

    Time: 12 weeks

    Description: EKG response from baseline to 12 weeks

    Measure: Assess the safety of Quintuple Therapy via EKG

    Time: 12 weeks

    Description: Assess Adverse Events and Serious Adverse Events due to Quintuple Therapy

    Measure: Assess Tolerability of Quintuple Therapy

    Time: 12 weeks
    25 Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo

    Healthcare workers are particularly at risk of SARS-CoV-2. This study aims to assess the efficacy of a daily single dose of tenofovir disoproxil fumarate (TDF) (245 mg)/ Emtricitabine (FTC) (200 mg), a daily single dose of hydroxychloroquine (HC) (200 mg), a daily single dose of TDF (245 mg)/FTC (200 mg) plus HC (200 mg) versus placebo, during 12 weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing clinical severity COVID-19 among hospital healthcare workers aged 18 to 70 years in public and private hospitals in Spain.

    NCT04334928
    Conditions
    1. Coronavirus Infection
    Interventions
    1. Drug: Emtricitabine/tenofovir disoproxil
    2. Drug: Hydroxychloroquine
    3. Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo
    4. Drug: Placebo: Hydroxychloroquine
    MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Measure: Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)

    Time: 12 weeks

    Secondary Outcomes

    Description: assessed by: No symptoms Mild symptoms: general malaise, fever, cough, myalgia, asthenia. Moderate symptoms: mild symptoms plus shortness of breath, Severe symptoms: mild symptoms plus respiratory insufficiency that requires admission in intensive care unit and mechanical ventilation

    Measure: Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)

    Time: 12 weeks

    Measure: Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days

    Time: 12 weeks
    26 Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment

    This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19

    NCT04334967
    Conditions
    1. COVID-19
    2. Corona Virus Infection
    3. SARS-CoV-2
    4. 2019-nCoV
    5. 2019 Novel Coronavirus
    Interventions
    1. Drug: Hydroxychloroquine
    2. Dietary Supplement: Vitamin C
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: This outcome will be assessed by comparing the percentages of enrolled patients that are hospitalized in the treatment and control arms.

    Measure: Total Hospitalization

    Time: 14 days

    Description: This outcome will be assessed by comparing the percentages of enrolled patients that have received mechanical ventilation in the treatment and control arms.

    Measure: Total Mechanical Ventilation

    Time: 14 days

    Secondary Outcomes

    Description: Self-reported body temperature. Each report scored low (less than 100.4), medium (100.4-102.2), or high (higher than 102.2). Outcome will be assessed by calculating percentage of patients with reported high, medium, low temperature at specified time points.

    Measure: Fever intensity measure

    Time: 2 days

    Description: Self-reported body temperature. Each report scored low (less than 100.4), medium (100.4-102.2), or high (higher than 102.2). Outcome will be assessed by calculating percentage of patients with reported high, medium, low temperature at specified time points.

    Measure: Fever intensity measure

    Time: 5 days

    Description: Self-reported body temperature. Each report scored low (less than 100.4), medium (100.4-102.2), or high (higher than 102.2). Outcome will be assessed by calculating percentage of patients with reported high, medium, low temperature at specified time points.

    Measure: Fever intensity measure

    Time: 10 days

    Description: Self-reported body temperature. Each report scored low (less than 100.4), medium (100.4-102.2), or high (higher than 102.2). Outcome will be assessed by calculating percentage of patients with reported high, medium, low temperature at specified time points.

    Measure: Fever intensity measure

    Time: 14 days

    Description: Self-reported worsening shortness of breath. Each report scored yes/no. Outcome will be assessed by calculating percentage of patients with reported worsening of shortness of breath at specified time points.

    Measure: Shortness of breath measure

    Time: 2 days

    Description: Self-reported worsening shortness of breath. Each report scored yes/no. Outcome will be assessed by calculating percentage of patients with reported worsening of shortness of breath at specified time points.

    Measure: Shortness of breath measure

    Time: 5 days

    Description: Self-reported worsening shortness of breath. Each report scored yes/no. Outcome will be assessed by calculating percentage of patients with reported worsening of shortness of breath at specified time points.

    Measure: Shortness of breath measure

    Time: 10 days

    Description: Self-reported worsening shortness of breath. Each report scored yes/no. Outcome will be assessed by calculating percentage of patients with reported worsening of shortness of breath at specified time points.

    Measure: Shortness of breath measure

    Time: 14 days

    Description: Self reported changes in daytime cough. Each report scored 0 (no cough), 1 (one short coughing attack), 2 (two or more short coughing attacks), 3 (frequent coughing that did not interfere with activities), 4 (frequent coughing that did interfere with activities, 5 (distressing cough throughout most of the day). Outcome will be measured by calculating change in reported cough at each time point.

    Measure: Changes in daytime cough measure

    Time: 2 days

    Description: Self reported changes in daytime cough. Each report scored 0 (no cough), 1 (one short coughing attack), 2 (two or more short coughing attacks), 3 (frequent coughing that did not interfere with activities), 4 (frequent coughing that did interfere with activities, 5 (distressing cough throughout most of the day). Outcome will be measured by calculating change in reported cough at each time point.

    Measure: Changes in daytime cough measure

    Time: 5 days

    Description: Self reported changes in daytime cough. Each report scored 0 (no cough), 1 (one short coughing attack), 2 (two or more short coughing attacks), 3 (frequent coughing that did not interfere with activities), 4 (frequent coughing that did interfere with activities, 5 (distressing cough throughout most of the day). Outcome will be measured by calculating change in reported cough at each time point.

    Measure: Changes in daytime cough measure

    Time: 10 days

    Description: Self reported changes in daytime cough. Each report scored 0 (no cough), 1 (one short coughing attack), 2 (two or more short coughing attacks), 3 (frequent coughing that did not interfere with activities), 4 (frequent coughing that did interfere with activities, 5 (distressing cough throughout most of the day). Outcome will be measured by calculating change in reported cough at each time point.

    Measure: Changes in daytime cough measure

    Time: 14 days

    Description: Self reported changes in nighttime cough. Each report scored 0 (no cough), 1 (cough on waking only), 2 (wake once or early due to cough), 3 (frequent waking due to cough), 4 (frequent coughing throughout the night, 5 (distressing cough preventing any sleep). Outcome will be measured by calculating change in reported cough at each time point.

    Measure: Changes in nighttime cough measure

    Time: 2 days

    Description: Self reported changes in nighttime cough. Each report scored 0 (no cough), 1 (cough on waking only), 2 (wake once or early due to cough), 3 (frequent waking due to cough), 4 (frequent coughing throughout the night, 5 (distressing cough preventing any sleep). Outcome will be measured by calculating change in reported cough at each time point.

    Measure: Changes in nighttime cough measure

    Time: 5 days

    Description: Self reported changes in nighttime cough. Each report scored 0 (no cough), 1 (cough on waking only), 2 (wake once or early due to cough), 3 (frequent waking due to cough), 4 (frequent coughing throughout the night, 5 (distressing cough preventing any sleep). Outcome will be measured by calculating change in reported cough at each time point.

    Measure: Changes in nighttime cough measure

    Time: 10 days

    Description: Self reported changes in nighttime cough. Each report scored 0 (no cough), 1 (cough on waking only), 2 (wake once or early due to cough), 3 (frequent waking due to cough), 4 (frequent coughing throughout the night, 5 (distressing cough preventing any sleep). Outcome will be measured by calculating change in reported cough at each time point.

    Measure: Changes in nighttime cough measure

    Time: 14 days

    Description: Number of enrolled patients who have died within the specified time frame

    Measure: Total mortality

    Time: 28 days
    27 A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

    This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19

    NCT04335084
    Conditions
    1. COVID-19
    2. Coronavirus Infection
    3. Sars-CoV2
    4. Corona Virus Infection
    5. COVID
    6. Coronavirus
    7. Coronavirus-19
    8. Coronavirus 19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Dietary Supplement: Vitamin C
    3. Dietary Supplement: Vitamin D
    4. Dietary Supplement: Zinc
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Any symptoms of COVID-19 will be recorded in a daily diary. Symptoms (including fever measured in degrees Fahrenheit, dry cough, productive cough, difficulty speaking, wheezing, dry mouth, headache, chest tightness, difficulty with exertion, shortness of breath, sore throat, malaise, and diarrhea) will be rated as not present, mild, moderate, or severe.

    Measure: Prevention of COVID-19 symptoms as recorded in a daily diary

    Time: 24 weeks

    Description: To assess the presence or absence of side effects (graded 1-5), and whether they are tolerable (grade 1-2). AE and SAE will be recorded.

    Measure: Safety as determined by presence or absence of Adverse Events and Serious Adverse Events

    Time: 24 weeks
    28 Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection

    This is a pragmatic, randomized, open-label, incomplete factorial with nested randomization clinical trial evaluating the efficacy and safety of two potential treatments for hospitalized patients with confirmed SARS-CoV-2 infection. Participants who are hospitalized and have a positive nucleic acid amplification test for SARS-CoV-2 will undergo an initial randomization in a 1:1 ratio to one of the following regimens: Arm 1: Standard of care alone Arm 2: Standard of care plus hydroxychloroquine Participants who meet eligibility criteria to receive azithromycin will undergo a second randomization in a 1:1 ratio to receive additional concurrent therapy. This will effectively result in four treatment groups: 1. Standard of care alone 2. Standard of care plus hydroxychloroquine 3. Standard of care plus azithromycin 4. Standard of care plus hydroxychloroquine plus azithromycin

    NCT04335552
    Conditions
    1. SARS-CoV-2
    Interventions
    1. Other: Standard of care
    2. Drug: Hydroxychloroquine
    3. Drug: Azithromycin
    MeSH:Infection

    Primary Outcomes

    Description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.

    Measure: World Health Organization (WHO) ordinal scale measured at 14 days after enrollment

    Time: Day 14

    Secondary Outcomes

    Measure: Rates of death during the index hospitalization

    Time: Index hospitalization, up to 46 days

    Measure: Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline

    Time: Baseline

    Measure: Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization

    Time: Index hospitalization, up to 46 days

    Description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.

    Measure: WHO ordinal scale measured at 28 days after enrollment

    Time: Day 28

    Measure: Hospital length of stay in days for the index hospitalization

    Time: Index hospitalization, up to 46 days

    Measure: Rates of all-cause study medication discontinuation

    Time: Index hospitalization, up to 46 days

    Measure: Rates of severe adverse events

    Time: Day 14
    29 Low-dose Hydroxychloroquine for Primary Prophylaxis Against SARS-CoV-2 in Health-care Workers - a Randomized, Double-blind, Controlled Trial

    Background: Aim: To demonstrate the efficacy of low-dose hydroxychloroquine as primary prevention in healthcare workers Design, participants and interventions: Prospective, randomized, parallel group, double-blinded, placebo controlled, study. including 440 participants who will be randomised to 2 treatment arms: hydroxychloroquine or placebo. Outcome variables: symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR, viral load during SARS-CoV-2 infection, seroconversion during the study period, incidence of any acute respiratory infection, days of sick leave. Statistical considerations: No trials have been published investigating the efficacy of HCQ as primary prophylaxis of SARS-CoV-2 infection in health care workers. Thus, sample size calculations in the proposed trial are based on the investigators' best estimates for several parameters. In accordance to the effect of oseltamivir against symptomatic influenza, we assumed an approximate effectiveness of approximately 60% (HR of 0.4) (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464969/) as realistic. As a prophylactic intervention with HCQ, which may have side effects and for which supply shortage can be expected, was judged justifiable only if its effectiveness is high, we based our sample size consideration on a HR of 0.3. To estimate the probability of an event in both the experimental and the control group, very little data is available. In a Dutch point-prevalence study 0-10% of health-care workers were infected depending on the healthcare institution, depending on the hospital. This point-prevalence study was performed between 6 and 9 March, when the reported number of cases in the Netherlands was 33 and 77, respectively, according to the RIVM (https://www.rivm.nl/nieuws/resultaat-steekproef-4-ziekenhuismedewerkers-heeft-coronavirus). Additionally, in an a report published in the Lancet, 20% of responding healthcare workers in Italy were found to be infected with SARS-CoV2 within less than one month (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30627-9/fulltext). Several media reports indicate that this proportion is similar across various healthcare institutions and countries (https://www.nytimes.com/2020/03/24/world/europe/coronavirus-europe-covid-19.html) and (https://www.aljazeera.com/news/2020/03/spain-tightens-restrictions-week-lockdown-begins-2003 30191539568.html). As the proposed study will be performed in a high-risk setting, we assumed an event (i.e. PCR positivity) probability of 10% in the control group and 3% in the experimental arm after the maximum study period. In summary, a sample size of 210 participants per arm is necessary to detect a HR of 0.3 with a power of 80.3% with an alpha-error of 0.05. To account for drop-outs and asymptomatic, undetected infection at inclusion or past infection with existing immunity, an additional 10 participants will randomized per treatment arm. The overall study population is therefore 440 participants. Statistical analysis will be based on two populations: A Modified Intention to Treat population excluding those who withdrew consent after randomization and those with a positive serology at baseline. And a per protocol population including all randomized subjects who completed at least 3 out of 4 follow-up visits and took at least 80% of all doses of study medication.

    NCT04336748
    Conditions
    1. Sars-CoV2
    2. Infection Viral
    3. Healthcare Worker
    4. Prophylaxis
    Interventions
    1. Drug: Hydroxychloroquine
    MeSH:Virus Diseases

    Primary Outcomes

    Measure: Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR

    Time: 4 weeks

    Secondary Outcomes

    Measure: Viral load during SARS-CoV-2 infection

    Time: 4 weeks

    Measure: Seroconversion during the study period

    Time: 4 weeks

    Measure: Incidence of any acute respiratory infection

    Time: 4 weeks

    Measure: Days of sick leave

    Time: 4 weeks
    30 Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment

    To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8hr thrice a day for 5 days) vs oseltamivir (75 mg orally twice a day for 5 days) vs Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in clearing the coronavirus nucleic acid from throat and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary outcomes).

    NCT04338698
    Conditions
    1. COVID 19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Oseltamivir
    3. Drug: Azithromycin

    Primary Outcomes

    Description: The laboratory-based primary outcome will be turning test negative for COVID-19 on RT-qPCR calculated as viral load of < 150 i.u

    Measure: Laboratory Result

    Time: Day 07 on follow-up

    Description: The clinical primary outcome will be improvement of two points on a seven-category ordinal scale shown below: Not hospitalized, able to resume normal activities Not hospitalized, but unable to resume normal activities Hospitalization, not requiring supplemental oxygen Hospitalization, requiring supplemental oxygen Hospitalization, requiring noninvasive mechanical ventilation Hospitalization, requiring invasive mechanical ventilation Death

    Measure: Clinical Outcome

    Time: Day 07 on follow-up
    31 Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection

    Evaluation of the efficacy and safety of hydroxychloroquine - camostat combination therapy in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial Primary Objectives: The primary objective of this study is to demonstrate, that a combination therapy of hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in participants with moderate COVID-19.

    NCT04338906
    Conditions
    1. COVID
    Interventions
    1. Drug: Camostat Mesilate
    2. Drug: Placebo
    3. Drug: Hydroxychloroquine

    Primary Outcomes

    Measure: Not hospitalized

    Time: day 14 from baseline

    Secondary Outcomes

    Measure: Time to improvement of 2 categories from admission on a 7-point ordinal scale

    Time: day 14

    Measure: Proportion of participants in each group with normalization of fever

    Time: day 7 and day 14

    Measure: Proportion of participants in each group with oxygen saturation > 94% on room air for >24h

    Time: day 7 and day 14

    Measure: Time to fever normalization (if febrile at baseline)

    Time: within 14 days

    Measure: Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)

    Time: within 14 days

    Measure: Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)

    Time: within 14 days

    Measure: Duration of oxygen therapy

    Time: within 28 days

    Measure: Proportion of participants in each group with need for mechanical ventilation

    Time: within 28 days

    Measure: Duration of hospitalization

    Time: within 28 days

    Measure: All cause mortality

    Time: day 28
    32 Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial

    Trial design: Prospective, multi-centre, randomised, pragmatic, double blind trial Methods: Participants: Adult (>18 years) within 24 hours of admission to intensive care unit with proven or suspected COVID-19 infection, whether or not mechanically ventilated. Exclusion criteria: symptoms of febrile disease for ≥1 week, treatment limitations in place or moribund patients, allergy or intolerance of any study treatment, incl. long QT syndromes, participation in another outcome-based interventional trial within last 30 days, patients taking Hydrochloroquine for other indication than COVID-19, pregnancy. Interventions: Patients will be randomised in 1:1:1 ratio to receive Hydrochloroquine 800mg orally in two doses followed by 400mg daily in two doses and Azithromycin 500 mg orally in one dose followed by 250 mg in one dose for a total of 5 days (HC-A group) or Hydrochloroquine+ placebo (HC group) or placebo + placebo (C-group) in addition to best standard of care, which may evolve during the trial period but will not differ between groups. Objective: To test the hypothesis that early administration of combination therapy slows disease progression and improves mechanical-ventilation free survival. Outcomes: Primary outcome: Composite percentage of patients alive and not on end-of-life pathway who are free of mechanical ventilation at day 14. Secondary outcomes: Composite percentage of patients alive and not on end-of-life pathway who are free of mechanical ventilation at day 14 in the subgroup of patients without the need of mechanical ventilation at baseline. ICU-LOS D28 and D 90 mortality (in hospital) Tertiary (exploratory) outcomes: Viral load at D7 of study enrolment (No of viral RNA copies/ml of blood), proportion of patients alive and rtPCR negative from nasal swab at D14, Difference of FiO2 requirement and respiratory system compliance between day 0 and 7. Randomization: In 1:1:1 ratio and stratified according to study centre and patients age (cut-off 70 years) Blinding (masking): Patients, treating clinicians, outcome assessors and data analyst will be blinded to study treatment allocation. Unblinded study pharmacist or research nurse will prepare investigational products.

    NCT04339816
    Conditions
    1. COVID-19
    2. Respiratory Failure
    Interventions
    1. Drug: Azithromycin
    2. Drug: Hydroxychloroquine
    3. Drug: Placebo
    MeSH:Respiratory Insufficiency

    Primary Outcomes

    Description: Composite percentage of patients alive and not on end-of-life pathway who are free of mechanical ventilation at day 14.

    Measure: Proportion of alive patients free off mechanical ventilation

    Time: 14 days after enrolment

    Secondary Outcomes

    Description: Composite percentage of patients alive and not on end-of-life pathway who are free of mechanical ventilation at day 14 in the subgroup of patients without the need of mechanical ventilation at baseline.

    Measure: Proportion of patients who avoided the need of mechanical ventilation

    Time: 14 days

    Description: Length of stay in intensive care unit

    Measure: ICU LOS

    Time: 28 days

    Description: Proportion of patients who died by day 28

    Measure: Mortality28

    Time: 28 days

    Description: Proportion of patients who died by day 90

    Measure: Mortality90

    Time: 90 days
    33 Hydroxychloroquine for the Treatment of Mild COVID-19 Disease

    The current outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is a global health emergency with a case fatality rate so far approximately 4% and a growing number of confirmed cases (>57.000) in Germany. There is no data available on the efficacy of antiviral agents for the treatment of COVID-19. In-vitro data show that hydroxychloroquine can inhibit SARS-CoV-2 [1] replication and anecdotal reports from Chinese COVID-19 patients [2, 3] suggest that chloroquine is a good candidate for treatment. No data have been published and reported evidence is based on non-controlled use of hydroxychloroquine. The aim of this placebo-controlled trial is to assess the effect of hydroxychloroquine on duration of symptoms in mild COVID-19 patients and time of virus shedding as an important tool to reduce the risk of further community transmissions. This data will inform practice for the design of larger trials on clinical efficacy of hydroxychloroquine in the treatment and post- and preexposure prophylaxis of COVID-19 and as a tool for reduction of community transmission.

    NCT04340544
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo

    Primary Outcomes

    Measure: Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment

    Time: 28±2 days

    Secondary Outcomes

    Measure: Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)

    Time: 28±2 days

    Measure: All-cause mortality within 28 days

    Time: 28±2 days

    Other Outcomes

    Measure: Proportion of patients with negative COVID-19 PCR test at day 14 in per protocol population as per throat swab

    Time: 28±2 days

    Measure: Change in COVID-19 virus load from baseline to day 14

    Time: 28±2 days
    34 COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients

    To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part A). To evaluate the Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin (Part B).

    NCT04341207
    Conditions
    1. Cancer
    2. Cancer &
    3. Cancer & COVID 19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin

    Primary Outcomes

    Measure: Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients

    Time: Up to 3 months

    Measure: Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin

    Time: Up to 12 months
    35 Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome

    Coronaviruses (CoV) are positive-sense single-stranded RNA viruses that infect a wide range of hosts producing diseases ranging from the common cold to serious / fatal events. Nitazoxanide (NTZx) is a derivative of 5-nitrothiazole, synthesized in 1974 by Rosignol - Cavier. NTZx has powerful antiviral effects through the phosphorylation of protein kinase activated by double-stranded RNA, which leads to an increase in phosphorylated factor 2-alpha, an intracellular protein with antiviral effects. The purpose of this study is to contrast the beneficial effect of NTZx vs NTZx plus hydroxychloroquine in patients Coronavirus Disease (COVID-19) as well as against other treatments.

    NCT04341493
    Conditions
    1. Coronavirus Infection
    Interventions
    1. Drug: Nitazoxanide 500 MG
    2. Drug: Hydroxychloroquine
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Percentage of patients COVID-19 positive that required mechanical ventilation

    Measure: Mechanical ventilation requirement

    Time: Since the diagnosis until two weeks after
    36 Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial

    The overall objective of the study is to determine the therapeutic effect and tolerance of Sarilumab in combination with Azithromycin and Hydroxychloroquine, compared to Sarilumab only, patients with moderate, severe pneumonia associated with Coronavirus disease 2019 (COVID-19). Sarilumab is a human IgG1 monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6Rs (sIL-6Rα and mIL-6Rα) and has been shown to inhibit IL-6-mediated signaling through these receptors. The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering investigational treatments administration to patients enrolled in the CORIMUNO-19 cohort (NCT04324047). Sarilumab+Azithromycin+Hydroxychloroquine, or Sarilumab only will be administered to consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation. All patients will receive standard of care along with randomized investigational treatments. Outcomes of included patients will be compared between groups as well as with outcomes of patients in the CORIMUNO-19 cohort treated with other immune modulators or standard of care.

    NCT04341870
    Conditions
    1. COVID19
    2. SARS-CoV-2 Infection
    Interventions
    1. Drug: Sarilumab
    2. Drug: Azithromycin
    3. Drug: Hydroxychloroquine

    Primary Outcomes

    Description: Events considered are: need for ventilation (including invasive and non invasive ventilation), transfer to the Intensive Care Unit, death or new do-not-resuscitate (DNR) decision in the absence ventilation and outside ICU.

    Measure: Need for ventilation (including invasive and non invasive ventilation), intensive care or death

    Time: 14 days

    Secondary Outcomes

    Description: WHO progression scale: Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2>=150 OR SpO2/FIO2>=200: 7 Mechanical ventilation, (pO2/FIO2<150 OR SpO2/FIO2<200) OR vasopressors (norepinephrine >0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2<150 AND vasopressors (norepinephrine >0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10

    Measure: Early improvement: OMS progression scale <= 5

    Time: 4 days

    Description: WHO progression scale: Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2>=150 OR SpO2/FIO2>=200: 7 Mechanical ventilation, (pO2/FIO2<150 OR SpO2/FIO2<200) OR vasopressors (norepinephrine >0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2<150 AND vasopressors (norepinephrine >0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10

    Measure: OMS progression scale

    Time: 4, 7 and 14 days

    Description: Overall survival

    Measure: Survival

    Time: 14, 28 and 90 days

    Description: Number of ICU-free days alive

    Measure: ICU-free days alive

    Time: 14, 28 and 90 days

    Description: Number of ventilation(invasive or non invasive)-free days alive

    Measure: Ventilation-free days alive

    Time: 14 and 28 days

    Description: Number of hospital-free days alive

    Measure: Hospital-free days alive

    Time: 14, 28 and 90 days

    Description: Number of oxygen therapy-free days alive

    Measure: Oxygen therapy-free days alive

    Time: 14 and 28 days

    Description: SARS-CoV-2 viral load measurement by rtPCR

    Measure: Time to negative viral excretion

    Time: 90 days

    Description: Immunophenotyping and multiplex cytokines (blood sample)

    Measure: Immunophenotyping and multiplex cytokines

    Time: 8 days
    37 Hydroxychloroquine for Outpatients With Confirmed COVID-19

    A novel coronavirus, SARS-CoV-2, is responsible for a rapidly spreading pandemic that has reached 160 countries, infecting over 500,000 individuals and killing more than 24,000 people. SARS-CoV-2 causes an acute and potentially lethal respiratory illness, known as COVID-19, that is threatening to overwhelm health care systems due to a dramatic surge in hospitalized and critically ill patients. Patients hospitalized with COVID-19 typically have been symptomatic for 5-7 days prior to admission, indicating that there is a window during which an effective intervention could significantly alter the course of illness, lessen disease spread, and alleviate the stress on hospital resources. There is no known treatment for COVID-19, though in vitro and one poorly controlled study have identified a potential antiviral activity for HCQ. The rationale for this clinical trial is to measure the efficacy and safety of hydroxychloroquine for reducing viral load and shedding in adult outpatients with confirmed COVID-19.

    NCT04342169
    Conditions
    1. Coronavirus Infection
    2. Coronavirus
    3. Infectious Disease
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Communicable Diseases Infection Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Measure: Duration of viral shedding

    Time: Days 1-14

    Secondary Outcomes

    Measure: Duration of COVID-19-attributable symptoms

    Time: Everyday through 6 months

    Measure: Hospitalization

    Time: within 14 days of enrollment

    Measure: Duration of viral shedding

    Time: Days 1-14 and Day 28

    Measure: Adult household contact viral acquisition

    Time: Days 1-14 and Day 28
    38 An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

    The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the three arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

    NCT04343768
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Lopinavir / Ritonavir
    3. Drug: Interferon Beta-1A
    4. Drug: Interferon Beta-1B

    Primary Outcomes

    Description: Improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization) or discharge from the hospital, whichever came first.

    Measure: Time to clinical improvement

    Time: From date of randomization until 14 days later.

    Secondary Outcomes

    Description: If the patient dies, we have reached an outcome.

    Measure: Mortality

    Time: From date of randomization until 14 days later.

    Description: Pulse-oxymetry

    Measure: SpO2 Improvement

    Time: Days 1, 2, 3, 4, 5, 6, 7 and 14.

    Description: Incidence of new mechanical ventilation use

    Measure: Incidence of new mechanical ventilation use

    Time: From date of randomization until 14 days later.

    Description: Duration of hospitalization (days)

    Measure: Duration of hospitalization

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 14 days.
    39 Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial

    This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the hospital and randomized to one of three arms. Patients will be randomized to supportive care, OR hydroxychloroquine alone, OR hydroxychloroquine and azithromycin.

    NCT04344444
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin

    Primary Outcomes

    Description: ordinal outcome of most severe a patient experienced after inpatient admission

    Measure: Most severe outcome

    Time: 5 days
    40 An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms

    Currently there are no US Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with COVID-19. At present, clinical management includes infection prevention and control measures, as well as supportive care, including supplementary oxygen and mechanical ventilatory support when indicated. An array of drugs approved for other indications as well as several investigational drugs are being studied in several hundred clinical trials that are underway across the globe; however, currently there are no clinical trials available to patients in Arizona. This study will determine if a specific drug cocktail can improve clinical outcomes in patients with confirmed Mild SARS-CoV-2

    NCT04344457
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Indomethacin
    3. Drug: Zithromax Oral Product

    Primary Outcomes

    Description: measured by time (days) required from initiation of treatment to improvement of clinical status from mild to symptom free

    Measure: Improvement of clinical status

    Time: up to 28 days

    Secondary Outcomes

    Description: the time of normalization of fever as measured by daily temperature ( - ≤36.6°C or -axilla, ≤37.2 °C oral or ≤37.8°C rectal or tympanic)

    Measure: Time of clinical recovery of fever

    Time: up to 15 days

    Description: the time of alleviation of cough as measured by self reported visual analog scale (VAS) cough scale. 1=no cough, 2-3=cough sometimes, 4-6=have a cough but can still do things, 7-8=persistent cough, prevents from doing things, 9-10=cough presents a great deal of discomfort

    Measure: Time of clinical recovery of cough

    Time: up to 28 days

    Description: to determine the safety of these therapies in combination

    Measure: Safety as determined by changes in QTC intervals measured by ECG

    Time: up to 15 days

    Description: to assess the presence or absence of side effects and whether they are tolerable

    Measure: Safety as determined by presence of side effects

    Time: up to 15 days

    Description: improvement in Wisconsin Upper Respiratory Symptom Survey (WURSS-44) 0 to 7 scale, with 0 = Do not have, 1 = Very mild, 3 = Mild, 5 = Moderate, 7 = Severe

    Measure: Time to improvement

    Time: up to 28 days
    41 A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients

    This study is a randomized, open label clinical trial to evaluate the safety and efficacy of hydroxychloroquine (HCQ) plus usual care compared to usual care in approximately 350 hospitalized patients diagnosed with COVID-19. The study will be a 2-arm, non-blinded comparison between open label hydroxychloroquine and usual care. The course of treatment (HCQ) is five days. Participants will be followed to study day 28.

    NCT04345692
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine

    Primary Outcomes

    Description: Clinical Status (on a 7-point ordinal scale) at day 15 Not hospitalized, no limitations on activities Not hospitalized, limitation on activities Hospitalized, not requiring supplemental oxygen Hospitalized, requiring supplemental oxygen Hospitalized, on non-invasive ventilation or high flow oxygen devices Hospitalized, on invasive mechanical ventilation or ECMO Death

    Measure: i. Clinical status

    Time: Clinical Status (on a 7-point ordinal scale) at day 15

    Secondary Outcomes

    Description: Oxygenation free days in the first 28 days Incidence and duration of new oxygen use during the study

    Measure: Oxygenation

    Time: up to day 28

    Description: Ventilator free days in the first 28 days Incidence and duration of new mechanical ventilation use during hospitalization

    Measure: Mechanical Ventilation

    Time: up to day 28

    Description: Duration of hospitalization (days)

    Measure: Hospitalization

    Time: up to day 28

    Description: 28-day mortality

    Measure: Mortality

    Time: up to day 28
    42 Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2

    This is a PILOT STUDY, a Phase III double-blind, randomized, placebo-controlled clinical study in which we assess the clinical effect of the prophylactic administration of hydroxychloroquine vs. placebo to healthcare workers working at our University Hospital (HUN). Participants in each arm (n = 43) will be administered with a unique loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days. The population to be studied (uninfected healthcare personnel) will be highly exposed to SARS-CoV-2 infection. An active search should be made for individuals who become infected while participating in the study, hence, once the informed consent form is signed, the molecular test for the diagnosis of SARS-CoV-2 infection by RT-PCR will be carried out every 4 days in order to determine as closely as possible the moment the participant becomes positive. The results of the diagnostic RT-qPCR tests will be confronted with: (i) the results of immune monitoring of at least 30 immunological parameters in leukocytes and in plasma (levels of selected cytokines and chemokines analyzed by automated flow cytometry software and (ii) the daily recording of data for the presence or absence of signs and symptoms associated with SARS-Cov-2 infection. For the recording of immune monitoring 20mL blood samples will be taken at eight-time points throughout the 90 days of the stud.

    NCT04346329
    Conditions
    1. COVID
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: Number of participants with treatment-related adverse events as associated administration of hydroxychloroquine or placebo.

    Measure: Adverse effects

    Time: six months after administration of hydroxychloroquine or placebo

    Secondary Outcomes

    Description: Percentage of expression of immune senescence in cells of the immune system of individuals highly exposed to COVID-19 who receive hydroxychloroquine prophylactically vs. placebo.

    Measure: Immune-score

    Time: six months after administration of hydroxychloroquine or placebo

    Description: Correlate the immunological profile of highly exposed individuals with SARS-CoV-2 with the clinic of COVID-19.

    Measure: COVID-19 prevention

    Time: six months after administration of hydroxychloroquine or placebo

    Description: Determine the clinical outcome in observation timeframe of highly exposed personnel when receiving hydroxychloroquine vs. placebo prophylactically.

    Measure: Clinical response

    Time: six months after administration of hydroxychloroquine or placebo
    43 An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC "Farmzashita" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19

    Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by FSUE "SPC" Farmzaschita " FMBA of Russia (Russia), in comparison with the drug Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection, in the "off-label" mode, to make a decision on the possibility of expanding the indications for use.

    NCT04347031
    Conditions
    1. Pneumonia, Viral
    2. Respiratory Failure
    Interventions
    1. Drug: Mefloquine
    2. Drug: Hydroxychloroquine
    3. Combination Product: Mefloquine + azithromycin + / - tocilizumab
    4. Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab
    MeSH:Pneumonia, Viral Pneumonia Respiratory Insufficiency
    HPO:Pneumonia

    Primary Outcomes

    Description: The number of patients with development of respiratory failure requiring transfer to the ICU.

    Measure: 1st primary endpoint for group 1

    Time: up to 10 days

    Description: The period of clinical recovery.

    Measure: 2nd primary endpoint for group 1

    Time: up to 10 days

    Description: The period of clinical recovery.

    Measure: 1st primary endpoint for group 2

    Time: up to 10 days

    Description: Frequency of fatal outcomes associated with coronavirus infection disease (COVID19)

    Measure: 2nd primary endpoint for group 2

    Time: through study completion, an average of 3 months

    Secondary Outcomes

    Description: A change in viral load by conducting PCR assay through different timeframes

    Measure: 1st secondary endpoint for group 1

    Time: on days 5 and 10

    Description: Frequency of clinical cure on day 10 from the start of therapy

    Measure: 2nd secondary endpoint for group 1

    Time: on day 10

    Description: The retention time of the reaction temperature from the start of the treatment.

    Measure: 3d secondary endpoint for group 1

    Time: up to 10 days

    Description: Concentration of C-reactive protein in blood plasma.

    Measure: 4th secondary endpoint for group 1

    Time: up to 10 days

    Description: Respiratory index.

    Measure: 5th secondary endpoint for group 1

    Time: up to 10 days

    Description: Frequency appearance unwanted phenomena and serious unwanted phenomena

    Measure: 6th secondary endpoint for group 1

    Time: up to 10 days

    Description: A change in viral load by conducting PCR assay through different timeframes

    Measure: 1st secondary endpoint for group 2

    Time: on days 5 and 10

    Description: Respiratory index.

    Measure: 2nd secondary endpoint for group 2

    Time: up to 10 days

    Description: The retention time of the reaction temperature from the start of treatment.

    Measure: 3d secondary endpoint for group 2

    Time: up to 10 days

    Description: Concentration of C-reactive protein in blood plasma.

    Measure: 4th secondary endpoint for group 2

    Time: up to 10 days

    Description: Number of patients required transition to alternative therapy schedule

    Measure: 5th secondary endpoint for group 2

    Time: up to 10 days

    Description: Frequency of adverse events and serious adverse events

    Measure: 6th secondary endpoint for group 2

    Time: up to 10 days
    44 EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA

    Since end of December, a new coronavirus, close to the 2002 SARS coronavirus, cause serious pneumonias throughout world. There is currently no strong evidence of an efficient specific treatment. Hydroxychloroquine is an old chloroquine-derived drug, prescribed for auto-immune disorders. It has shown efficacy against Sars-CoV-2 in vitro. Some studies showed that Hydroxychloroquine might improve the clinical status of Sars-CoV-2 infected patients. Azithromycin is a macrolide antibiotic, with immunomodulatory properties. Adding Azithromycin to a hydroxychloroquine-based treatment showed an apparent accelerated viral clearance in infected patients. This study wants to evaluate the clinical impact of adding Azithromycin to Hydroxychloroquine in the treatment of Sars-CoV-2 pneumonia

    NCT04347512
    Conditions
    1. Sars-CoV-2, Community-Acquired Pneumonia,COVID-19
    Interventions
    1. Drug: Hydroxychloroquine and azithromycin treatment arm.
    2. Drug: Hydroxychloroquine
    3. Drug: Control arm
    MeSH:Pneumonia
    HPO:Pneumonia

    Primary Outcomes

    Description: A significant hypoxemia is an arterial partial pressure of oxygen of less than 60 mmHg despite an oxygen flow of more than 6 L/min, patient at rest.

    Measure: Rate of patients reaching a significant hypoxemia, in each arms.

    Time: From day 0 to day 7
    45 Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19: A RCT

    Healthcare workers (HCW) at risk of Covid-19 will have baseline serology for SARS-CoV-2 to see if they are already immune to Covid-19. HCW will get baseline assessment and if meeting inclusion criteria and no exclusion criteria they will be randomized in a 2:1 ratio to hydroxychloroquine or Vitamin C on a weekly basis for three months. Subjects will complete daily diary of symptoms and temperature, and will have repeat SARS-CoV-2 serology at 6 weeks and 3 months to determine seroconversion.

    NCT04347889
    Conditions
    1. Covid-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Other: Vitamin C

    Primary Outcomes

    Description: Percentage of healthcare worker who develop antibodies to SARS-CoV-2

    Measure: COVID-19 Seroconversion rate

    Time: 3 months

    Secondary Outcomes

    Description: Percentage of study subjects who require admission to a hospital for Covid-19

    Measure: Admission for Covid-19

    Time: 3 months
    46 Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19): a Multicentre, Randomised Controlled Trial

    Single blind randomized clinical trial designed to evaluate the efficacy of the combination of hydroxychloroquine and dexamethasone as treatment for severe Acute Respiratory Distress Syndrome (ARDS) related to coronavirus disease 19 (COVID-19). We hypothesize that dexamethasone (20 mg for 5 days followed by 10 mg for 5 days) combined with 600 mg per day dose of hydroxychloroquine for 10 days will reduce the 28-day mortality compared to hydroxychloroquine alone in patients with severe ARDS related COVID-19.

    NCT04347980
    Conditions
    1. Respiratory Distress Syndrome, Adult
    2. COVID-19
    Interventions
    1. Drug: Dexamethasone and Hydroxychloroquine
    2. Drug: Hydroxychloroquine
    MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

    Primary Outcomes

    Description: Mortality rate evaluated 28 days after randomization

    Measure: Day-28 mortality

    Time: 28 days after randomization

    Secondary Outcomes

    Description: Ventilator-free days (VFDs) at 28 days are one of several organ failure-free outcome measures to quantify the efficacy of therapies and interventions. VFDs are typically defined as follows: VFDs = 0 if subject dies within 28 days of mechanical ventilation. VFDs = 28 - x if successfully liberated from ventilation x days after initiation. VFDs = 0 if the subject is mechanically ventilated for >28 days.

    Measure: Ventilator-free days

    Time: 28 days after randomization

    Description: Mortality rate evaluated during Intensive care unit stay

    Measure: Intensive Care Unit mortality

    Time: Up to 60 days after randomization

    Description: Mortality rate evaluated 60 days after randomization

    Measure: Day-60 mortality

    Time: 60 days after randomization

    Description: Number of patients with pneumonia diagnosed during intensive care unit stay

    Measure: Nosocomial pneumonia

    Time: Up to 60 days after randomization

    Description: Number of patients with bacteremia diagnosed during intensive care unit

    Measure: Bacteremia

    Time: Up to 60 days after randomization

    Other Outcomes

    Description: Placement of ECMO during intensive care unit stay

    Measure: Extra corporeal membrane oxygenation (ECMO)

    Time: Up to 60days after randomization

    Description: Number of patients who underwent tracheostomy during intensive care unit stay

    Measure: Tracheostomy

    Time: Up to 60 days after randomization

    Description: Number of Prone position session

    Measure: Prone Position

    Time: Up to 60 days after randomization
    47 Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19

    Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.

    NCT04349592
    Conditions
    1. Covid19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin
    3. Other: Placebo Tablet
    4. Other: Placebo capsules

    Primary Outcomes

    Description: Days

    Measure: Proportion of virologically cured (PCR-negative status) as assessed on day six

    Time: Day 6

    Secondary Outcomes

    Description: Days

    Measure: virologic cure on other study days

    Time: Day14 and Day 21

    Description: Days

    Measure: virologic semiquantitative analysis of changing viral load

    Time: Day 1 to Day 21

    Description: Days

    Measure: proportion of initially symtomatic subjects with disappearance of clinical symptoms

    Time: Day14 and Day 21

    Description: Days

    Measure: proportion of initially asymtomatic subjects with appearance of new clinical symptoms

    Time: Day14 and Day 21

    Description: grades

    Measure: proportions of subjects with potentially medication- related adverse events

    Time: 7 day
    48 An Open-label Randomized Controlled Trial on Interferon β-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection

    The novel coronavirus (SARS-CoV-2), is a single-stranded RNA coronavirus. The virus was first isolated from patients presented with pneumonia in Wuhan in December 2019. Sequences of the Wuhan betacoronavirus show similarities to betacoronaviruses found in bats, sharing a common ancestor with the 2003 SARS coronavirus (SARS-CoV) and the bat coronavirus HKU9, a virus found in fruit bats. Similar to SARS-CoV, it is a member of Beta-CoV lineage B. Five genomes of the novel coronavirus have been initially isolated and reported including BetaCoV/Wuhan/IVDC-HB-01/2019, BetaCoV/Wuhan/IVDC-HB-04/2020, BetaCoV/Wuhan/IVDC-HB-05/2019, BetaCoV/Wuhan/WIV04/2019, and BetaCoV/Wuhan/IPBCAMS-WH-01/2019 from the China CDC. The SARS-CoV-2 has since spread from China to the rest of the world. As of 5 April 2020, more than 1.05 million people been confirmed to have infected by SARS-CoV-2, resulting in more than 500,000 deaths. No specific antiviral treatment for the SARS-CoV-2 is currently available, but existing medication could be repurposed. Genetic sequencing demonstrated similarity of the SARS-CoV-2 to the SARS-CoV and MERS CoV.2 We expect patients infected with the SARS-CoV-2 will also present similarly with initial upper respiratory tract symptoms including fever, cough, sputum, myalgia and shortness or breath. More severe cases might complicate with pneumonia and required ventilatory or ECMO support. According to our previous studies in 2003 on patients hospitalized for severe SARS-CoV, the viral load peaked between day 7 from symptoms onset and coincided with clinical deterioration of pneumonia and respiratory failure, with majority of the patients required intensive care support. Higher viral load isolated from different human system also correlated with worsened SARS manifestation and complications. Previously, the investigators have demonstrated that interferon-beta 1b, commonly used in the treatment of multiple sclerosis and lopinavir/ ritonavir, also demonstrated to improve the outcome of MERS-CoV infection in a non-human primate model of common marmoset. A non-randomized trial has also suggested that a combination of hydroxychloroquine and azithromycin might be effective in suppressing SARS-CoV-2 viral load in patients, despite in-vitro activity was only found in hydroxychloroquine. Therefore, the investigators propose to conduct an open-label randomized controlled trial on a short course of interferon β-1b and hydroxychloroquine combination treatment for patients hospitalized for COVID-19 infection.

    NCT04350281
    Conditions
    1. COVID
    Interventions
    1. Drug: Interferon Beta-1B
    2. Drug: Hydroxychloroquine

    Primary Outcomes

    Description: Time to negative NPS SARS-CoV-2 viral RT-PCR

    Measure: Time to negative NPS viral load

    Time: 4 weeks

    Secondary Outcomes

    Description: Time to complete allevation of symptoms as defined by NEWS of 0 maintained for 24 hours

    Measure: Time to NEWS 0

    Time: 4 weeks

    Description: Days of hospital stay

    Measure: Length of Hospitalisation

    Time: 4 weeks

    Description: Time to negative SARS-CoV-2 viral RT-PCR in all clinical samples

    Measure: Time to negative viral load in all clinical samples

    Time: 4 weeks

    Description: Treatment related adverse events

    Measure: Adverse events

    Time: 4 weeks

    Description: 30-day mortality

    Measure: Mortality

    Time: 30 days

    Description: Cytokine/ chemokine

    Measure: Inflammatory markers changes

    Time: 4 weeks from diagnosis
    49 Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore: a Review of Process Feasibility, Safety, and Clinical Outcomes

    Given the high prevalence of COVID19 illness (both SARS-CoV-2 RT-PCR confirmed and highly suspect cases) among healthcare workers (HCW) within the Montefiore Health System (MHS), hydroxychloroquine (HCQ) will be prescribed to healthcare workers who are at the highest risk for severe COVID19 illness.

    NCT04350450
    Conditions
    1. COVID
    2. Coronavirus
    3. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    MeSH:Coronavirus Infections

    Primary Outcomes

    Description: Time that it takes for symptoms to be resolved in those who were treated vs untreated

    Measure: Time to resolution of symptoms

    Time: up to 4 weeks

    Secondary Outcomes

    Measure: Number of days from onset of illness to symptom resolution

    Time: up to 4 weeks

    Measure: Number of days to return to work

    Time: up to 4 weeks

    Measure: Rate of hospital admission in treated and untreated healthcare workers

    Time: up to 4 weeks

    Measure: Adverse effect of HCQ during treatment

    Time: up to 5 days
    50 Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients

    Patients over equal or older than 65 yearswill be treated with a hydroxychloroquine versus placebo reduced loading dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days resulting in a total duration of therapy of 7 days. Measurement of Hydroxychloroquine-levels will be performed on day 7, . A follow-up by video or telephone conference will be performed to observe drug intake and collect adverse events during treatment phase on a daily base on working days and once during the weekend (i.e. 6 out of 7 days). After treatment phase follow-up by telephone calls will be done on day 10, 30, 60 (+/- 2 days).

    NCT04351516
    Conditions
    1. SARS-CoV 2
    2. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Other: Placebo

    Primary Outcomes

    Measure: ● Rate of hospitalization or death at day 7 after study inclusion

    Time: 7 days
    51 High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19

    This study aims to examine the tolerability of high dose hydroxychloroquine in patients with COVID-19 who are not yet hospitalized, but have risk factors for disease progression and complications.

    NCT04351620
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine

    Primary Outcomes

    Description: Number of subjects requiring HCQ dose modifications

    Measure: Tolerability of high dose HCQ as measured by HCQ dose modification

    Time: 14 days

    Description: Number of subjects that discontinue HCQ

    Measure: Tolerability of high dose HCQ as measured by discontinuation of HCQ

    Time: 14 days

    Description: Number of Adverse Events observed in all subjects for the duration of the study

    Measure: Tolerability of High Dose HCQ as measured by Adverse Events

    Time: 14 days

    Secondary Outcomes

    Description: Number of patients admitted to hospital during study period

    Measure: Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized

    Time: 14 days

    Description: The number of days to reach first fever normalization (criteria for normalization: temperature < 100.4 F)

    Measure: Time to defervescence as measured in days while on treatment protocol

    Time: 14 days

    Description: Number of days to resolve other symptoms, as assessed by a standardized questionnaire for symptom assessment.

    Measure: Resolution of other COVID-19 symptoms measured in days while on treatment protocol

    Time: 14 days
    52 A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics

    To test if the medication Hydroxychloroquine will decrease the amount of virus(as measured by PCR) , 7 days after initiation of therapy compared to control patients receiving placebo. The study design is a randomized (5 days of medication v. 5 days of placebo) clinical trial initiated immediately after diagnosis in ambulatory health care workers at University of South Alabama Health, or in ambulatory USA patients. At 7 days after enrollment another nasopharyngeal swab will be taken to measure if the virus is still present. At 10 weeks we will measure immunity from Covid-19 using a single blood sample. It is a phase 2/3 clinical trial.

    NCT04353271
    Conditions
    1. Covid 19
    2. Corona Virus Infection
    Interventions
    1. Drug: Hydroxychloroquine
    2. Other: Placebo
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs

    Measure: Percentage of virus free subjects

    Time: 7 days after initiation of trial

    Description: Participants will self-report disease severity status as one of the following 5 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization (score of 3), or Covid 19 with care requiring hospitalization (score of 4), or Covid 19 with death (Score of 5) .

    Measure: Disease severity

    Time: 6 days

    Secondary Outcomes

    Description: Number of subjects in each arm who are hospitalized for Covid 19 infection

    Measure: Incidence of hospitalization

    Time: 14 days

    Description: Number of subjects in each arm who die secondary to Covid-19 infection

    Measure: Incidence of Death

    Time: 70 Days (10 weeks)

    Description: Number of subjects in each arm who have confirmed Covid-19 infection

    Measure: Incidence of confirmed SARS-CoV-2 Detection

    Time: 14 days

    Description: Number of subjects in each arm who discontinue or withdraw medication use for any reason

    Measure: Incidence of all-cause study medication discontinuation or withdrawal

    Time: 14 days

    Description: Blood tests to determine level of immunity in each subject

    Measure: Immunity to Covid-19

    Time: 70 days (10 weeks)
    53 Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial

    Introduction: The COVID-19 pandemic is characterized by significant morbidity and mortality. It is caused by a novel coronavirus with no current specific prevention nor treatment therapies. Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab). Clinical trials offer conflicting evidence regarding the effectiveness and safety of therapies The real effectiveness and safety profile of the treatments for COVID-19 remains unknown. Objective: Evaluate the effectiveness and safety of pharmacological therapies used to treat adult patients with COVID-19. Methods: Pragmatic randomized controlled trial. Study population: Adults aged 18 years or over with a positive real-time polymerase chain reaction (RT-PCR) for Severe Acute Respiratory Syndrome CoV-2 (SARS CoV-2) and diagnosis of mild, severe or critical pneumonia, requiring hospital management at six hospitals in Colombia. Exclusion criteria: Pregnancy, known allergy to treatment, cirrhosis or hepatic abnormality (transaminases greater than 5 reference values), prolonged QT interval, glomerular filtration rate lesser than 30 ml/min/1.73m^2, history of lung fibrosis, advanced or metastatic cancer. Sample size: 1,600 participants. The study will be carried out in two phases. The first phase will be conducted with 480 participants and aims to identify treatments with higher or minimum potential, discontinue treatments with higher toxicity and have opportunity of introducing new treatments with potential efficacy. The second phase will be conducted with 1,120 participants to evaluate the effectiveness of the selected treatments. Four interventions have been defined: I1 HCQ, I2 HCQ plus Lop/r, I3 HCQ plus Azithro and I4 standard treatment. Within each institution, participants will be randomly assigned to one of the treatment arms assigned to that institution. Concealment will be kept through a central telephone. Treatment administration will be open. Variables: Sociodemographic and clinical at recruitment; (comorbidities, need for therapeutic support , grade of invasion at admission). Primary outcomes. Effectiveness: Mortality. Safety: Serious adverse events (AE) assessed by the NCI Community Oncology Research Program (NCORP) Guidance for Collection of Adverse Events Related to COVID-19 Infection. Secondary outcomes: Intensive care unit (ICU) admission, requirement of respiratory support, time to death, number of participants cured, any adverse event related to treatment. Analysis: Descriptive for the presentation of summary measures of the basal conditions by type of variable. Bivariate. Description of the basal conditions (with organic failure at admission, without failure at admission), by type of treatment, by participating institution. Description of crude effectiveness and safety by means of the difference of accumulated incidences, each one with 95% confidence intervals (95% CI) Intention to treat analyisis will be done. Adjusted analysis: The ratio and difference of cumulative incidences of mortality at 7 and 28 days and severe adverse events between treatments will be estimated, adjusting for confounding variables using logistic regression models with mixed effects considering each institution as a level or from equations. generalized estimation (GEE). Ethical considerations: The study has a risk beyond minimum according to the Resolution 8430/1993 of the Colombian Ministry of Health. Informed consent will be explained and signed if the patient is in condition to do so. This protocol will undergo evaluation by the ethics committee at each of the participating institutions and at the National University of Colombia. The protocol follows the Helsinki Declaration and institutional protocols for clinical investigation.

    NCT04359095
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Lopinavir / Ritonavir Pill
    3. Drug: Azithromycin
    4. Other: Standard treatment

    Primary Outcomes

    Description: Cumulative incidence

    Measure: Mortality

    Time: Post-intervention at day 28

    Description: Number of participants that develop severe adverse events related to the treatment

    Measure: Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection

    Time: Post-intervention at day 28

    Secondary Outcomes

    Description: Cumulative incidence

    Measure: Mortality

    Time: Post-intervention at day 7

    Description: Number of participants that develop severe adverse events related to the treatment

    Measure: Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection

    Time: Post-intervention at day 7

    Description: Time from the date of assignment until the date of death from any cause

    Measure: Time to death

    Time: Assessed up to 28 days postintervention

    Description: Number of Participants that require management in the ICU

    Measure: Number of Participants that are transferred to the Intensive Care Unit (ICU)

    Time: Post-intervention at day 28

    Description: Participants requiring invasive mechanical ventilation

    Measure: Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.

    Time: Up to 28 days after hospital admission

    Description: Number of participants cured assessed RT-PCR for SARS CoV-2, without clinical symptoms and no radiological signs assessed by chest X ray

    Measure: Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray

    Time: Up to 28 days after hospital admission

    Description: Any adverse event

    Measure: Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection

    Time: Up to 28 days after hospital admission

    Other Outcomes

    Description: Interim assessment of safety, which will be conducted after 480 participants are recruited. It will be evaluated through absolute frequency of severe AE and relative frequency measurements (proportion of total number of participants with severe adverse events divided by the total number of participants treated). It aims to aid the decision of excluding an active treatment arm should that arm have more than 3 serious adverse events in the first 30 participants or a serious adverse events incidence of 10 percent or higher.

    Measure: Severe Adverse events

    Time: Up to 28 days after hospital admission

    Description: Interim assessment of minimum effectiveness, which will be conducted after 480 participants are recruited. It will be evaluated through relative frequency measurements (mortality proportion at 28 days of treatment). It aims to aid the decision of excluding an active treatment arm should that treatment arm have an efficacy lower than 0.2, calculated through futility analysis that assumes an expected difference of 10 percent at the end of the first phase of the study. For all the tests carried out in the interim analysis, the correction of the type I error will be made using the O'Brien-Fleming method.

    Measure: Mortality

    Time: Up to 28 days after hospital admission
    54 Efficacy and Safety of Azithromycin Compared to the Base Therapeutic Regiment of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial

    The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

    NCT04359316
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin

    Primary Outcomes

    Description: Improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization) or discharge from the hospital, whichever came first.

    Measure: Time to clinical improvement

    Time: From date of randomization until 14 days later.

    Secondary Outcomes

    Description: If the patient dies, we have reached an outcome.

    Measure: Mortality

    Time: From date of randomization until 14 days later.

    Description: Pulse-oxymetry

    Measure: SpO2 Improvement

    Time: Days 1, 2, 3, 4, 5, 6, 7 and 14.

    Description: Incidence of new mechanical ventilation use (Rate)

    Measure: Incidence of new mechanical ventilation use

    Time: From date of randomization until 14 days later.

    Description: Duration of hospitalization (Days)

    Measure: Duration of hospitalization

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 14 days.

    Description: With incidence of any serious adverse effects, the outcome has happened.

    Measure: Cumulative incidence of serious adverse events

    Time: Days 1, 2, 3, 4, 5, 6, 7 and 14.
    55 Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial

    The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

    NCT04359615
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Favipiravir
    2. Drug: Hydroxychloroquine

    Primary Outcomes

    Description: Improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization) or discharge from the hospital, whichever came first.

    Measure: Time to clinical improvement

    Time: From date of randomization until 14 days later.

    Secondary Outcomes

    Description: If the patient dies, we have reached an outcome.

    Measure: Mortality

    Time: From date of randomization until 14 days later.

    Description: Pulse-oxymetry

    Measure: oxygen saturation by pulse oximetry (SpO2) Improvement

    Time: Days 1, 2, 3, 4, 5, 6, 7 and 14.

    Description: Incidence of new mechanical ventilation use

    Measure: Incidence of new mechanical ventilation use

    Time: From date of randomization until 14 days later.

    Description: Duration of hospitalization (days)

    Measure: Duration of hospitalization

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 14 days.

    Description: With incidence of any serious adverse effects, the outcome has happened.

    Measure: Cumulative incidence of serious adverse events

    Time: Days 1, 2, 3, 4, 5, 6, 7 and 14.
    56 Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19: a Randomized, Multicenter, Adaptative Study

    In November 2019, Wuhan city in China, became the center of an outbreak of pneumonia due to a novel coronavirus SARS-CoV-2, which disease was named coronavirus disease 2019 (COVID19) in February, 2020. The COVID19 is much more dangerous for people over 60 with a death rate of 3.6% after 60, 8.0% after 70 and 14.8% after 80 -and according to our Italian colleagues over 20% after 90- against 2.3% in the general population. The elderly patients who died most often had multiple comorbidities and in particular: cardiovascular disease (10.5% mortality), diabetes (7.3%), chronic respiratory disease (6.3%) and hypertension (6%). These elderly patients with COVID19 are therefore very fragile and require treatment that fights the virus but is also adapted to their state of health and age. Most of current therapeutic trials worldwide exclude people aged over 75 years, which is precisely the age group affected by COVID19. We therefore propose to carry out a therapeutic trial specific to the elderly with drugs at doses that are bearable for these patients. Using the WHO, clinicaltrial, pubmed and the Chinese CCDC/CHCTR websites to find the better drugs adapted to elderly people, we decided after concertation between infectiologists and geriatricians to do a four arms clinical trial during two weeks twice a day: Hydroxychloroquine 200mg, Telmisartan 40mg, Azithromycin 250mg and standard care. We therefore hypothesize that one or more of these treatments may have a beneficial effect in controlling COVID19, without major and repeated side effects in elderly patients.

    NCT04359953
    Conditions
    1. COVID-19 Infection
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin
    3. Drug: Telmisartan

    Primary Outcomes

    Measure: Two-weeks survival rate

    Time: Day 14

    Secondary Outcomes

    Measure: Rate of undetectable RT-PCR of SARS-CoV-2

    Time: Day 7

    Measure: Rate of undetectable RT-PCR of SARS-CoV-2

    Time: Day 14

    Measure: Rate of death

    Time: Day 28

    Measure: Hypotension

    Time: Day 7

    Measure: Hypotension

    Time: Day 14

    Measure: Hypothermia and hyperthermia

    Time: Day 7

    Measure: Hypothermia and hyperthermia

    Time: Day 14

    Measure: Pneumonia severity according to WHO

    Time: Day 7

    Measure: Pneumonia severity according to PSI (Hung et al 2017)

    Time: Day 7

    Measure: Pneumonia severity according to WHO

    Time: Day 14

    Measure: Pneumonia severity according to PSI (Hung et al 2017)

    Time: Day 14

    Measure: Rate of no cough

    Time: Day 7

    Measure: Rate of no cough

    Time: Day 14

    Measure: Rate of no dyspnea

    Time: Day 7

    Measure: Rate of no dyspnea

    Time: Day 14

    Measure: Rate of no fever

    Time: Day 7

    Measure: Rate of no fever

    Time: Day 14

    Measure: Rate of no requiring supplemental oxygen

    Time: Day 7

    Measure: Rate of no requiring supplemental oxygen

    Time: Day 14

    Measure: Rate of SARS-Cov-2 undetectable

    Time: Day 7

    Measure: Rate of SARS-Cov-2 undetectable

    Time: Day 14

    Measure: Recovery time

    Time: Day 28

    Measure: Critical admission rate

    Time: Day 28

    Measure: Mechanical ventilation rate

    Time: Day 28

    Measure: Changes in Activity of Daily Living (ADL) Activity of Daily Living)

    Time: Day 13

    Measure: Changes in Activity of Daily Living IADL (Instrumental Activity of Daily Living)

    Time: Day 13

    Measure: The number and dose of added corticosteroids, immonumodulators or immunosuppressants

    Time: Day 14
    57 An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19

    Rationale: Currently there are no approved treatments for COVID-19. In the Dutch treatment protocol guideline (SWAB) designated treatment is supportive care with the option to add chloroquine base (CQ) or hydroxychloroquine (HCQ). CQ and HCQ are implemented because of their in vitro activity, results from small animal studies, and anecdotal patient's data. There are no published randomized studies with these medications in patients with disease caused by any coronavirus. Objective: To evaluate if treatment with only supportive care or addition of one of two anti-COVID_19 agents (chloroquine or hydroxychloroquine) results in less disease progression in patients with moderate to severe COVID-19 who require hospital admission. Study design: Multicentre, cluster randomized cross-over, open label trial. Hospitals will be randomly allocated to one of 3 treatment arms in sequential periods of one week: chloroquine base versus hydroxychloroquine versus supportive care without any drug presumed active against SARS-COV-2. Patients will be treated based on the date of inclusion. Study population: Adults aged of 18 years and older with moderate to severe, with a NEWS-2 score ≤ 5, laboratory confirmed COVID-19, who require hospital admission in a ward outside the Medium Care or Intensive Care. Intervention (if applicable): Depending on the treatment arm, the study subject will receive only supportive care or an addition with one of the two agents active against SARS-CoV-2 (chloroquine or hydroxychloroquine). Main study parameters/endpoints: Disease progression defined as a NEWS-2 score ≥ 7 within 14 days, or admission to Medium Care or Intensive Care Unit, or death.

    NCT04362332
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Chloroquine Sulfate
    2. Drug: Hydroxychloroquine
    3. Other: Standard supportive care

    Primary Outcomes

    Description: Composite endpoint with disease progression defined as a NEWS2score ≥ 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.

    Measure: Composite endpoint with disease progression defined as a NEWS2score ≥ 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.

    Time: 14 days

    Secondary Outcomes

    Description: Secondary study parameters/endpoints Side effects of different drugs leading to regimen change or discontinuation of the antiviral treatment

    Measure: Side effects

    Time: 28 days
    58 VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

    We propose a 3-arm RCT to determine the efficacy of hydroxychloroquine or azithromycin in treating mild to moderate COVID-19 among Veterans in the outpatient setting.

    NCT04363203
    Conditions
    1. SARS-CoV-2
    2. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin
    3. Drug: Placebo oral tablet

    Primary Outcomes

    Measure: Days to resolution of cough, fever and shortness of breath

    Time: 30-days

    Secondary Outcomes

    Measure: Days to resolution of all COVID-19 symptoms

    Time: 30-days

    Measure: All cause hospitalization

    Time: 30-days

    Measure: All cause mortality

    Time: 30-days

    Measure: COVID-19 specific mortality

    Time: 30-days

    Measure: COVID-19 specific hospitalization

    Time: 30-days
    59 Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)

    This a double-blind, randomized, placebo-controlled clinical trial to determine if primary prophylaxis with hydroxychloroquine in healthcare workers reduces symptomatic COVID-19 infection. Healthcare workers will be randomized at a 1:1 allocation between intervention and placebo arms and followed for 12 weeks. This study will enroll up to 1,700 participates in Lafayette, Louisiana. The primary outcome will number of symptomatic COVID-19 infections. Secondary endpoints included number of days healthcare workers are absent from work and rate of severe infection.

    NCT04363450
    Conditions
    1. COVID-19
    2. Corona Virus Infection
    3. Wuhan Coronavirus
    4. Prophylaxis
    5. Healthcare Worker
    6. Sars-CoV2
    7. Hydroxychloroquine
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Number of participants who develop symptoms of COVID-19 in the setting of a positive COVID-19 assay

    Measure: Incidence of symptomatic COVID-19 infection in healthcare workers

    Time: 12 weeks

    Secondary Outcomes

    Description: Number of days healthcare workers are absent from work due to symptomatic COVID-19 infection

    Measure: Absenteeism from work due to COVID-19

    Time: 12 weeks

    Description: Rate of severe COVID-19 infection in healthcare works (hypoxia in setting of chest imaging >50% lung involvement, respiratory failure, end organ damage or shock)

    Measure: Severity of COVID-19 infection

    Time: 12 weeks
    60 PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19)

    This is a Italian, superiority, open label cluster-randomised, interventional clinical trial aimed at assessing whether the treatment with Hydroxychloroquine can reduce the percentage of symptomatic subjects compared to observation only in household members/contacts of COVID-19 patients (Group 1) and if the treatment with Hydroxychloroquine could be introduced in early phase COVID-19 population (Group 2). The participants will be randomised to receive either: Arm A) hydroxychloroquine vs Arm B) Observation (2:1 randomisation).

    NCT04363827
    Conditions
    1. COVID19
    2. Hydroxychloroquine
    3. Prophylaxis
    4. Treatment
    5. SARS-CoV-2
    Interventions
    1. Drug: Hydroxychloroquine
    MeSH:Coronavirus Infections

    Primary Outcomes

    Description: Group 1:The primary endpoint/outcome measure is the proportion of subjects of Group 1 who become symptomatic and/or swab positive in each arm within 1 month from randomization.

    Measure: the proportion of subjects of Group 1 who become symptomatic and/or swab positive in each arm within 1 month from randomization.

    Time: within 1 month from randomization

    Description: Group 2: The primary endpoint/outcome measure is the proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.

    Measure: the proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.

    Time: within 14 days from randomization

    Secondary Outcomes

    Description: The proportion of subjects with positive swabs in randomized population of SARS-CoV-2-exposed subjects ( Group 1) within 1 month from randomization in both arms

    Measure: The proportion of subjects with positive swabs in Group 1 within 1 month from randomization in both arms

    Time: within 1 month from randomization

    Description: The proportion of subjects of Group 1 who become symptomatic in each arm within 1 month from randomization, in subgroup population identified by stratification factors, class of age and gender.

    Measure: The proportion of subjects of Group 1 who become symptomatic in each arm within 1 month from randomization

    Time: within 1 month from randomization

    Description: The proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization, in subgroup population identified by stratification factors, class of age and gender.

    Measure: The proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.

    Time: within 14 days from randomization

    Description: The proportion of subjects of Group 2 who become swab negative in each arm within 1 month from randomization in overall population and in subgroup population identified by stratification factors, class of age and gender.

    Measure: The proportion of subjects of Group 2 who become swab negative in each arm within 1 month from randomization in overall population and in subgroup population

    Time: within 1 month from randomization

    Description: Absolute and relative frequencies of Serious Adverse Events (CTCAE version 5.0) in both arms for the Group 1 and Group 2.

    Measure: Absolute and relative frequencies of Serious Adverse Events

    Time: up to 10 months

    Description: Variation in Quality of Life scores EQ-5D-5L (EQ-5D descriptive system with 5 severity levels from better to worse, and the EQ visual analogue scale (EQ VAS, scale from 100 to 0, high is better) in different time points (weekly) respect to baseline values in both Group 1 and Group 2 populations.

    Measure: Variation in Quality of Life scores in different time points

    Time: up to 10 months
    61 A Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19)

    This is a prospective, randomized, participant-blinded, placebo-controlled, pilot study to assess the preliminary efficacy and safety of hydroxychloroquine for the treatment of patients with lower respiratory tract SARS-CoV-2 infection.

    NCT04363866
    Conditions
    1. COVID-19
    2. SARS-CoV-2
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo

    Primary Outcomes

    Description: A 6-point ordinal scale ranging from "Death" to "Not hospitalized with full resumption of normal activities" is used to evaluate differences in the clinical status between participants that receive placebo vs hydroxychloroquine

    Measure: Clinical Status at Day 5 Assessed by a 6-Point Ordinal Scale

    Time: Day 5

    Secondary Outcomes

    Description: Assess differences in SARS-CoV-2 viral shedding between participants that receive placebo vs hydroxychloroquine

    Measure: Number of Participants with Detectable SARS-CoV-2 Virus from Day 0 to Day 28 and at Day 5

    Time: Day 0 to Day 28 and at Day 5

    Description: Assess by incidence of Grade 3, Grade 4, and Serious Adverse Events (AEs)

    Measure: Toxicity of Study Drug Assessed by Incidence of Adverse Events

    Time: Day 0 to Day 28

    Other Outcomes

    Description: Assess length of hospitalization

    Measure: Duration of Initial Hospitalization

    Time: Day 0 to Day 28

    Description: Assess number of deaths during study follow-up

    Measure: Mortality During Follow-Up

    Time: Day 0 to Day 28

    Description: Assess number of deaths in the hospital during initial hospitalization

    Measure: Mortality During Initial Hospitalization

    Time: Day 0 to Day 28

    Description: Assessing utilization of hospital resources

    Measure: Incidence of New Hospital Resource Utilization

    Time: Day 0 to Day 28

    Description: Assessing duration of hospital resource utilization

    Measure: Duration of Hospital Resource Utilization

    Time: Day 0 to Day 28

    Description: Provide preliminary characterization of differences in inflammatory response between participants that receive placebo vs hydroxychloroquine

    Measure: Changes in Cytokine Profile

    Time: Day 0 to Day 28
    62 A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization

    COVID-19 is a respiratory disease due to a novel coronavirus (SARS-CoV-2) that causes substantial morbidity and mortality. To date, no treatment has been proved to be effective in COVID-19. Elderly patients and patients with comorbidities have the worse prognosis with a higher risk of hospitalization, ICU admission and death. The efficacy of an early outpatient treatment could be suggested but need to be confirmed. This confirmation is mandatory to improve prognosis of COVID-19 but also to avoid unsuspected deleterious effect of drugs already used in clinical practice but not based on evidence.

    NCT04365582
    Conditions
    1. COVID
    Interventions
    1. Drug: Azithromycin
    2. Drug: Hydroxychloroquine
    3. Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab

    Primary Outcomes

    Description: Hospitalization at D20

    Measure: Hospital admission

    Time: Day 20

    Secondary Outcomes

    Description: This outcome corresponds to the number of patients who died on day 20.

    Measure: Effect of treatment on Death at D20

    Time: Day 20

    Description: This outcome corresponds to the number of patients who died on day 60.

    Measure: Effect of treatment on Death at D60

    Time: Day 60

    Description: This outcome corresponds to the number of patients who died due to COVID on day 20.

    Measure: Effect of treatment on Death due to COVID at D20

    Time: Day 20

    Description: This outcome corresponds to the number of patients who died due to COVID on day 60.

    Measure: Effect of treatment on Death due to COVID at D60

    Time: Day 60

    Description: This outcome corresponds to the number of participants who need ICU stay at day 20.

    Measure: Effect of treatment on need for ICU stay at D20

    Time: Day 20

    Description: This outcome corresponds to the number of participants who need ICU stay at day 60.

    Measure: Effect of treatment on need for ICU stay at D60

    Time: Day 60

    Description: This outcome evaluates the duration of patient's ICU stay at day 20.

    Measure: Effect of treatment on duration of ICU stay at D20

    Time: Day 20

    Description: This outcome evaluates the duration of patient's ICU stay at day 60.

    Measure: Effect of treatment on duration of ICU stay at D60

    Time: Day 60

    Description: This outcome corresponds to the number of participants who need mechanical ventilation at D20.

    Measure: Effect of treatment on need of mechanical ventilation at D20

    Time: Day 20

    Description: This outcome corresponds to the number of participants who need mechanical ventilation at D60.

    Measure: Effect of treatment on need of mechanical ventilation at D60

    Time: Day 60

    Description: This outcome corresponds to the duration of patient's mechanical ventilation at D20.

    Measure: Effect of treatment on duration of mechanical ventilation at D20

    Time: Day 20

    Description: This outcome corresponds to the duration of patient's mechanical ventilation at D60.

    Measure: Effect of treatment on duration of mechanical ventilation at D60

    Time: Day 60

    Description: This outcome evaluates the delay between inclusion and hospitalization at D20.

    Measure: Effect of treatment on time to hospitalization at D20

    Time: Day 20

    Description: This outcome evaluates the delay between inclusion and hospitalization at D60.

    Measure: Effect of treatment on time to hospitalization at D60

    Time: Day 60

    Description: This outcome evaluates the duration of patient's Hospital stay at D20.

    Measure: Effect of treatment on Duration of Hospital stay et D20

    Time: Day 20

    Description: This outcome evaluates the duration of patient's Hospital stay at D60.

    Measure: Effect of treatment on Duration of Hospital stay et D60

    Time: Day 60

    Description: This outcome evaluates the duration of symptoms at D20 after treatment.

    Measure: Effect of treatment on Duration of symptoms at D20

    Time: Day 20

    Description: This outcome evaluates the duration of symptoms at D60 after treatment.

    Measure: Effect of treatment on Duration of symptoms at D60

    Time: Day 60

    Description: This outcome measures the number of participants with treatment-related adverse events as assessed by CTCAE v4.0, at the end of study.

    Measure: Incidence of Treatment-Emergent Adverse Events

    Time: Month 6

    Other Outcomes

    Description: This outcome evaluates the chest radiological features on Chest HRCT, at 6 months, after treatment.

    Measure: Effect of treatment on chest radiological features

    Time: Month 6

    Description: This outcome evaluates the Pulmonary function test at 6 month, after treatment.

    Measure: Effect of treatment on respiratory capacity

    Time: Month 6

    Description: This ouctome eavaluates costs and consequences which will be presented for each stakeholder in a disaggregated way at the end of study.

    Measure: Cost consequence analysis

    Time: Month 6
    63 Efficacy and Safety of Hydroxychloroquine in Primary Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers at Risk of Exposure: Randomised Control Trial

    Healthcare personnel are at an increased risk of exposure to SARS-CoV-2 infection while handling such patients. Currently, there is no treatment available for SARS-CoV-2 and stringent preventive measures are advised to avoid or minimize risk of exposure to healthcare workers. There are in vitro studies available which show inhibition of corona virus by hydroxychloroquine, a widely-used agent against malaria and certain autoimmune conditions and of low-cost and limited toxicity. However, evidence regarding its effects in patients is limited. We plan to conduct a randomized controlled trial to evaluate the safety and potential prophylactic efficacy of hydroxychloroquine in preventing secondary SARS-CoV-2 infection among healthcare workers at high-risk of exposure while managing such patients.

    NCT04370015
    Conditions
    1. SARS-CoV-2
    2. Healthcare Workers
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Infection

    Primary Outcomes

    Description: Negative RT-PCR for SARS-CoV-2 both at baseline and at end of 12 weeks in experimental arm

    Measure: Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period

    Time: From date of randomization until study completion 12 weeks after treatment initiation

    Description: To assess the presence or absence of side effects from HCQ treatment.

    Measure: Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment

    Time: From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation

    Secondary Outcomes

    Description: Symptomatic infection by SARS-CoV-2 defined as cough, dyspnea, fever, myalgia, arthralgia or rhinorrhea.

    Measure: Confirmed SARS-CoV-2 infection based on symptoms and confirmed by RT-PCR

    Time: From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation

    Description: Disease severity including i) asymptomatic. ii) Mild symptoms but ambulatory. iii) Moderate symptoms requiring hospitalisation. iv) severe symptoms requiring ICU care and oxygen. v) Severe symptoms requiring assisted mechanical ventilation. vi) Death.

    Measure: Clinical disease severity in confirmed SARS-CoV-2 participants

    Time: From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation

    Description: Symptomatic non-COVID viral infection (any other acute respiratory illness with fever but without evidence of epidemiological risk factors such as close contact with SARS-CoV-2 positive patient or travel to or residence in high-risk area).

    Measure: Incidence of any acute respiratory infection

    Time: From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation
    64 A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting

    This is a randomized, open-label trial to assess the safety and efficacy of hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a higher risk COVID-19 positive outpatient population.

    NCT04370782
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin
    3. Drug: Zinc Sulfate
    4. Drug: Doxycycline

    Primary Outcomes

    Description: Patients will be assessed on day 5 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)

    Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial)

    Time: Day 5

    Description: Patients will be assessed on day 14 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)

    Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial)

    Time: Day 14

    Description: Patients will be assessed on day 21 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)

    Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial)

    Time: Day 21

    Description: Number of participants hospitalized and/or requiring repeat ER visits related to COVID-19 complications

    Measure: Number of participants hospitalized and/or requiring repeat ER visits

    Time: 21 days

    Description: If hospitalized, number of participants admitted to the ICU, and number of days in the ICU

    Measure: ICU Length of Stay

    Time: Until Discharged up to 30 days

    Description: If placed on ventilator, number of days on a ventilator

    Measure: Ventilator

    Time: Until extubated up to 30 days

    Secondary Outcomes

    Description: Severity of symptoms evaluated at day 5, day 14, and day 21 scored by the participant for feverishness, sore throat, cough, shortness of breath, myalgias. (0 =none; 1 = mild; 2 = moderate; 3 = severe)

    Measure: Severity of symptoms

    Time: Day 5, Day 14, and Day 21

    Description: Number of participants with adverse events due to drug regimen

    Measure: Number of participants with adverse events due to drug regimen

    Time: 21 days

    Description: Assess all patients to evaluate for QTc prolongation >500ms

    Measure: Number of participants with QTc prolongation >500ms

    Time: Days 1 thru 5, Day 10, Day 21
    65 Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection

    This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.

    NCT04372017
    Conditions
    1. COVID-19
    2. SARS-CoV 2
    Interventions
    1. Drug: Hydroxychloroquine
    2. Dietary Supplement: Vitamin D
    MeSH:Infection

    Primary Outcomes

    Description: Determine whether post-exposure prophylaxis with hydroxychloroquine can prevent COVID-19 in healthcare workers who have been exposed to a known case of COVID-19.

    Measure: Cohort A: Percentage of COVID-19 exposed healthcare workers treated with hydroxychloroquine with a positive COVID-19 test.

    Time: At enrollment completion outcome 1 will be analyzed.

    Description: Determine whether post-exposure prophylaxis with hydroxychloroquine can prevent COVID-19 in high-risk individuals who have been exposed to a known case of COVID-19.

    Measure: Cohort B: Percentage of COVID-19 exposed high-risk individuals treated with hydroxychloroquine with a positive COVID-19 test.

    Time: At enrollment completion outcome 2 will be analyzed.
    66 Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities: Multicenter, Randomized, Open-labeled Controlled Trial

    No optimal antiviral intervention has been yet validated to treat COVID-19 disease. Comorbidities, such as older age, obesity, diabetes, history of cardiovascular diseases are associated with poor prognosis. This study aims to evaluate the efficacy of two experimental antiviral treatments, compared to standard of care (SOC), to prevent clinical worsening, hospitalization or death at day 14 in adults with documented SARS-CoV-2 infection, asymptomatic or with symptoms lasting less than 8 days, and associated comorbidities without any severity criteria of the disease at inclusion. Participants will be randomized to receive SOC alone or SOC + hydroxychloroquine 200 mg three times a day during 10 days or SOC + association of niclosamide 2 g at J1 then 500 mg two times a day with diltiazem 60 mg three times a day during 10 days. Efficacy and tolerance of each treatments will be compared across the three treatment groups during the 28 days of follow-up.

    NCT04372082
    Conditions
    1. Sars-CoV2
    Interventions
    1. Other: Standard of care (SOC)
    2. Drug: Hydroxychloroquine
    3. Drug: Association of diltiazem and niclosamide

    Primary Outcomes

    Description: Composite criteria

    Measure: death

    Time: At day 14

    Description: clinical worsening defined by at least one of the NEWS score item > 2 (temperature >39,1°C or<35°C, cardiac rate >111 or ≤40 bpm, respiratory rate > 21 or ≤8 cycles par minute, SaO2 ≤ 93% room air (if its measure is available),need of oxygen

    Measure: clinical worsening (composite criteria)

    Time: At day 14

    Measure: Assisted-ventilation and/or hospitalization (composite criteria)

    Time: At day 14

    Secondary Outcomes

    Description: clinical state as reflected by NEWS scoring, the clinical state of the patient regarding respiratory state as defined by the NEWS scoring system

    Measure: National Early Warning Score (NEWS)

    Time: at day 3, day 8, day 14 day 28

    Measure: cumulative incidence of hospitalizations

    Time: at day 14

    Measure: cumulative incidence of the use of oxygen therapy, non-invasive ventilation or invasive ventilation ( composite criteria)

    Time: at day 14

    Description: Number of patients death

    Measure: Mortality

    Time: at day 14 and at day 28

    Measure: cumulative incidence of viral shedding on SARS-CoV-2 rt-PCR on nasopharyngeal swab;

    Time: at day 3, day 8

    Measure: adverse drug reactions

    Time: during study, up to 28 days
    67 A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19

    This phase II trial studies the effect of baricitinib in combination with antiviral therapy for the treatment of patients with moderate or severe coronavirus disease-2019 (COVID-19). Treatment with antiviral medications such as hydroxychloroquine, lopinavir/ritonavir, and/or remdesivir may act against infection caused by the virus responsible for COVID-19. Baricitinib may reduce lung inflammation. Giving baricitinib in combination with antiviral therapy may reduce the risk of the disease from getting worse and may help prevent the need for being placed on a ventilator should the disease worsen compared to antiviral therapy alone.

    NCT04373044
    Conditions
    1. Symptomatic COVID-19 Infection Laboratory-Confirmed
    Interventions
    1. Drug: Baricitinib
    2. Drug: Hydroxychloroquine
    3. Drug: Placebo Administration
    MeSH:Laboratory Infection

    Primary Outcomes

    Description: Descriptive statistics, including means, standard deviations, and ranges for continuous variables, as well as percentages and frequencies for categorical variables, will be provided to describe all the clinical findings in a cohort of symptomatic coronavirus disease 2019 (COVID-19)-infected subjects. The collected data will also be graphically presented in boxplots, histograms, and scatter plots. Investigations for outliers and assumptions for statistical analysis, e.g., normality and homoscedasticity, will be made. Group comparisons will be made using either the parametric tests such as t-test and analysis of variance (ANOVA), or the non-parametric statistical method such as Wilcoxon and Kruskal-Wallis tests for continuous variable and Chi-square test for categorical variables. Point estimates, along with the corresponding p-values and 95% confidence intervals will be reported.

    Measure: Proportion of patients requiring invasive mechanical ventilation or dying

    Time: Up to 14 days

    Secondary Outcomes

    Description: Body temperature will be measured in degrees Fahrenheit using an automated thermometer.

    Measure: Identification of clinical features (vitals signs - body temperature)

    Time: Up to 28 days

    Description: Respiratory rate in times/minute

    Measure: Identification of clinical features (vital signs - respiratory rate)

    Time: Up to 28 days

    Description: Heart rate in beats/minute

    Measure: Identification of clinical features (vital signs - heart rate)

    Time: Up to 28 days

    Description: Blood pressure in mmHg

    Measure: Identification of clinical features (vital signs - blood pressure)

    Time: Up to 28 days

    Description: Chest X-ray or pulmonary computed tomography (CT) will be performed

    Measure: Identification of clinical features (Imaging)

    Time: Up to 28 days

    Description: Assessment via standard blood chemistry and metabolic panel

    Measure: Identification of clinical features (Lab - White Blood Count)

    Time: Up to 28 days

    Description: Assessment via standard blood chemistry and metabolic panel

    Measure: Identification of clinical features (Lab - Absolute Lymphocyte Count)

    Time: Up to 28 days

    Description: Assessment via standard blood chemistry and metabolic panel

    Measure: Identification of clinical features (Lab - Hemoglobin)

    Time: Up to 28 days

    Description: Assessment via standard blood chemistry and metabolic panel

    Measure: Identification of clinical features (Lab - Creatinine)

    Time: Up to 28 days

    Description: CRP is assessed by routinely used determination of CRP.

    Measure: Identification of biomarkers (C-reactive protein)

    Time: Up to 14 days

    Description: IL-6 levels will be assessed using commercial ELISA method

    Measure: Identification of biomarkers (Interleukin-6)

    Time: Up to 14 days

    Description: Tumor Necrosis Factor-alpha as measured in hospital laboratory

    Measure: Identification of biomarkers (Tumor Necrosis Factor-alpha)

    Time: Up to 14 days

    Description: Descriptive statistics, including means, standard deviations, and ranges for continuous variables, as well as percentages and frequencies for categorical variables, will be provided to describe all the clinical findings in a cohort of symptomatic COVID-19-infected subjects. The collected data will also be graphically presented in boxplots, histograms, and scatter plots. Investigations for outliers and assumptions for statistical analysis, e.g., normality and homoscedasticity, will be made. Group comparisons will be made using either the parametric tests such as t-test and ANOVA, or the non-parametric statistical method such as Wilcoxon and Kruskal-Wallis tests for continuous variable and Chi-square test for categorical variables. Point estimates, along with the corresponding p-values and 95% confidence intervals will be reported.

    Measure: Identification of adverse events

    Time: Up to 14 days

    Other Outcomes

    Measure: Measurement of COVID19 viral burden

    Time: Up to 14 days
    68 Protecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada

    On 11 March 2020, the World Health Organization declared SARS-CoV-2 (commonly called COVID-19) a global pandemic. As in any pandemic, maintaining the health and safety of the healthcare workforce is of great importance as health care workers (HCW) remain a critical line of defence against the spread of COVID-19 and play a vital role in the recovery of those already infected. Frontline HCW, such as those in the emergency department (ED), are at high risk of contracting COVID-19 due to their close proximity to patients who may have the virus. The impact of frontline HCW becoming ill and thus unable to go to work is equally high, and of grave risk to the function of the healthcare system and the ability to minimize the impact of the current pandemic. This study aims to evaluate whether hydroxychloroquine (HCQ), a well-tolerated drug typically used in the prevention of malaria transmission and rheumatic disease, taken before and during exposure to patients with COVID-19, is effective at reducing COVID-19 infections among ED health care workers.

    NCT04374942
    Conditions
    1. Pre-Exposure Prophylaxis
    2. Coronavirus
    3. SARS-CoV 2
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Coronavirus Infections

    Primary Outcomes

    Description: This is a composite endpoint which includes any positive result from a validated SARS-CoV-2 diagnostic assay including detection of viral RNA, or seroconversion by day 104 (14 days after end of the randomization period).

    Measure: Microbiologically confirmed COVID-19 (SARS-CoV-2 infection)

    Time: Samples collected at day 0, 30, 60, 90 and 120

    Secondary Outcomes

    Description: Assessed using the DAIDS Table for Grading the Severity of Adverse Events

    Measure: Adverse events

    Time: Assessed at day 30, 60, 90, and day 120

    Description: Collected weekly from participants via self-report, sent by email

    Measure: Symptom duration of COVID-19

    Time: Collected every 7 days from day 7 to day 120

    Description: The number of days (or partial days) spent admitted to an acute care hospital during the study period

    Measure: Days of hospitalization attributable to COVID-19

    Time: Collected every 7 days from day 7 to day 120

    Description: the number of days (or partial days) requiring i) non-invasive and ii) endotracheal intubation with ventilation during the study period

    Measure: Respiratory failure requiring ventilatory support attributable to COVID-19

    Time: Collected every 7 days from day 7 to day 120

    Description: Mortality attributable to COVID-19 and all-cause mortality during the study period

    Measure: Mortality

    Time: Collected every 7 days from day 7 to day 120

    Description: Number of days ineligible/unable to work due to COVID-19

    Measure: Impact on work eligibility

    Time: Collected every 7 days from day 7 to day 120

    Description: COVID-19 reactive serology

    Measure: Seropositivity

    Time: Blood collected at day 0, 30, 60, 90, 120

    Description: Short-term psychological impact of exposure to COVID-19 measured using the K10, a validated measure of non-specific psychological distress, with a standard cutoff score of ≥16

    Measure: Short-term psychological impact

    Time: Measured at day 1, 60, 120
    69 The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study

    This is an open-label, non-randomized clinical trial study. The number of 40 COVID-19 patients with moderate severity will be admitted in progressive care units (PCUs) and intensive care units (ICUs) enrolled in the study. The sampling will be purposive and based on the same independent variables, including age, gender, past medical histories, and the situation of the patient at the admission day, and ventilator support. The patients will be allocated into two groups with different regimens. Group "A" (regimen A)will be defined as Favipiravir 1600 mg a first dose and 600 mg in 3 divided doses daily plus 400 mg in 2 divided doses of Hydroxychloroquine every day. The group "B" (regimen B) will be contained 400 mg of Lopinavir/Ritonavirin 2 divided doses plus the first dose (400 mg) of Hydroxychloroquine. Hydroxychloroquine will not be used for adverse drug reactions. The regimen remained at least 7 up to 10 days. Data will be analyzed using statistical package for social sciences (SPSS) version 18 (SPSS Inc. Chicago, IL, USA) for windows. The variables will be compared using independent and paired T-test for normally distributed variables and Wilcoxon, Chi-square for non-normal distributed variables. The Kaplan Meier test will be used for survival analysis and the one-sample Kolmogorov-Smirnov test for the evaluation of distributions.

    NCT04376814
    Conditions
    1. COVID-19
    2. Favipiravir
    3. Kaletra
    4. Hydroxychloroquine
    5. Lopinavir/Ritonavir
    Interventions
    1. Drug: Favipiravir
    2. Drug: Hydroxychloroquine
    3. Drug: Lopinavir / Ritonavir

    Primary Outcomes

    Description: In-hospital mortality

    Measure: Mortality

    Time: Up to 28 days

    Description: long of hospitalization

    Measure: long of hospitalization

    Time: Up to 28 days

    Description: Laboratory Treatment Response; return of blood cell count to normal

    Measure: Laboratory Treatment Response (Blood cell count)

    Time: Up to 28 days

    Description: Laboratory Treatment Response; return of CRP values to normal

    Measure: Laboratory Treatment Response (CRP )

    Time: Up to 28 days

    Description: shortness of breath based on symptoms of Dyspnea and questioning the patient

    Measure: Dyspnea

    Time: Up to 28 days

    Description: Oxygen saturation without supplemental oxygen. Measurement will be done after discontinuation of oxygen therapy for 5 minutes.

    Measure: Oxygen saturation without supplemental oxygen.

    Time: Up to 28 days

    Description: Oxygen therapy maximum flow during the day (lit/min)

    Measure: Oxygen therapy

    Time: Up to 28 days
    70 A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit)

    A multicenter randomized clinical trial aiming to assess the efficacy of hydroxychloroquine associated to Zinc compared to hydroxychloroquine, in the prevention of Military Health Professionals Exposed to SARS CoV2 in Tunisia

    NCT04377646
    Conditions
    1. Sars-CoV2
    2. COVID19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Hydroxychloroquine (placebo)
    3. Drug: Zinc
    4. Drug: Zinc (Placebo)
    MeSH:Infection

    Primary Outcomes

    Description: Frequency of confirmed SARS CoV2 infection

    Measure: SARS CoV2 infection

    Time: At 2 months of follow-up

    Secondary Outcomes

    Description: Any COVID-19 related symptoms (cough, fever, headache, vomiting, nausea, dyspnea, diarrhea, smell disorder,conjunctivitis, dizziness)

    Measure: COVID-19 symptoms description

    Time: At 2 months of follow-up

    Description: Any adverse event or serious adverse event

    Measure: Adverse Events

    Time: each month up to 2 months
    71 Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

    This study is being done to see if hydroxychloroquine is an effective treatment for COVID-19.

    NCT04379492
    Conditions
    1. COVID-19
    2. COVID19
    3. Sars-CoV2
    4. SARS-Cov-2
    Interventions
    1. Drug: Hydroxychloroquine
    2. Other: Placebo

    Primary Outcomes

    Description: Clinical improvement is defined as a composite endpoint of a two-point clinical improvement on the Ordinal Scale for Clinical Improvement (OSCI). The OSCI is an ordinal scale of 9 severity levels (from 0 to 8) for COVID-19

    Measure: Clinical improvement on the Ordinal Scale for Clinical Improvement (OSCI)

    Time: 14 days

    Description: Clinical improvement is defined as no mechanical ventilation for respiratory failure attributed to SARS-CoV-2 within 14 days of randomization.

    Measure: Number of participants requiring mechanical ventilation for respiratory failure

    Time: 14 days
    72 Randomised Evaluation of COVID-19 Therapy

    RECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Convalescent plasma or Tocilizumab prevents death in patients with COVID-19.

    NCT04381936
    Conditions
    1. Severe Acute Respiratory Syndrome
    Interventions
    1. Drug: Lopinavir-Ritonavir
    2. Drug: Corticosteroid
    3. Drug: Hydroxychloroquine
    4. Drug: Azithromycin
    5. Biological: Convalescent plasma
    6. Drug: Tocilizumab
    7. Biological: Immunoglobulin
    MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections

    Primary Outcomes

    Description: For each pairwise comparison with the 'no additional treatment' arm, the primary objective is to provide reliable estimates of the effect of study treatments on all-cause mortality.

    Measure: All-cause mortality

    Time: Within 28 days after randomisation

    Secondary Outcomes

    Description: To assess the effects of study treatment on number of days stay in hospital

    Measure: Duration of hospital stay

    Time: Within 28 days and up to 6 months after the main randomisation

    Description: Among patients not on mechanical ventilation at baseline, the number of patients with a composite endpoint of death or need for mechanical ventilation or ECMO.

    Measure: Composite endpoint of death or need for mechanical ventilation or ECMO

    Time: Within 28 days and up to 6 months after the main randomisation

    Other Outcomes

    Description: To assess the effects of study treatment on number of patients who needed ventilation and the number of days it was required

    Measure: Need for (and duration of) ventilation

    Time: Within 28 days and up to 6 months after the main randomisation

    Description: To assess the effects of study treatment on number of patients who needed renal replacement therapy

    Measure: Need for renal replacement

    Time: Within 28 days and up to 6 months after the main randomisation

    Description: To assess the effects of study treatment on number of patients who develop new major cardiac arrythmias

    Measure: Development of new major cardiac arrythmias

    Time: Within 28 days and up to 6 months after the main randomisation
    73 A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID)

    The researchers are doing this study to find out whether the study drug hydroxychloroquine can prevent infection with the COVID-19 virus, compared with placebo, in people who are receiving radiation therapy for their cancer. The placebo used in this study is a tablet that looks the same as the study drug and is taken in the same way, but it does not contain any active ingredients.

    NCT04381988
    Conditions
    1. COVID-19
    2. Cancer
    Interventions
    1. Drug: Hydroxychloroquine
    2. Other: Placebo
    3. Radiation: Radiation therapy

    Primary Outcomes

    Description: Any patients who are enrolled and subsequently test positive for SARS-CoV-2 by RT-PCR (outside RT-PCR test results allowed) at any point during the 9 weeks following enrollment will be an event that is considered in the 9-week SARS-CoV-2 infection rate primary endpoint.

    Measure: cumulative incidence of SARS-CoV-2 infection

    Time: within 9 weeks from randomization

    Secondary Outcomes

    Description: Patients who are positive for SARS-CoV-2 (as defined above) who develop a new oxygen requirement attributable to COVID-19, tachypnea (RR > 20), or those who require hospitalization due to COVID-19 will be considered to have severe COVID-19.

    Measure: cumulative incidence of severe COVID-19 or death

    Time: within 12 weeks of randomization
    74 Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial

    Novel coronavirus SARS(Severe Acute Respiratory Syndrome)-CoV-2 was first identified during the outbreak in Wuhan, China in December 2019 with the now resulting pandemic. Aggressive supportive care is the mainstay of treatment currently and rescue with lung protective mechanical ventilation is essential for survival in patients with severe acute respiratory distress syndrome. Despite supportive care, mortality is significant in hospitalized patients in the U.S., especially among patients > 65 years of age. Pharmacologic treatments to decrease disease severity are urgently needed. Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria. In vitro and in vivo antiviral activity towards SARS-CoV-2 has been reported. Since hydroxychloroquine has been used for decades its properties as a drug are well known. The investigators propose a pragmatic trial of hydroxychloroquine in moderately ill hospitalized adults with SARS-CoV-2 pneumonia with the hypothesis that hydroxychloroquine reduces severity of acute lung injury caused by SARS-CoV-2 infection.

    NCT04382625
    Conditions
    1. SARS-CoV-2 Pneumonia
    2. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    MeSH:Pneumonia
    HPO:Pneumonia

    Primary Outcomes

    Description: paO2

    Measure: Change from Baseline Oxygenation on Day 1 to Day 5

    Time: Day 1 of treatment to day 5 of treatment

    Description: FIO2

    Measure: Change from Baseline Oxygenation at Day 5

    Time: Day 1 of treatment to day 5 of treatment

    Secondary Outcomes

    Description: Length in hours

    Measure: Intensive Care length of stay

    Time: Day 0 to Day 28

    Description: Length in hours

    Measure: Required Mechanical Ventilation

    Time: Day 0 to Day 28

    Description: Length in hours

    Measure: Required Oxygen supplementation

    Time: Day 0 to Day 28

    Description: Length in hours

    Measure: Hospitalization length of Stay

    Time: Day 0 to Day 28

    Description: Date of Death

    Measure: Mortality

    Time: Day 0 to Day 28

    Description: Cardiologist Diagnostic Documentation

    Measure: Cardiac Arrhythmia - Polymorphic Ventricular Tachycardia

    Time: Day 0 to Day 28

    Description: Cardiologist Diagnostic Documentation

    Measure: Cardiac Arrhythmia - Ventricular Tachycardia

    Time: Day 0 to Day 28

    Description: Cardiologist Diagnostic Documentation

    Measure: Cardiac Arrhythmia - Lengthening QTc

    Time: Day 0 to Day 28
    75 Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis

    We have to be aware of the challenge and concerns brought by 2019-nCoV to our healthcare workers. Front-line healthcare workers can become infected in the management of patients with COVID-19; the high viral load in the atmosphere, and infected medical equipment are sources for the spread of SARS-CoV-2. If prevention and control measures are not in place, these healthcare workers are at great risk of infection and become the inadvertent carriers to patients who are in hospital for other diseases. Nowadays a question that has not yet been clarified by science has been arises: is hydroxychloroquine associated with zinc compared to ivermectin associated with zinc effective as a prophylaxis for asymptomatic professionals involved in the treatment of suspected or confirmed case of COVID-19?

    NCT04384458
    Conditions
    1. Coronavirus Infections
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Ivermectin
    MeSH:Coro Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Proportion of participants in whom there was a a positivity for SARS-CoV-2 through specific examination (RT-PCR) or by serology for antibodies specific (IgM and IgG), corroborated or not with clinical finding of COVID-19, defined as the occurrence of signs and symptoms suggestive of this disease.

    Measure: Proportion of participants in whom there was a positivity for SARS-CoV-2.

    Time: Post-intervention at day 52

    Secondary Outcomes

    Description: Proportion of participants who developed mild, moderate, or severe forms of COVID-19.

    Measure: Participants who developed mild, moderate, or severe forms of COVID-19.

    Time: Post-intervention at day 52.

    Description: Measurement of the QT interval through electrocardiogram evaluation.

    Measure: Measurement of the QT interval.

    Time: Baseline, 3, 15 and 45 days post-intervention.

    Description: Proportion of participants who evolved with widening of the corrected QT interval or with changes in heart rate on the ECG.

    Measure: Widening of the corrected QT interval or with changes in heart rate on the ECG.

    Time: Day 52.

    Description: Comparison of baseline (visit 0) and final (visit 5) values of hematological and biochemical parameters.

    Measure: Comparison of hematological and biochemical parameters.

    Time: Day 52.

    Description: Proportion of occurrence of adverse events reported by participants or verified by the attending physician, or even observed in laboratory tests.

    Measure: Occurrence of adverse events.

    Time: Post-intervention at day 52.

    Description: Severity of symptoms of COVID-19 measured by a visual analog scale (VAS), with scores ranging from zero to 10, where zero represents the absence of the symptom and 10 corresponds to the most intense manifestation of symptoms (severe dyspnoea).

    Measure: Assessment of COVID-19 symptom severity.

    Time: Post-intervention at day 52.

    Description: Proportion of participants who discontinue study intervention,

    Measure: Proportion of participants who discontinue study intervention.

    Time: Post-intervention at day 52.

    Description: Proportion of participants who required hospital care.

    Measure: Proportion of participants who required hospital care.

    Time: Post-intervention at day 52.

    Description: Proportion of participants who required mechanical ventilation.

    Measure: Proportion of participants who required mechanical ventilation.

    Time: Post-intervention at day 52.
    76 #StayHome: Efficacy of Early Hydroxychloroquine in Outpatients to Reduce Secondary Hospitalisation and Household Transmission of COVID-19 in Switzerland: A Double-blind, Randomised, Placebo-controlled Trial

    BACKGROUND Despite drastic quarantine measures, COVID-19 continues to propagate and threatens global healthcare systems by saturating their capacity with high transmissibility and the particularly protracted length of stay needed by those requiring intensive care. Indeed, once patients advance to the ICU, prognosis is poor and it is thus critical to test medications that may prevent complications and reduce viral shedding. i.e. to protect ambulatory patients and their families from complications and transmission and allow them to #StayHome. To date, no treatment has been reliably demonstrated as effective in COVID-19 patients. Hydroxychloroquine (HCQ), a common and well tolerated medication, has shown promise in vitro for reducing viral replication (for SARS-CoV-2 as well as other coronaviruses with pandemic potential such as SARS-CoV-1 and MERS). Since then, several small-scale hospital-based clinical studies have indicated the potential for reduced viral shedding and hospitalisation as well as favourable evolution of lung pathology. If started earlier, this treatment could prevent complications requiring hospitalisation and intensive care, which may not be available in low-income countries. Robust clinical trials are required to assess the potential of HCQ in COVID-19. OBJECTIVES This trial assesses the efficacy of early treatment with HCQ in COVID-19 outpatients to reduce the incidence and severity of complications including secondary hospitalisation, ICU admissions, lung pathology and death. Secondarily, this trial will also assess its efficacy to reduce viral transmission among household contacts during self-quarantine. The clinical data collected in this trial will also be critical in creating early prognostication models to better predict healthcare needs and have evidence-based prioritization of resource allocation, which is especially critical in low-resource settings. METHODS The trial will recruit 800 SARS-CoV-2+ patients and their household contacts at triage sites across Switzerland. Patients included are 1) at risk of poor outcome (comorbidities or >65y) and 2) well enough to self-isolate at home. These patients will be randomised 1:1 in HCQ:Placebo and given 6 days of early treatment (within 24 hours of the SARS-CoV-2 test). Intensive pragmatic multiparameter at-home follow-up (including point-of-care lung ultrasound in some sites) will continue until their outcome (resolution, or complications, such as hospitalisation, ICU admission, death). Household contacts will have before and after serological testing and social distancing knowledge and practices questionnaires to assess risk factors for infections. The household attack rate of new-onset infections can then assess the efficacy of HCQ to prevent transmission.

    NCT04385264
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Mannitol

    Primary Outcomes

    Description: Proportion of secondary hospitalisations (and their length), ICU admissions (and their length) and deaths.

    Measure: Proportion of poor outcomes (in index cases)

    Time: During the period that the subject is considered as COVID-19-positive: Average of 11 days

    Secondary Outcomes

    Description: Proportion of a household with new seropositivity for SARS-CoV-2

    Measure: Secondary household attack rate (in household contacts)

    Time: From day 0 (diagnosis and enrolment of index case) to 14 days after the outcome of the index case is recorded (recovery, hospitalisation or death): Average of 25 days

    Description: An ordinal scale of disease severity using a visual analogue scale (0-10 where 0 is asymptomatic)

    Measure: Subjective disease severity (in index cases)

    Time: During the period that the subject is considered as COVID-19-positive: Average of 11 days

    Description: As recorded during hospitalisation

    Measure: Rate of acute respiratory distress syndrome (in index cases)

    Time: During the period that the subject is considered as COVID-19-positive: Average of 11 days

    Description: Measured with lung ultrasound, CT or x-ray

    Measure: Severity of radiological lung pathology (in index cases)

    Time: During the period that the subject is considered as COVID-19-positive: Average of 11 days

    Description: An ordinal scale of disease severity using the evolution of clinical biomarkers such as oxygen saturation, respiration rate etc.

    Measure: Objective disease severity (in index cases)

    Time: During the period that the subject is considered as COVID-19-positive: Average of 11 days

    Description: Plasma concentrations of HCQ measured by liquid chromatography-tandem mass spectrometry

    Measure: Safety: Unintended toxic HCQ accumulation (in index cases)

    Time: During the period that the subject is considered as COVID-19-positive : Average of 11 days

    Description: Ambulatory ECG and intensive monitoring for adverse events

    Measure: Safety: Adverse events (in index cases)

    Time: During the period that the subject is considered as COVID-19-positive : Average of 11 days

    Description: Visual analogue scores for social distancing practices (0-5, where 0 is no social distancing at all)

    Measure: Social distancing knowledge, attitudes and practices amongst index cases and household contacts

    Time: During the period that the subject is considered as COVID-19-positive: Average of 11 days
    77 Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19

    The aim of this study is to reduce COVID-19 related pulmonary complications in adult patients undergoing all types of elective or emergency surgery in a COVID-19 exposed environment. A Trial in Low and Middle Income Countries (LMICs) and A Trial in High Income Countries (HICs)

    NCT04386070
    Conditions
    1. Pulmonary Complications in Surgical Patients
    2. COVID
    3. Severe Acute Respiratory Syndrome
    Interventions
    1. Drug: Lopinavir-Ritonavir
    2. Drug: Hydroxychloroquine
    MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections

    Primary Outcomes

    Description: The primary outcome is any one of the following COVID-19 specific, inpatient, postoperative pulmonary complications: Pneumonia Acute respiratory distress syndrome (ARDS) Death

    Measure: Pneumonia free survival; acute respiratory distress syndrome (ARDS) free survival; or death

    Time: From randomisation until discharge from hospital, average less than 30 days

    Secondary Outcomes

    Description: Pneumonia will be presented and analysed separately as a secondary outcome measure as well as within the composite primary outcome measure.

    Measure: Rate of Pneumonia

    Time: From randomisation until discharge from hospital, average less than 30 days

    Description: ARDs will be presented and analysed separately as a secondary outcome measure

    Measure: Rate of ARDs

    Time: From randomisation until discharge from hospital, average less than 30 days

    Description: Death will be presented and analysed separately as a secondary outcome measure

    Measure: Death rate

    Time: From randomisation until discharge from hospital, average less than 30 days

    Description: Unexpected inability to extubate and wean patient from ventilation after general anaesthesia, or reintubation and ventilation by 30 days after surgery

    Measure: Rate of unexpected ventilation

    Time: From operation until 30 days post operation

    Description: Postoperative diagnosis of proven COVID-19 pulmonary complications

    Measure: COVID-19 pulmonary complications

    Time: 30 days post-surgery

    Description: Overall SARS-CoV-2 infected rate (symptomatic and/or asymptomatic)

    Measure: Overall SARS-CoV-2 infected rate

    Time: 30 days post-surgery

    Description: Duration of hospital stay (including time spent in intensive care, time ventilated)

    Measure: Duration of hospital stay

    Time: 30 days post-surgery

    Description: Pulmonary function in keeping with the World Health Organisation (WHO) Solidarity Trial outcome scale

    Measure: Pulmonary function

    Time: 30 days post-surgery
    78 Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial

    Hydroxychloroquine is widely used to treat autoimmune diseases. Clinical investigation has found that a high concentration of cytokines were detected in the plasma of critically ill patients infected with SARS-CoV-2, therefore, hydroxychloroquine as anti-inflammatory agents may reduce this response in accord with their use in autoimmune disease where the cytokine response can be reduced. Favipiravir is an antiviral drug developed in Japan that the data sheet notes that it is a pyrazinecarboxamide derivative with activity against influenza viruses, west nile virus, yellow fever virus, foot and mouth disease virus as well as against flaviviruses, arenaviruses, bunyaviruses and alphaviruses. In February the drug was used for COVID-19 disease in China and was declared effective in treatment, and a report published (in press) comparing Favipiravir with Lopinavir /ritonavir suggested that Favipiravir was superior for prevention of disease progression and viral clearance. The objective of this pilot study is to compare three arms: hydroxychloroquine; favipiravir; standard care (no specific SARS-CoV-2 treatment) only, in symptomatic patients infected by SARS-CoV-2 in an open label randomized clinical trial. The difference between groups will allow an effect size to be determined for a definitive clinical trial.

    NCT04387760
    Conditions
    1. SARS-CoV 2
    2. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Favipiravir
    3. Other: Routine care for COVID-19 patients

    Primary Outcomes

    Description: Single negative SARS-CoV2 PCR NP Swab

    Measure: Primary outcome measure will be time to viral clearance

    Time: Until discharge or for a maximum of 14 days or readmission

    Secondary Outcomes

    Description: Implementation of escalation of Respiratory Support

    Measure: Requirement of Escalation of Respiratory Support

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: Monitor and document all adverse effects during therapy

    Measure: Adverse effects(cardiac, renal, hepatic, hypoglycaemia (defined as RBS <3.9 mmol/L))

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: Deterioration of clinical condition requiring ICU admission

    Measure: Requirement of ICU Admission

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: Mortality rate due to COVID-19

    Measure: Mortality rate

    Time: Mortality will be collected up to 30 day

    Description: Determination of the change in lactate levels before and after treatment as a measure of disease activity

    Measure: Serum lactate measurement

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: Determination of the change in ferritin levels before and after treatments as a measure of disease activity

    Measure: Serum Ferritin measurement

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: Determination of the change in D Dimer levels before and after treatments as a measure of disease activity

    Measure: Serum D Dimer measurement

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: Determination of the change in Ratio of Lymphocyte to Neutrophil, before and after treatments as a measure of disease activity

    Measure: Ratio of Lymphocyte to Neutrophil, measurement

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: Patients will be followed during their hospital stay until discharge

    Measure: Discharge and Length of Hospital Stay

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: Capturing readmission data

    Measure: Readmission Rate

    Time: Until 30 days from the start of the trial

    Description: SOFA score can identify the critical point at which patients exhibit the highest degree of organ dysfunction

    Measure: Daily Sequential Organ Failure Assessment (SOFA) score

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: NEWS is a tool which improves the detection and response to clinical deterioration in adult patients and is a key element of patient safety and improving patient outcomes

    Measure: Daily National Early Warning Score (NEWS) 2 score

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: its defined as patient discharge or a reduction of 2 points on a 6-point disease severity clinical scale

    Measure: Clinical improvement

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: Determination of the change in QT prolongation, before and after treatments as a measure of disease activity

    Measure: QT prolongation

    Time: Until discharge or for a maximum of 14 days or readmission

    Description: Determination of the change in Cardiac arrythmia (fatal and non fatal), before and after treatments as a measure of disease activity

    Measure: Cardiac arrythmia (fatal and non fatal)

    Time: Until discharge or for a maximum of 14 days or readmission
    79 Antimalarial and Covid 19 in Rheumatoid Arthritis

    The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action differ them from glucocorticoids and nonsteroidal antiinflammatory agents. Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA).

    NCT04389320
    Conditions
    1. Rheumatoid Arthritis
    Interventions
    1. Drug: Hydroxychloroquine
    MeSH:Arthritis Arthritis, Rheumatoid
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Description: serum level

    Measure: immunoglobulin mesurement

    Time: 1 month
    80 TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia:a Multicenter Randomized Controlled Open Label Trial

    Multifocal interstitial pneumonia represents the most common cause of admission in intensive care units and death in SARS-CoV2 infections. In our Hospital, similarly to what reported in literature, up to 25% of admitted patients with pneumonitis requires mechanical ventilation or oro-tracheal intubation within 5-10 days. No established treatment is available for this condition. Preliminary evidence is accumulating about the efficacy of an aggressive treatment of the corona virus-induced inflammation and, in particular, investigators believe that blocking JAK1 is clinically rewarding in down-regulating IL-6 driven inflammation in patients with corona-virus infection. Thus, investigators designed a randomized controlled trial to test the hypothesis that adding Tofacitinib to the standard treatment in the early phase of COVID related pneumonitis could prevent the development of severe respiratory failure needing mechanical ventilation.

    NCT04390061
    Conditions
    1. Pneumonitis, Interstitial
    2. COVID-19
    Interventions
    1. Drug: Tofacitinib
    2. Drug: Hydroxychloroquine
    MeSH:Pneumonia Lung Diseases, Interstitial
    HPO:Interstitial pneumonitis Interstitial pulmonary abnormality Pneumonia

    Primary Outcomes

    Description: Rate of patients needing mechanical ventilation to maintain PaO2/FIO2>150

    Measure: Prevention of severe Respiratory Failure requiring mechanical ventilation

    Time: 14 days

    Secondary Outcomes

    Description: Rate of patients needing admission to the intensive care unit

    Measure: Prevention of need of ICU admission

    Time: 28 days

    Description: Rate of patients who die due to COVID-19 related conditions

    Measure: Prevention of COVID-19 related Deaths

    Time: 28 days

    Description: Role of some clinical and laboratory factors in predicting outcome (Age, sex, smoking status, Body Mass Index (BMI), Comorbidities (Diabetes, number of comorbidities), Respiratory Failure at admission defined as PaO2/FiO2<300, Extension of Ct-scan involvement, basal level of serum IL-6, vW-Factor, Thrombomodulin, KL-6, sACE2 and SP-D )

    Measure: Identification of predictors of outcome

    Time: 14 days

    Description: Rate of severe drug-related adverse events

    Measure: Incidence of Treatment-Emergent Adverse Events

    Time: 28 days
    81 Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial

    Background: In December 2019, patients with pneumonia secondary to a new subtype of Coronavirus (COVID-19) were identified in China. In a few weeks the virus spread and cases started practically all over the world. In February 2020, the WHO declared a pandemic. Severe symptoms have been found in patients mainly with comorbidities and over 50 years of age. At this time there is no proven therapeutic alternative. In vitro studies and observational experiences showed that antimalarial drugs (Chloroquine and hydroxychloroquine) had antiviral activity and increased viral clearance. Ivermectin, on the other hand, has been shown in vitro to reduce viral replication and in an observational cohort, greater viral clearance with promising clinical results. So far there is no standard of treatment and clinical trials are needed to find effective treatment alternatives. Objective: To evaluate the safety and efficacy of treatment with hydroxychloroquine and ivermectin for serious COVID-19 infections in no critical hospitalized patients. Material and methods: Randomized controlled trial of patients diagnosed with respiratory infection by COVID-19, who present criteria for hospitalization. Randomization will be performed to receive hydroxychloroquine at a dose of 400 mg every 12 hours for one day and then 200 mg every 12 hours, to complete a 5-day treatment schedule. Group 2: Ivermectin 12 mg every 24 hours for one day (less than 80 kg) or Ivermectin 18 mg every 24 hours for one day (greater than 80 kg) + placebo until the fifth day. Group 3: Placebo. Prior to randomization, the risk of cardiovascular complications determined by corrected QT interval, related to hydroxychloroquine intake will be assessed. If the patient is at high risk, the allocation will be to ivermectin only or to placebo in an independent randomization, if the risk is low, any of the three groups could be assigned. Outcomes: The primary outcome will be discharge from hospital for improvement. The safety outcomes will be requirement of mechanical intubation, septic shock or death. Viral clearance will also be evaluated by means of PCR, which will be taken on the 5th day after admission, day 14 and 21.

    NCT04391127
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Ivermectin
    3. Drug: Placebo
    MeSH:Infection

    Primary Outcomes

    Description: Days from admission as a suspected case of COVID with hospitalization criteria until discharge

    Measure: Mean days of hospital stay

    Time: Three months

    Description: Respiratory deterioration defined by respiratory rate > 25 per minute, requirement of high oxygen supply (FiO2 > 80% ) to maintain oxygen saturation > 90 %, invasive mechanical ventilation or dead.

    Measure: Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead

    Time: Three months

    Description: Daily delta of oxygenation index during the hospitalization

    Measure: Mean of oxygenation index delta

    Time: Three months

    Secondary Outcomes

    Description: Mean time to viral negativization of RT-qPCR SARS-CoV-2. Pre Specified time: 5, 14, 21 and 28 days after the first positive PCR.

    Measure: Mean time to viral PCR negativization

    Time: 5, 14, 21 and 28 days after the first positive PCR
    82 Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia: Prospective Multicentric Study in Radiation Oncology Centers

    The host response against the coronavirus 2 (SARS-CoV-2) appears to be mediated by a 'cytoquine storm' developing a systemic inflammatory mechanism and an acute respiratory distress syndrome (ARDS), in the form of a bilateral pneumonitis, requiring invasive mechanical ventilation (IMV) in an important group of patients. In terms of preventing progression to the critical phase with the consequent need of admission to the intensive care units (ICU), it has been recently proposed that this inflammatory cytoquine-mediated process can be safely treated by a single course of ultra-low radiotherapy (RT) dose < 1 Gy. The main purpose of the study was to analyze the efficacy of ultra low-dose pulmonary RT, as an anti-inflammatory intention in patients with SARS-Cov-2 pneumonia with a poor or no response to standard medical treatment and without IMV.

    NCT04394182
    Conditions
    1. Pneumonia, Viral
    2. Cytokine Storm
    Interventions
    1. Radiation: Ultra-Low-dose radiotherapy
    2. Device: ventilatory support with oxygen therapy
    3. Drug: Lopinavir/ritonavir
    4. Drug: Hydroxychloroquine
    5. Drug: Azithromycin
    6. Drug: Piperacillin/tazobactam
    7. Drug: Low molecular weight heparin
    8. Drug: Corticosteroid injection
    9. Drug: Tocilizumab
    MeSH:Pneumonia, Viral Pne Pneumonia
    HPO:Pneumonia

    Primary Outcomes

    Description: To evaluate the efficacy of ultra low-dose pulmonary RT through clinical evaluation.It was performed by oxygen therapy status assessment after RT treatment. Improvement criteria is considered as an oxygen therapy de-escalation (more to less need for support: Ventimask (VMK) with reservoir >VMK >Nasal Cannula-(NC).)

    Measure: Oxygen Therapy Status at Day 2

    Time: At 2 after RT

    Description: To evaluate the efficacy of ultra low-dose pulmonary RT through clinical evaluation. .It was performed by oxygen saturation (Sat02 %) status assessment after RT treatment. Improvement criteria is considered as a Sat02 with/without oxygen therapy >93% (Pulse oximeter measurement)

    Measure: Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2

    Time: At 2 days after RT

    Secondary Outcomes

    Description: Pa02 / Fi02 > 300 mmHg

    Measure: Blood Gas Analysis at Day 2

    Time: At 2 days after RT

    Description: Achievement of normal range value in 1 or more of the inflammatory and immunological parameters (lymphocytes, IL-6, D-dimer, ferritin, LDH, C Reactive Protein (CRP) and fibrinogen)

    Measure: Blood Test at Day 2

    Time: At 2 days after RT

    Description: To evaluate the efficacy of ultra low-dose pulmonary RT through clinical evaluation.It was performed by oxygen therapy status assessment after RT treatment. Improvement criteria is considered as an oxygen therapy de-escalation (more to less need for support: Ventimask (VMK) with reservoir >VMK >Nasal Cannula-(NC).)

    Measure: Oxygen Therapy Status at Day 5

    Time: At 5 after RT

    Description: To evaluate the efficacy of ultra low-dose pulmonary RT through clinical evaluation. .It was performed by oxygen saturation (Sat02 %) status assessment after RT treatment. Improvement criteria is considered as a Sat02 with/without oxygen therapy >93% (Pulse oximeter measurement)

    Measure: Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5

    Time: At 5 days after RT

    Description: Achievement of normal range value in 1 or more of the inflammatory and immunological parameters (lymphocytes, IL-6, D-dimer, ferritin, LDH, C Reactive Protein (CRP) and fibrinogen)

    Measure: Blood Test at Day 5

    Time: At 5 days after RT

    Description: To evaluate the efficacy of ultra low-dose pulmonary RT through clinical evaluation.It was performed by oxygen therapy status assessment after RT treatment. Improvement criteria is considered as an oxygen therapy de-escalation (more to less need for support: Ventimask (VMK) with reservoir >VMK >Nasal Cannula-(NC).)

    Measure: Oxygen Therapy Status at Day 7

    Time: At 7 after RT

    Description: To evaluate the efficacy of ultra low-dose pulmonary RT through clinical evaluation. .It was performed by oxygen saturation (Sat02 %) status assessment after RT treatment. Improvement criteria is considered as a Sat02 with/without oxygen therapy >93% (Pulse oximeter measurement)

    Measure: Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7

    Time: At 7 days after RT

    Description: Achievement of normal range value in 1 or more of the inflammatory and immunological parameters (lymphocytes, IL-6, D-dimer, ferritin, LDH, C Reactive Protein (CRP) and fibrinogen)

    Measure: Blood Test at Day 7

    Time: At 7 days after RT

    Description: To evaluate the efficacy of ultra low-dose pulmonary RT through radiological evaluation.It was performed by thoracic CT scan after RT treatment . It is considered a radiological improvement the decrease of the Total Severity Score (TSS) from the baseline in > or = 1 point. NOTE: The score values ranged from 0 to 4 according to the sum of the percentage involvement of each of the 5 lung lobes. The total severity score (TSS), was reached by summing the overall involvement in the lung (0-20 points)

    Measure: Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7

    Time: At 7 days after RT

    Description: Recovery time after RT administration until hospital discharge or death (<48h; 2-7 days; >7 days; clinical worsening or death)

    Measure: Recovery time

    Time: From RT administration until hospital discharge or death

    Description: COVID-19 negativization test

    Measure: COVID-19 status

    Time: At 7 days after RT

    Description: To evaluate the efficacy of ultra low-dose pulmonary RT through radiological evaluation.It was performed by thoracic CT scan after RT treatment . It is considered a radiological improvement the decrease of the Total Severity Score (TSS) from the baseline in > or = 1 point. NOTE: The score values ranged from 0 to 4 according to the sum of the percentage involvement of each of the 5 lung lobes. The total severity score (TSS), was reached by summing the overall involvement in the lung (0-20 points)

    Measure: Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1

    Time: At 1 month after RT

    Description: Toxicity was assessed and rated according to the NIH Common Terminology Criteria for Adverse Events (CTCAE version 5.0) and RTOG scales.

    Measure: Acute Toxicity

    Time: 1-3 months after RT
    83 Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial

    Many reports argued about the possible beneficial effects of Hydroxychloroquine in treating COVID-19 patients and this study was designed to investigate this claim

    NCT04394442
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine

    Primary Outcomes

    Description: PCR will be done every 72 h day till 2 consecutive negative PCR tests(24h apart) which is the viral clearance.The time between randomization and viral clearance is the viral clearance time

    Measure: time to viral clearance

    Time: 21 days after patients randomization

    Description: total number of deaths divided by total number of the group

    Measure: % of mortality

    Time: 60 days after randomization

    Secondary Outcomes

    Description: time from patients randomization till discharge

    Measure: Length of stay

    Time: 60 days after randomization

    Description: time from randomization till day of fever subsiding

    Measure: time to be afebrile

    Time: 60 days after randomization

    Description: %of deteriorated patients necessitates mechanical ventilation

    Measure: need for mechanical ventilation

    Time: 60 days after randomization
    84 Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial: The International ALLIANCE Study

    COVID-19 is a global pandemic. So far encouraging results have been shown in different parts of the world with the utilisation of hydroxycloroquine, zinc, and azithromycin, and early studies into some of these, plus some with Vitamin C, have also proven beneficial. Vitamin D levels have also been shown to be an important indicator to the severity of symptoms in COVID-19 patients.

    NCT04395768
    Conditions
    1. COVID19
    Interventions
    1. Dietary Supplement: Vitamin C
    2. Drug: Hydroxychloroquine
    3. Drug: Azithromycin
    4. Dietary Supplement: Zinc Citrate
    5. Dietary Supplement: Vitamin D3
    6. Dietary Supplement: Vitamin B12
    MeSH:Disease Progression

    Primary Outcomes

    Description: Composite measure: Change in severity and duration of symptoms

    Measure: Symptoms

    Time: once daily for 15 days since enrollment/baseline at admission to hospital

    Description: total number of days in hospital since admission

    Measure: Length of hospital stay

    Time: at 15 and 45 days since admission/ enrolment

    Description: need for invasive mechanical ventilation or mortality within 15 days from enrolment

    Measure: invasive mechanical ventilation or mortality

    Time: any time within 15 days from enrolment

    Secondary Outcomes

    Description: Death

    Measure: Mortality

    Time: 15 and 45 days since enrolment

    Description: need for and number of days of invasive mechanical ventilation, in case of no need for mechanical ventilation: days=0

    Measure: mechanical ventilation

    Time: at 15 and 45 days since enrolment

    Description: need for and number of days for humidified high-flow oxygen

    Measure: oxygen

    Time: 15 and 45 days since enrolment

    Description: admission to ICU (intensive care unit)

    Measure: ICU

    Time: 15 and 45 days since enrolment

    Description: days in hospital

    Measure: days in hospital

    Time: 15 and 45 days since enrolment

    Description: days in ICU

    Measure: days in ICU

    Time: 15 and 45 days since enrolment

    Description: need for and days of renal replacement therapy

    Measure: renal replacement therapy

    Time: 15 and 45 days since enrolment

    Description: need for and days of Extracorporeal support

    Measure: Extracorporeal support

    Time: 15 and 45 days since enrolment
    85 Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial

    Older adults are at the highest risk of complications and severe illness for 2019-nCoV infections. Hydroxychloroquine (HCQ), an emerging chemoprophylaxis, which holds clinical and mechanistic plausibility, will help to reduce disease incidence and mitigate disease severity across in-patient settings. This study is designed to assess the safety and efficacy of post-exposure prophylaxis with hydroxychloroquine (HCQ) for the prevention of Coronavirus Infectious Disease-19 (COVID-19) in high-risk older individuals in long-term and specialized care.

    NCT04397328
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo

    Primary Outcomes

    Measure: Incidence of symptomatic fever >37.8, dry cough, or shortness of breath (resident/patient report or nurse observation) respiratory infection with confirmed PCR+ result for SARS-CoV-2.

    Time: baseline through day 90

    Secondary Outcomes

    Measure: Requirement for admission to acute care hospital and/or ICU admission or death

    Time: baseline through day 90

    Measure: Asymptomatic PCR+ SARS-CoV-2 test result

    Time: baseline, days 2, 5, 12, and 19

    Measure: Time to clinical recovery (TTCR).

    Time: baseline through day 90
    86 Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy

    It still unclear how SARS-CoV-2 affects pregnant women and their offspring, as well as which factors may influence obstetrical disease and outcomes, including the timing of maternal viral exposure by gestational age, the effects of parity, age, host immune responses, coexisting medical and obstetrical conditions and the effects of treatment regimens. While further information is gathered, based on the existing evidence from other infections causing pneumonia, pregnant women should be considered to be at high risk for developing severe infection during the current COVID-19 epidemic. Results from clinical trials with HCQ in nonpregnant adults may not be directly extrapolated to pregnant women given the special features of the pregnancy status. Thus, clinical research is urgently needed to improve the care and reduce the risk of poor pregnancy outcomes of women in this and in future epidemics.

    NCT04410562
    Conditions
    1. Pregnancy Related
    2. COVID
    3. Covid-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo
    MeSH:Infection

    Primary Outcomes

    Description: Number of PCR-confirmed infected pregnant women assessed from collected nasopharyngeal and oropharyngeal swabs at day 21 after treatment start

    Measure: Number of PCR confirmed cases among pregnant women

    Time: 21 days after intervention

    Secondary Outcomes

    Measure: Incidence of COVID-19 disease during pregnancy

    Time: through study completion, an average of 1 year

    Measure: Incidence of COVID-19-related admissions

    Time: through study completion, an average of 1 year

    Measure: Incidence of all-cause admissions

    Time: through study completion, an average of 1 year

    Measure: Incidence of all-cause outpatient attendances

    Time: through study completion, an average of 1 year

    Measure: Mean duration of symptoms-signs of COVID-19

    Time: through study completion, an average of 1 year

    Measure: Frequency and severity of adverse events

    Time: through study completion, an average of 1 year

    Measure: Incidence of preeclampsia

    Time: through study completion, an average of 1 year

    Measure: Incidence of gestational diabetes

    Time: through study completion, an average of 1 year

    Measure: Incidence of SARS-CoV-2 infections during pregnancy

    Time: through study completion, an average of 1 year

    Measure: Prevalence of intrauterine growth restriction

    Time: through study completion, an average of 1 year

    Measure: Maternal mortality rate

    Time: through study completion, an average of 1 year

    Measure: Proportion of neonates with SARS-CoV-2- intrauterine infection by PCR-confirmed SARS-CoV-2-infection in nasopharyngeal aspirate.

    Time: through study completion, an average of 1 year

    Measure: Proportion of neonates with clinical signs/symptoms of COVID-19

    Time: through study completion, an average of 1 year

    Measure: Prevalence of low birth weight (<10th centile according to local standards)

    Time: through study completion, an average of 1 year

    Measure: Prevalence of preterm birth (<37 weeks of gestational age)

    Time: through study completion, an average of 1 year

    Measure: Prevalence of embryo and foetal losses (miscarriages and stillbirths)

    Time: through study completion, an average of 1 year

    Measure: Frequency of congenital malformations

    Time: through study completion, an average of 1 year

    Measure: Proportion of adverse perinatal outcome

    Time: through study completion, an average of 1 year

    Measure: Neonatal morbidity

    Time: through study completion, an average of 1 year

    Measure: Neonatal mortality rate

    Time: through study completion, an average of 1 year
    87 An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

    This is an open-label, multicenter, parallel-group, randomized, phase III trial that evaluates the efficacy and safety of hydroxychloroquine and favipiravir in the treatment of patients with possible or confirmed COVID-19 observed within the last 5 days. 1000 patients will be randomized in 2:1:2:2:2:1 ratio and divided into six groups.

    NCT04411433
    Conditions
    1. Sars-CoV2
    2. COVID-19
    Interventions
    1. Drug: Favipiravir (3200 mg + 1200 mg)
    2. Drug: Favipiravir (3600 mg + 1600 mg)
    3. Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine
    4. Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin
    5. Drug: Hydroxychloroquine
    6. Drug: Hydroxychloroquine combined with Azithromycin

    Primary Outcomes

    Description: The evaluation of recovery (discharge) period until 14th day after administration.

    Measure: Time to recovery (discharge)

    Time: 14 days

    Description: The evaluation of decrease in viral load until 14th day after administration.

    Measure: Decrease in viral load

    Time: 14 days

    Secondary Outcomes

    Description: Number/characteristics of Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment due to study drug from baseline until the end of study

    Measure: Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment

    Time: 14 days

    Description: Clinical evaluation of occurrence of lymphopenia from baseline until the end of study.

    Measure: Frequency of occurrence of lymphopenia from baseline

    Time: 14 days

    Description: Clinical evaluation of occurrence of thrombocytopenia from baseline until the end of study.

    Measure: Frequency of occurrence of thrombocytopenia from baseline

    Time: 14 days

    Description: Clinical evaluation of ALT levels from baseline until the end of study.

    Measure: Changes in alanine aminotransferase (ALT) levels from baseline

    Time: 14 days

    Description: Clinical evaluation of AST levels from baseline until the end of study.

    Measure: Changes in aspartate aminotransferase (AST) levels from baseline

    Time: 14 days

    Description: Clinical evaluation of CRP levels from baseline until the end of study.

    Measure: Changes in C-reactive protein (CRP) levels from baseline

    Time: 14 days

    Description: Clinical evaluation of D-dimer levels from baseline until the end of study.

    Measure: Changes in level of D-dimer levels from baseline

    Time: 14 days

    Description: Clinical evaluation of PT values for blood to coagulate from baseline until the end of study.

    Measure: Changes in prothrombin time (PT) values from baseline

    Time: 14 days

    Description: Clinical evaluation of PTT values for blood to coagulate from baseline until the end of study.

    Measure: Changes in partial thromboplastin time (PTT) values from baseline

    Time: 14 days

    Description: Clinical evaluation of systolic and diastolic blood pressure levels from baseline until the end of study.

    Measure: Changes in blood pressure from baseline

    Time: 14 days

    Description: Clinical evaluation of respiratory rate levels from baseline until the end of study.

    Measure: Changes in respiratory rate from baseline

    Time: 14 days

    Description: Clinical evaluation of pulse oxymetry levels from baseline until the end of study.

    Measure: Changes in pulse oxymetry from baseline

    Time: 14 days

    Description: Clinical evaluation of changes in fever from baseline until the end of study.

    Measure: Changes in fever from baseline

    Time: 14 days
    88 Hydroxychloroquine to Prevent SARS-CoV-2 Infection Among Healthcare Workers: Randomized Controlled, Open-label, Phase 3 Clinical Trial

    The purpose of this study is to determine whether hydroxychloroquine is an effective prophylactic regimen to prevent SARS-CoV-2 infection among healthcare workers. Participants will be randomized into two parallel groups. The first arm will evaluate the use of hydroxychloroquine every-other-day plus standard measures of protection for the prevention of SARS-CoV-2. The second arm will evaluate the use of standard measures of protection for the prevention of SARS-CoV-2. The target enrollment is 320 participants. Each study participant will be monitored for SARS-CoV-2 seroconversion in weekly visits or for the development of COVID-19 symptoms for 8 weeks.

    NCT04414241
    Conditions
    1. SARS-CoV-2
    Interventions
    1. Drug: Hydroxychloroquine
    MeSH:Infection

    Primary Outcomes

    Measure: Efficacy: Proportion of participants with positive molecular or serologic testing for SARS-CoV-2

    Time: Eight weeks

    Measure: Safety: Proportion of participants with grade 3 or more adverse events

    Time: Eight weeks

    Secondary Outcomes

    Measure: Tolerability: Proportion of participants that discontinue prophylactic treatment due to grade 1 or 2 adverse events

    Time: Eight weeks
    89 Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19

    Facing the challenge of finding an efficient treatment for COVID-19, the viral pneumonia caused by the Coronavirus SARS-Cov-2, this study intended to test if Chloroquine or Hydroxychloroquine, two drugs with strong in-vitro antiviral role proven by numerous studies and with a well defined safety profile established, for efficacy in treating COVID-19 and improving an ordinal primary outcome composed by a 9-levels scale, which was recomended by the World Health Organization.

    NCT04420247
    Conditions
    1. COVID
    2. COVID-19
    3. SARS-CoV 2
    4. Coronavirus
    5. Corona Virus Infection
    Interventions
    1. Drug: Chloroquine
    2. Drug: Hydroxychloroquine
    3. Other: standard care
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia
    HPO:Pneumonia

    Primary Outcomes

    Description: 9-levels scale recomended by WHO for studies related to treating COVID-19

    Measure: World Health Organization (WHO) 9-levels scale (from 0-8)

    Time: Day14

    Description: 9-levels scale recomended by WHO for studies related to treating COVID-19, with lower scores meaning better outcomes (0 means at home with no symptoms and

    Measure: WHO 9-levels scale (from 0-8)

    Time: Day 28

    Secondary Outcomes

    Description: 28day mortality

    Measure: Mortality

    Time: Day 28

    Description: Days without need of Mechanical Ventilation

    Measure: Ventilation free days

    Time: Day 28.

    Measure: Duration of mechanical ventilation

    Time: Day 28.

    Description: Trigger system aligned to the scale of clinical risk. Minimum score is 0 (better outcome) and maximum score is 20 (worse outcome). The higher the score, the higher the risk.

    Measure: National Early Warning Score (NEWS)

    Time: Day 7

    Description: Trigger system aligned to the scale of clinical risk. Minimum score is 0 (better outcome) and maximum score is 20 (worse outcome). The higher the score, the higher the risk.

    Measure: National Early Warning Score (NEWS)

    Time: Day 14

    Description: Trigger system aligned to the scale of clinical risk. Minimum score is 0 (better outcome) and maximum score is 20 (worse outcome). The higher the score, the higher the risk.

    Measure: National Early Warning Score (NEWS)

    Time: Day 28

    Measure: ICU Lenght of Stay

    Time: Day 28.

    Measure: Hospital Lenght of Stay

    Time: Day 28.

    Measure: Acute Kidney Disease incidence

    Time: Day 28.

    Measure: Percentage of patients needing Dialysis

    Time: Day 28.

    Measure: Mean of C Reactive Protein Levels

    Time: Days 3.

    Measure: Mean of C Reactive Protein Levels

    Time: Days 5.

    Measure: Mean of C Reactive Protein Levels

    Time: Days 7.

    Measure: Mean of C Reactive Protein Levels

    Time: Days 10.

    Measure: Mean of C Reactive Protein Levels

    Time: Days 14.

    Measure: Mean of Leucocytes Levels

    Time: Days 3.

    Measure: Mean of Leucocytes Levels

    Time: Days 5.

    Measure: Mean of Leucocytes Levels

    Time: Days 7.

    Measure: Mean of Leucocytes Levels

    Time: Days 10.

    Measure: Mean of Leucocytes Levels

    Time: Days 14.

    Measure: Mean of Lymphocyte Levels

    Time: Days 3.

    Measure: Mean of Lymphocyte Levels

    Time: Days 5.

    Measure: Mean of Lymphocyte Levels

    Time: Days 7.

    Measure: Mean of Lymphocyte Levels

    Time: Days 10.

    Measure: Mean of Lymphocyte Levels

    Time: Days 14.
    90 Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)

    Study Objective: To test if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.

    NCT04421664
    Conditions
    1. Corona Virus Infection
    2. SARS-CoV Infection
    3. Coronavirus
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the percent of participants who fall into each category per arm.

    Measure: Ordinal Scale of COVID19 Disease Severity at 14 days

    Time: 14 days

    Secondary Outcomes

    Description: Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease.

    Measure: Incidence of Hospitalization

    Time: 14 days

    Description: Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease.

    Measure: Incidence of COVID-19 related Death

    Time: 90 days

    Description: Outcome reported as the number of participants in each arm who expire due to all causes.

    Measure: Incidence of all-cause Death

    Time: 90 days

    Description: Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason.

    Measure: Incidence of All-Cause Study Medicine Discontinuation or Withdrawal

    Time: 14 days

    Description: Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)

    Measure: Overall symptom severity at 5 and 14 days

    Time: 5 and 14 days

    Description: Repeated Measure mixed regression model of change in: Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)

    Measure: Overall change in disease severity over 14 days among those who are symptomatic at baseline

    Time: 14 days
    91 Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease

    The primary objective is to assess the impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe/critical disease.

    NCT04429867
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo
    MeSH:Disease Progression

    Primary Outcomes

    Description: The impact will be evaluated by comparing rates of a composite primary outcome in patients randomized to hydroxychloroquine versus those randomized to placebo. The composite outcome includes progression to severe/critical disease or death (including withdrawal of care/hospice transfer). Progression to severe/critical disease is defined by requiring oxygen delivery via high flow nasal cannula, non-rebreather mask, bipap, or transfer to intensive care (ICU) or intermediate care units (IMCU) due to COVID-19-related complications.

    Measure: Impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe/critical disease.

    Time: 30 Days

    Secondary Outcomes

    Measure: Hospital length of stay

    Time: 30 Days

    Measure: 30-Day Mortality

    Time: 30 Days

    Description: Resolution of symptoms will be assessed using standard medical interview procedures with the subject and review of the medical records.

    Measure: Resolution of Symptoms

    Time: 14 Days

    Measure: Incidence of QTc >500ms after initiation of therapy

    Time: 30 Days

    Measure: Incidence of discontinuation of therapy

    Time: 30 Days
    92 Off Label Study to Evaluate the Efficacy of Hydroxychloroquine as Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers at High Risk of Occupational Exposure to SARS-CoV-2

    The HCW Prophylaxis (HCWP) Study, single, open and off label intervention study. Up to 350 participants will be assigned to group that takes HCQ or group that opts to not take study medication. Participants will be UNM HEALTH SYSTEM HCW at high risk for occupational exposure to SARSCoV- 2. Study timepoints will include Day 1 screening/enrollment, 30 day, 60 day, and 90 day assessments. Questionnaires will be collected in all timepoints.

    NCT04435808
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine

    Primary Outcomes

    Description: Number of health care workers who become infected with SARS-CoV-2 as detected by PCR

    Measure: SARS-CoV-2 Infection

    Time: 3 months

    Secondary Outcomes

    Description: Determine the frequency of symptomatic vs. asymptomatic SARS-CoV-2 infections in health care workers during the study via serial PCR testing and symptom surveys

    Measure: Symptomatic vs. Asymptomatic Infection with SARS-CoV-2

    Time: 3 months

    Description: Assess the role of exposure levels to Covid-19 patients amongst health care workers and its impact of infection rates

    Measure: Occupational Health Exposure

    Time: 3 months

    Description: Will assess the severity of any SARS-CoV-2 infections amongst health care workers taking and not taking hydroxychloroquine. This will include assessments of hospital admissions.

    Measure: Impact of Hydroxychloroquine use on Need for Hospitalization with SARS-CoV-2 Infection

    Time: 3 months

    Description: Will assess the severity of any SARS-CoV-2 infections amongst health care workers taking and not taking hydroxychloroquine. This will include determination of the need for ICU care.

    Measure: Impact of Hydroxychloroquine use on Need for ICU Care with SARS-CoV-2 Infection

    Time: 3 months

    Description: Will assess the adverse effect profile of the study drug via serial surveys

    Measure: Adverse Effect Profile of Hydroxychloroquine

    Time: 3 months

    Description: Will collect monthly blood samples for serological analysis

    Measure: Seroconversion Following SARS-CoV-2 Infection

    Time: 3 months

    Description: Will perform mNGS on any recovered SARS-CoV-2 isolates from subjects to identify the genomic lineage of the virus and to compare this with SARS-CoV-2 genomes circulating in the hospital system, the community and nationally. This may provide evidence as to the source of the infection (e.g. a hospital-based infection vs. a community infection vs. a travel-associated infection out of state).

    Measure: Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates

    Time: 3 months
    93 Post Exposure Prophylaxis (PEP) in Healthcare Workers Exposed to COVID-19 Patients: A Double-blind Randomized Clinical Trial

    More cases of COVID-19 pandemic are being reported daily around the world. It is highly infectious and, over 7 million people have been infected and more than 400,000 people have died globally till this date. Countries around the world are struggling to avoid the spread of this pandemic. Center for Disease Control and Prevention (CDC) confirmed that there are no approved drugs for COVID-19 treatment. Researchers around the globe, however, are researching different medications for COVID-19 patients, including the drug Hydroxychloroquine (HCQ), which is mainly used for Rheumatoid Arthritis and Malaria. Not enough data was obtained yet to know how well all of these medications are functioning. Therefore, aim to perform a randomized placebo-controlled trial to assess the impact of these medications on COVID -19 healthcare workers exposed while treating COVID 19 patients in Qatar to avoid causality and comorbidities in healthcare workers. It is considered as a weak base. Many viruses enter the host cells via endocytosis, as a result of which they are initially taken up into an intracellular compartment that is "typically fairly acidic" whereas; Hydroxychloroquine would alter the acidity of this compartment, which can interfere with the ability of viruses to escape into the host cell and start replicating. Another hypothesis on the rationale of the Antiviral activity of HCQ, is that HCQ may also alter the ability of the virus to bind to the outside of a host cell in the first place. An interventional, double-blind, placebo-controlled randomized trial that will include participants who will be healthcare workers at risks of exposure to COVID-19 while managing patients with confirmed infection. Study will compare the safety, efficacy and effectiveness of Post Exposure Prophylaxis (PEP) use of HCQ in healthcare workers at risk of exposure to COVID-19 patients, in comparison to Placebo in Qatar.

    NCT04437693
    Conditions
    1. COVID 19
    Interventions
    1. Drug: Hydroxychloroquine

    Primary Outcomes

    Description: Prevention of SARS-CoV-2 infection as determined by negative RT-PCR of the participants in the treatment group through swabbing that will be conducted on a weekly basis (Swabbing will be conducted at baseline and weekly through the end of the treatment period

    Measure: Prevention of SARS-CoV-2 infection

    Time: 7 Months

    Description: To find out the adverse effects related to HCQ such as : skin rashes, especially those made worse by sunlight, feeling sick (nausea) or indigestion, diarrhea, headaches, bleaching of the hair or mild hair loss, tinnitus (ringing in the ears) visual problem

    Measure: Presence of any adverse effects related to HCQ

    Time: 7 months

    Description: Incidence of COVID-19 related symptoms, that may include: Temperature over 37.8 degrees Celsius, Shortness of Breath, Cough.

    Measure: Incidence of COVID-19 related symptoms

    Time: 7 weeks
    94 Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers: A Randomized-Controlled Trial

    Background: The rapid spread and high infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) makes identifying an effective prophylaxis agent highly important. One of the important target populations for such intervention who are at high risk of exposure are health care workers (HCWs) who may develop disease and/or expose patients and other HCWs. Hydroxychloroquine (HCQ), currently in usage for treatment of severe Coronavirus Disease 2019 (COVID-19), has in addition to in-vitro activities of inhibition of virus replication and immunomodulation, an important role in the inhibition of pre-entry step of the virus to host cells. Such activity in the early stage of infection may play a role in prevention of disease progression. Objectives: To evaluate the effect of HCQ in prevention of clinical disease and reduction of viral shedding among HCWs following exposure to confirmed COVID-19 patients. Study design: Multi-center, randomized controlled, superiority, open label trial Setting: The study will be conducted at Rambam Health Care Campus. Eligibility: Participants eligible for inclusion will include non-pregnant adult (>18 years old) HCWs who were exposed to a confirmed case of COVID-19 without full adherence to droplet precautions. Participants will be eligible in a period no longer than 72 hours after exposure. Intervention: HCQ will be given in the intervention group in a dosage regimen of 400mg BID in the first day followed by 200mg BID for overall 10 days. Participants in the control group will receive no treatment. Treatment will be started no longer than 72 hours following exposure. Outcomes: The primary outcome will be the number of participants who develop clinical signs compatible with COVID 19 (defined in full protocol) within 14 days of exposure. Secondary outcomes will include virologically-confirmed COVID 19, disease severity (need for hospitalization, mechanical ventilation and 30-day mortality) and viral shedding duration (time between first positive PCR to last of two consecutive negative tests) for confirmed COVID 19 cases. Sample size: The trial will test for HCQ's superiority assuming a primary outcome incidence of 20% in the control group and a reduction of 50% with HCQ. The sample size required for a power of 80% (alpha 0.05) is 291 participants per each group.

    NCT04438837
    Conditions
    1. Coronavirus Disease 2019 (COVID-19)
    2. Post-Exposure Prophylaxis
    Interventions
    1. Drug: Hydroxychloroquine
    MeSH:Coronavirus Infections

    Primary Outcomes

    Description: Number of patients developing clinical symptoms and signs compatible with COVID-19 following exposure

    Measure: Clinical COVID-19

    Time: 14 days following exposure.

    Secondary Outcomes

    Description: PCR- proven COVID-19 (confirmed cases)

    Measure: Confirmed COVID-19

    Time: 14 days following exposure.

    Description: Time to virological recovery for participants who develop confirmed COVID-19

    Measure: Time to virological recovery

    Time: 30 days

    Description: Time to symptoms onset defined as days until start of fever, cough or shortness of breath.

    Measure: Time to symptoms onset

    Time: 14 days

    Description: Development of pneumonia- clinical and radiological (chest X ray or CT).

    Measure: Development of pneumonia

    Time: 14 days

    Description: Development of severe disease- respiratory failure, mechanical ventilation, severe sepsis, multi-organ failure or acute myocarditis)

    Measure: Development of severe disease

    Time: 14 days

    Description: Need for hospitalization, need for ICU admission

    Measure: Need for hospitalization or ICU

    Time: 14 days

    Description: Number of adverse events - prolonged QT, arrhythmias, nausea, vomiting

    Measure: Adverse events

    Time: 14 days

    Description: All-cause mortality at the end of follow up

    Measure: Mortality

    Time: 30 days

    Description: Number of days between exposure to de-isolation

    Measure: Time to de-isolation

    Time: 30 days
    95 Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients With Moderate or Severe COVID-19 Infection

    This research is designed as an open-label,non-comparative prospective trial.

    NCT04458948
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin

    Primary Outcomes

    Description: To measure the duration of viral shedding in respiratory secretions of patients with moderate or severe COVID-19 infection treated with the combination of Hydroxychloroquine and azithromycin. Measured via negative PCR test from nasopharyngeal swabs or oropharyngeal swabs in nonventilator dependent patient or tracheal secretions in ventilator dependent patient on days 3, 6, and 14.

    Measure: Duration of viral shedding

    Time: 1 month

    Description: Evaluate the case fatality rate in hospitalized patients with moderate and severe COVID-19 infection.

    Measure: Evaluation of Fatality Rate

    Time: 6 months

    Description: Evaluation of clinical response in hospitalized patients with moderate and severe COVID-19 infection.

    Measure: Evaluation of Clinical Response

    Time: 6 months

    Description: Evaluate the length of hospital stay in hospitalized patients with moderate and severe COVID-19 infection.

    Measure: Evaluation of Length of Hospital Stay

    Time: 6 months
    96 Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic: An Observational Study

    On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.

    NCT04460547
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Convalescent Plasma Transfusion
    2. Drug: Hydroxychloroquine
    3. Drug: DAS181
    4. Drug: Ivermectin
    5. Drug: Interferon Beta-1A

    Primary Outcomes

    Description: To understand the geographical distribution of the interventional studies after 11th of March 2020.

    Measure: Geographical distribution of the interventional studies after 11th of March 2020.

    Time: 15th of August 2020

    Description: To understand the geographical distribution of the Observational studies after 11th of March 2020.

    Measure: Geographical distribution of the Observational studies after 11th of March 2020.

    Time: 15th of August 2020

    Description: To understand the monthly Research study completion rate as per geographic distribution of the Research.

    Measure: Monthly Research study completion rate as per geographic distribution of the Research.

    Time: 15th of August 2020

    Secondary Outcomes

    Description: To understand the statistical correlation of the interventional studies Research with developed, developing and under developed countries.

    Measure: Statistical correlation of the interventional studies Research with developed, developing and under developed countries.

    Time: 15th of August 2020

    Description: To understand the statistical correlation of the observational studies Research with developed, developing and under developed countries.

    Measure: Statistical correlation of the observational studies Research with developed, developing and under developed countries.

    Time: 15th of August 2020

    Description: To understand the statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.

    Measure: Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.

    Time: 15th of August 2020

    Description: To understand the statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.

    Measure: Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.

    Time: 15th of August 2020

    Description: To understand the statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.

    Measure: Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.

    Time: 15th of August 2020
    97 Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19 Disease in Healthcare Providers at Baqiyatallah Hospital in Tehran

    180 people from the medical staff and high-risk people in Baqiyatallah Hospital, who are in close contact with patients, will enter the study. Participants will be divided into two intervention groups and one control group. The control group will use the full protective equipment assigned to the treatment staff. In addition to protective equipment, the first intervention team will receive a daily diet of 200 mg hydroxychloroquine tablets. The second intervention team, while observing and using the complete protective equipment, will place a thin layer of Mucodentol gel in the vestibular area of the mouth daily, every 6 to 8 hours. At the beginning of the treatment, qualified people will participate in the study while recording demographic and clinical information, PCR test will be performed, and if they have negative PCR, they will be in one of the 3 study groups. During the study, if the symptoms of the disease occur in each of the participants, the test will be taken again. If the test is positive, the person will withdraw from the study, and the patient's information will be recorded. Finally, the people present in the study will be tested for PCR, and the results of the disease and the side effects of the drugs will be compared.

    NCT04466280
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Mucodentol
    3. Device: Personal protective equipment

    Primary Outcomes

    Description: Laboratory PCR testing can help diagnose the disease

    Measure: PCR test

    Time: up to 1 month

    Secondary Outcomes

    Description: Normal blood cell count and CRP count (normal laboratory range)

    Measure: Laboratory Treatment Response

    Time: up to 1 month

    Description: Complications in both groups should be evaluated and evaluated during treatment.

    Measure: drug reactions Adverse

    Time: up to 1 month

    Description: There will be known allergic reactions to the drugs.

    Measure: Allergic drug

    Time: up to 1 month

    Description: CT scans help determine how much the lungs are affected by COVID-19.

    Measure: Radiological Treatment Response

    Time: up to 1 month
    98 Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19

    In December 2019, a group of patients with pneumonia of unknown cause was identified in Wuhan, in the Hubei province, China. Despite the need of target specific therapeutic options for COVID-19, until now there is no proof of effectiveness of any specific intervention. Some limited observational trials and also evidence from randomized trials have shown no benefit of hydroxychloroquine in inpatient context. Thus, studies evaluating interventions in an outpatient setting in non-severe patients can provide important information related to prognosis and safety. In this way, the present study will evaluate the effectiveness and safety of the use of hydroxychloroquine in COVID-19 outpatients by means of a Randomized, double-blind, placebo-controlled trial

    NCT04466540
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo

    Primary Outcomes

    Description: To assess if the treatment is able to avoid hospitalization due to a COVID-19-related clinical reason within 30 days of randomization in an outpatient setting. Hospitalization is considered to be hospital stay for a period > 24h or an additional hospitalized calendar day.

    Measure: Hospitalization

    Time: 30 days from randomization

    Secondary Outcomes

    Description: Affirmative answer in three or four items of the Global Initiative for Asthma (GINA) questionnaire

    Measure: Uncontrolled asthma after ≥ 5 days of starting study medication

    Time: within 30 days from randomization

    Description: Defined by clinical-radiological criteria - a history of cough and one or more of the following symptoms: sputum, dyspnea, chest pain, sweating or fever (T> 37.8o C) + Chest CT scan showing ground-glass opacity, focal consolidations or mixed opacities (including reverse halo sign), uni or bilateral

    Measure: Pneumonia

    Time: within 30 days from randomization

    Description: Defined by clinical criteria - Fever (T> 37.8o C) and otalgia + bulging of the tympanic membrane

    Measure: Otitis media

    Time: within 30 days from randomization

    Description: Day 0 of fever resolution will be defined as the first afebrile day (T <37.5o C) after inclusion in the study followed by at least two consecutive days. The temperature will be obtained through the participant report in the patient's diary

    Measure: Fever resolution time

    Time: within 30 days from randomization

    Description: Time to improve respiratory symptoms (cough, runny nose)

    Measure: Time to improve respiratory symptoms

    Time: within 30 days from randomization

    Description: Admission to ICU due to clinical reasons related to COVID-19

    Measure: Hospitalization in the Intensive Care Unit

    Time: within 30 days from randomization

    Description: Clinical need for Orotracheal Intubation as assessed by the physician responsible for the case

    Measure: Need for Orotracheal Intubation

    Time: within 30 days from randomization

    Description: Number of days on mechanical ventilation until extubation or death

    Measure: Mechanical Ventilation Time

    Time: within 30 days from randomization

    Description: Death due to any cause that occurred within 30 days after inclusion in the study

    Measure: Mortality

    Time: within 30 days from randomization

    Other Outcomes

    Description: Change in the frequency of hypoglycemic episodes in diabetic patients using hypoglycemic medication, perceived by clinical signs or symptoms or measured in a capillary or blood glucose device

    Measure: Hypoglycemia

    Time: within 30 days from randomization

    Description: Presence of cardiac arrhythmias in patients without known history of prolongation of the measure between Q wave and T wave in the heart's electrical cycle (QTc) or pre-existing heart disease;

    Measure: Palpitations

    Time: within 30 days from randomization

    Description: Change in visual acuity or new diagnosis of retinal disease not previously documented

    Measure: Reduced visual acuity

    Time: within 30 days from randomization

    Description: Change in bowel habit greater than three (3) diarrheal episodes per day during the use of hydroxychloroquine medication and 3 days after its end

    Measure: Diarrhea

    Time: within 30 days from randomization

    Description: Change in appetite during medication use hydroxychloroquine and 3 days after the end of treatment

    Measure: Anorexia

    Time: within 30 days from randomization

    Description: Perception of change in emotional lability (mood swings) during hydroxychloroquine use and 3 days after the end of treatment

    Measure: Emotional lability

    Time: within 30 days from randomization

    Description: Time from randomization to hospitalization

    Measure: Time to hospitalization after randomization

    Time: within 30 days from randomization

    Description: Clinical and vital signs assessed when admitted to hospital

    Measure: Assessment of the patient clinical status at the time of hospitalization

    Time: within 30 days from randomization
    99 An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)

    An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed with SARS-CoV-2 Infection (COVID-19).

    NCT04483960
    Conditions
    1. SARS-CoV-2 Infection (COVID-19)
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Lopinavir / Ritonavir
    3. Biological: Convalescent plasma
    MeSH:Infection

    Primary Outcomes

    Description: Morbidity

    Measure: Proportion of participants alive and not having required new intensive respiratory support (invasive or non-invasive ventilation) or vasopressors/inotropic support in the 28 days after randomisation.

    Time: 28 days

    Secondary Outcomes

    Description: Not hospitalized, no limitations on activities Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death.

    Measure: World Health Organization (WHO) 7-point outcome scale (clinician assessed)

    Time: 28 days

    Description: All cause mortality

    Measure: Mortality

    Time: 7, 15, 28, and 90 days

    Description: Number of days

    Measure: Time to death

    Time: 90 days

    Description: Number of days

    Measure: Length of hospital stay

    Time: 90 days

    Description: Yes/No

    Measure: Receipt of invasive or non-invasive ventilation

    Time: 28 days

    Description: Number of days

    Measure: Length of receipt of invasive or non-invasive ventilation

    Time: 28 days

    Description: Number of days

    Measure: Length of intensive care unit (ICU) stay

    Time: 90 days

    Description: Yes/No

    Measure: Presence of chest infiltrates on chest x-ray (CXR) or CT

    Time: 3 and 7 days

    Description: Number of days

    Measure: Time to defervescence from randomisation

    Time: 28 days

    Description: C-reactive protein (CRP) and Lactate dehydrogenase (LDH) and D-dimer

    Measure: Biomarker levels

    Time: 28 days

    Description: number of days of use in first 10 days

    Measure: Antibiotic use

    Time: 10 days

    Description: Recording of the following adverse events: Diarrhoea, Nausea, Vomiting, Pancreatitis, QTc prolongation (>500ms) 24 hours, serious allergic reaction or anaphylaxis, transfusion-related acute lung injury, transfusion-associated circulatory overload

    Measure: Adverse Events

    Time: 10 days

    Description: Yes/No

    Measure: Serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death in hospital

    Time: 28 days

    Description: Yes/No - based on the modified Kidney Disease Improving Global Outcomes (KDIGO) criteria; serum creatinine increase by≥ 26.5mol/L within 48 hours OR to ≥1.5 times baseline, known or presumed to have occurred within the prior 7 days

    Measure: Acute Kidney Injury (AKI)

    Time: 28 days

    Description: Confirmed deep vein thrombosis, pulmonary embolus, ischemic cerebrovascular event, acute myocardial infarction or other thrombotic event during index hospitalisation.

    Measure: Thrombotic events

    Time: 28 days

    Description: Proportion of patients with negative SARS-CoV-2 real time - polymerase chain reaction (RT-PCR) at day 3 and day 7 from upper or lower respiratory tract samples.

    Measure: Viral clearance

    Time: 3 and 7 days

    Related HPO nodes (Using clinical trials)


    HP:0001369: Arthritis
    Genes 263
    CCN6 IL2RA NFKBIL1 LBR SPTB BLNK TRAPPC2 EPB42 MVK CD79A IL36RN COMP STAT3 IL2RB TGFB3 MEFV IL12A-AS1 CASP10 MLX MMP13 SLCO2A1 COL2A1 COL2A1 ASAH1 IGHM COL2A1 APOE HNF4A COL2A1 ADA2 PTPN22 MMP14 NOD2 CD247 BTK SCARB2 COL2A1 GLA UMOD CCR1 COL11A2 LRBA CCR6 COMP EXT1 IL6 RREB1 KLRC4 COL11A1 PTPN22 PSTPIP1 HNF1B SAMHD1 HLA-C COL11A2 LRP6 GPR101 COL2A1 RAG1 KIF7 DCLRE1C NOD2 CTLA4 NLRP3 HPRT1 ABCG8 HGD MMP13 HLA-DRB1 NLRP3 SH3KBP1 SLC37A4 TF CCN6 ZNF687 GJB2 IL2RA PFKM AIP FASLG TREX1 HLA-B MATN3 ASPN TNFRSF1A C4A COL2A1 MYH14 UBAC2 FAS ARVCF ACP5 EXT2 PRG4 AEBP1 MTHFD1 ANKRD55 PTPN22 TFR2 GCH1 GJB6 COL9A1 COL11A2 PTPN22 SPP1 RNASEH2B TRAPPC2 OCRL TREX1 LRRC8A GBA COL1A1 LMX1B ACAN GP1BB TLR4 ANK1 COMP UFD1 SLC12A3 NLRP3 FAS HGD IL12A SEC61A1 PHEX COPA HPGD IRF5 FCGR2B TRPV4 PSMB9 WIPF1 CTLA4 CAV1 MVK HLA-DRB1 ATP7B MUC1 COL9A1 ACAN ATP7B EPCAM DNASE1L3 CLCNKB LMNA MMP2 IL10 IL12B RASGRP1 PTPN2 COMT COL2A1 STAT4 SLC37A4 GNAS MIF HLA-DRB1 WAS STAT4 RNF168 CLCN7 JMJD1C IL23R MEFV G6PC CFI ERAP1 F8 PSTPIP1 GHR HLA-B HIRA PRPS1 ADAR DNAJB11 MEFV PTPN2 IL10 ANKH IFIH1 STAT4 COL5A1 FRZB HPGD KIF22 TBX1 CIITA CD79B IGLL1 IRAK1 IL2RB MATN3 COL9A2 COL9A3 TNFRSF11B COMP HLA-B STAT4 PADI4 MATN3 HJV COL2A1 SMAD3 F9 TRPS1 UFSP2 RAG2 COL1A1 MEFV COL5A1 ANKRD55 SLC40A1 SLC4A1 SPTA1 FBN1 BTK RNASEH2C DNASE1 CANT1 TBX1 PHEX CD247 TCF3 PSMB4 PIK3R1 AGA CD244 COL5A2 LEMD3 FGFR3 RNASEH2A ACAN HPRT1 ANKH SEC24C GDF5 SLC22A4 UMOD HPRT1 TRPV4 HPGD BTK FAS COL9A3 UFSP2 ZMPSTE24 PTPN22 LACC1 HPRT1 NLRP3 HNF1B HOXD10 PRKCD SLC26A2 COL9A2 SMAD3 FCGR2A CCN2 CLCN7 COL3A1 ASAH1 NLRP12
    Protein Mutations 4
    A147T N363S R620W V600E
    HP:0011947: Respiratory tract infection
    Genes 664
    CCDC39 KMT2D RSPH1 DOCK8 NKX2-1 CCNO SPAG1 LIMK1 MPLKIP RAG1 DSG1 BIRC3 ELP1 TSC2 IL17F BLNK BACH2 SGSH IKBKB CD79A AFF4 ARID1B TNFRSF13C CD19 DNAH1 MYO5A AICDA NOTCH3 ELN LAMTOR2 NADK2 CTLA4 DPM2 PWAR1 GATA6 SFTPC FOXN1 MESP2 ELANE CD81 PNP MED25 ZAP70 RAG2 WRAP53 DNAAF1 STAT3 ATM LTBP3 CLCA4 DNAH9 BTK RSPH3 TERT TYK2 LRBA RSPH4A SOX11 RYR1 TNNT2 SMARCD2 GAS8 SLC5A7 KIF1A ROR2 NCF4 COLQ TNFRSF13B HLA-B CCDC65 COL11A2 ORC6 DCLRE1C CTLA4 CACNA1C GBA RNF113A ICOS SETBP1 CYBC1 MGP VPS33A COL13A1 MYSM1 DNAAF4 FLI1 MECP2 MAN2B1 HLA-DQA1 SCNN1A GLB1 IL21R CSF2RB SELENON INPPL1 CD3G ACADVL COL6A3 NSMCE3 AGA CCDC65 HGSNAT AP3D1 NFIX EXOSC9 RAG2 KIAA0586 FCGR2A ABCA12 NFKB2 TFRC NDN MAPK1 LAMA2 NCF4 ARSB LYST RAG1 TPP2 TGFB1 INPPL1 RAG2 TNFSF11 XIAP UNG SCNN1A DNAAF6 SCN10A IL2RG CCDC103 CLCN7 IGHM GNPTAB DNAAF4 CXCR4 PLEC HLA-DPB1 OCRL RFXAP SCN11A CFB TNNI3 TINF2 DCLRE1C MAGEL2 TAF1 SCNN1B CARD11 USB1 GTF2IRD1 CCDC103 SNORD115-1 IL2RG HLA-DQB1 TBC1D23 DLL3 RFXANK MYO9A SCNN1G CD79A ICOS RFC2 TAP1 CD3D FOXJ1 AGRN PIK3R1 WIPF1 RSPH4A IL2RG ACTA1 SRP54 RPGR SNAP25 TSC1 CORO1A IRF8 NCF2 GAS8 ZNHIT3 FOXP1 EP300 JAGN1 ZBTB24 TGFB1 TNFRSF13B CD3E DNAL1 EXTL3 NCF1 SNRPN B2M CLIP2 SCNN1G SFTPC LRRC56 WAS RMRP FUCA1 RSPH9 PEX13 GATA4 CFI ERCC3 FOXP1 ITGA3 PCGF2 TNFRSF13C ATP6V0A2 DNMT3B LEP BCR ZBTB24 NELFA RNF125 NECTIN1 EPM2A TGM1 CCDC40 JAK3 NEK10 MYPN RAC1 CREBBP DNAI2 PLG DDR2 UGP2 NME8 COL6A1 SLC25A1 ECM1 CD3E NFKBIA IGLL1 CHRM3 PRTN3 COG6 CD8A STX1A DNAI1 CYBB IDUA GSN EPG5 TCIRG1 DNAJB13 EDARADD TERT CR2 SOX4 NSD2 GAA TARS1 LEPR ELP1 ALMS1 IL2RB SULT2B1 RAG2 SLC25A24 SMPD1 WDR19 CHAMP1 DNAJB13 FOXP3 RNU4ATAC PLP1 ARID1A CFAP410 BTK TCTN3 RFXANK MYH3 FCN3 SMARCE1 ALPL SLC18A3 IL17RA NR2F2 NKX2-1 SCNN1G CCBE1 SLC52A3 PWRN1 DCLRE1C RYR1 AGA CIITA CR2 LRRC6 PIGN CFAP298 DNAAF5 CCNO BLM CFTR NCF1 CR2 IL2RA LCK UMPS USP9X CD3D ARID2 RUNX2 SLC35C1 TIMM8A NGLY1 NFKB2 CCDC114 TPM3 SCNN1B ADA LRRC56 PEPD IPW KATNIP LYST GRHL3 CCDC151 NBN SYT2 SPAG1 PRKCD LAMB2 CTC1 PMM2 DNAAF3 FLNC DNAAF1 POLR3A LIPN STAT1 TECPR2 SCNN1B RAG1 SDR9C7 ASAH1 DNAAF6 CRELD1 MYSM1 OSTM1 GBA CYBA RNU4ATAC COL13A1 VAMP1 MGP SMARCC2 MCIDAS G6PC3 IL17RC PSAP KAT6B PIK3R1 CD81 SLC1A4 NOP10 NGLY1 MANBA SHROOM4 ALB SMARCD1 SCNN1A CD19 ALMS1 GUSB TTC25 SMN1 RIPK1 UNC119 IGHM CD79B CFAP221 SAMD9 CYP4F22 GTF2H5 GLI3 IGLL1 SLC29A3 RPGR SCNN1B STK36 PLOD1 DNAAF5 GMNN RAG1 GNS COL11A2 OFD1 TNFRSF11A MALT1 NFE2L2 CD19 DCTN4 COG4 SCNN1A CD40LG NME8 SELENON ADNP CFTR NPAP1 CFTR DOCK8 CFAP298 SMPD1 RAG1 P4HTM MAN2B1 SLC26A2 CFAP300 RAB3GAP2 ALG12 JAK3 GTF2E2 IL21 BCL10 NRAS PRKDC TNFRSF13C SH3KBP1 ZNF341 NXN RSPH9 RFXAP SPEF2 MSN LIG4 MCM4 TBCE GALNS SLC12A6 NIPBL STAT3 ZMYND10 IL7R NAGLU HELLS CTSC NIPAL4 RASGRP1 SMARCB1 SP110 LETM1 RSPH1 CCDC39 ARMC4 LAMTOR2 TNFRSF1A IKZF1 IKBKB DNAI2 MBTPS2 FBLN5 ACP5 PTPRC NFKB2 ZAP70 TPM2 TCIRG1 NEK10 ARMC4 MS4A1 MTHFD1 CARMIL2 UBE2A EGFR RYR1 ADA DNAI1 PLCG2 PTPN22 DNMT3B BAZ1B TAPBP RTEL1 ABCA12 SNX10 CSF2RA MESP2 SMARCA4 AK2 DNAH11 KCNJ6 HACD1 DCLRE1C SAMD9L PNP ITGA7 ALOXE3 HLA-DPA1 HERC2 SLC46A1 LRRC8A IER3IP1 TSC2 TGFB1 TRAF3IP2 HPS6 ADA ICOS FLNA TRIP4 FMO3 DPF2 GFI1 ARID1B IRAK4 MKRN3-AS1 VPS33A DNAAF2 NOTCH2 SFTPA2 PCNT CRLF1 ELANE DNAH5 NFKB1 PANK2 GBA GAS2L2 GTF2I CD247 STAT1 RAG2 CCDC151 WAS EPG5 SLC25A22 DYNC2I2 XIAP SLC35A1 GNPTAB TK2 MS4A1 IFNGR1 LEPR CRKL CIITA NPM1 ZMYND10 COL6A2 ATM RNF168 GAS2L2 CDCA7 PRPS1 EHMT1 ERF NHLRC1 TBX6 MUC5B VPS13A RFX5 ASAH1 DNAH5 HYDIN FCGR3A RELB ADAMTS3 SCN9A TTC12 SH2D1A PTPN22 LEP CYBA PGM3 IL17RA MKRN3 NOS1 AFF4 ERCC2 SDCCAG8 IFIH1 CD79B TBC1D24 CHD7 GATA2 POLE LRRC6 TERC TNFRSF13B TAP2 CFTR OFD1 WASHC5 RANBP2 IL7R MYL2 TRAIP CCDC22 IGH CCDC40 IL2RG SNORD116-1 ALOX12B NFKB1 STING1 NCF2 TRPS1 SGCG PARN CHAT TSC1 TBL2 CTCF ACTA1 CACNA1B UBB PIK3CD PEPD DNAAF3 TTC25 CARD11 DNAAF2 CXCR4 MASP2 IL6ST TBC1D24 DRC1 TBCD TCF3 CYBB PIK3R1 SMN1 RSPH3 COG4 TNFSF12 CSPP1 KIF20A USP9X NHP2 HYDIN NBN PYROXD1 CASP8 IL7R SCNN1G CCDC114 TNFSF12 BTK SPINK5 BLNK CD55 IDUA USB1 SIK1 FLNA CLEC7A MAP3K20 KPTN RFX5 FAT4 DKC1 KDM6A IDUA POLA1 TRIP11 PGM3 GUSB DNAH11 KRAS
    Protein Mutations 1
    H275Y
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    Related HPO nodes (Using clinical trials)


    HP:0001369: Arthritis
    Genes 263
    CCN6 IL2RA NFKBIL1 LBR SPTB BLNK TRAPPC2 EPB42 MVK CD79A IL36RN COMP STAT3 IL2RB TGFB3 MEFV IL12A-AS1 CASP10 MLX MMP13 SLCO2A1 COL2A1 COL2A1 ASAH1 IGHM COL2A1 APOE HNF4A COL2A1 ADA2 PTPN22 MMP14 NOD2 CD247 BTK SCARB2 COL2A1 GLA UMOD CCR1 COL11A2 LRBA CCR6 COMP EXT1 IL6 RREB1 KLRC4 COL11A1 PTPN22 PSTPIP1 HNF1B SAMHD1 HLA-C COL11A2 LRP6 GPR101 COL2A1 RAG1 KIF7 DCLRE1C NOD2 CTLA4 NLRP3 HPRT1 ABCG8 HGD MMP13 HLA-DRB1 NLRP3 SH3KBP1 SLC37A4 TF CCN6 ZNF687 GJB2 IL2RA PFKM AIP FASLG TREX1 HLA-B MATN3 ASPN TNFRSF1A C4A COL2A1 MYH14 UBAC2 FAS ARVCF ACP5 EXT2 PRG4 AEBP1 MTHFD1 ANKRD55 PTPN22 TFR2 GCH1 GJB6 COL9A1 COL11A2 PTPN22 SPP1 RNASEH2B TRAPPC2 OCRL TREX1 LRRC8A GBA COL1A1 LMX1B ACAN GP1BB TLR4 ANK1 COMP UFD1 SLC12A3 NLRP3 FAS HGD IL12A SEC61A1 PHEX COPA HPGD IRF5 FCGR2B TRPV4 PSMB9 WIPF1 CTLA4 CAV1 MVK HLA-DRB1 ATP7B MUC1 COL9A1 ACAN ATP7B EPCAM DNASE1L3 CLCNKB LMNA MMP2 IL10 IL12B RASGRP1 PTPN2 COMT COL2A1 STAT4 SLC37A4 GNAS MIF HLA-DRB1 WAS STAT4 RNF168 CLCN7 JMJD1C IL23R MEFV G6PC CFI ERAP1 F8 PSTPIP1 GHR HLA-B HIRA PRPS1 ADAR DNAJB11 MEFV PTPN2 IL10 ANKH IFIH1 STAT4 COL5A1 FRZB HPGD KIF22 TBX1 CIITA CD79B IGLL1 IRAK1 IL2RB MATN3 COL9A2 COL9A3 TNFRSF11B COMP HLA-B STAT4 PADI4 MATN3 HJV COL2A1 SMAD3 F9 TRPS1 UFSP2 RAG2 COL1A1 MEFV COL5A1 ANKRD55 SLC40A1 SLC4A1 SPTA1 FBN1 BTK RNASEH2C DNASE1 CANT1 TBX1 PHEX CD247 TCF3 PSMB4 PIK3R1 AGA CD244 COL5A2 LEMD3 FGFR3 RNASEH2A ACAN HPRT1 ANKH SEC24C GDF5 SLC22A4 UMOD HPRT1 TRPV4 HPGD BTK FAS COL9A3 UFSP2 ZMPSTE24 PTPN22 LACC1 HPRT1 NLRP3 HNF1B HOXD10 PRKCD SLC26A2 COL9A2 SMAD3 FCGR2A CCN2 CLCN7 COL3A1 ASAH1 NLRP12
    Protein Mutations 4
    A147T N363S R620W V600E
    HP:0011947: Respiratory tract infection
    Genes 664
    CCDC39 KMT2D RSPH1 DOCK8 NKX2-1 CCNO SPAG1 LIMK1 MPLKIP RAG1 DSG1 BIRC3 ELP1 TSC2 IL17F BLNK BACH2 SGSH IKBKB CD79A AFF4 ARID1B TNFRSF13C CD19 DNAH1 MYO5A AICDA NOTCH3 ELN LAMTOR2 NADK2 CTLA4 DPM2 PWAR1 GATA6 SFTPC FOXN1 MESP2 ELANE CD81 PNP MED25 ZAP70 RAG2 WRAP53 DNAAF1 STAT3 ATM LTBP3 CLCA4 DNAH9 BTK RSPH3 TERT TYK2 LRBA RSPH4A SOX11 RYR1 TNNT2 SMARCD2 GAS8 SLC5A7 KIF1A ROR2 NCF4 COLQ TNFRSF13B HLA-B CCDC65 COL11A2 ORC6 DCLRE1C CTLA4 CACNA1C GBA RNF113A ICOS SETBP1 CYBC1 MGP VPS33A COL13A1 MYSM1 DNAAF4 FLI1 MECP2 MAN2B1 HLA-DQA1 SCNN1A GLB1 IL21R CSF2RB SELENON INPPL1 CD3G ACADVL COL6A3 NSMCE3 AGA CCDC65 HGSNAT AP3D1 NFIX EXOSC9 RAG2 KIAA0586 FCGR2A ABCA12 NFKB2 TFRC NDN MAPK1 LAMA2 NCF4 ARSB LYST RAG1 TPP2 TGFB1 INPPL1 RAG2 TNFSF11 XIAP UNG SCNN1A DNAAF6 SCN10A IL2RG CCDC103 CLCN7 IGHM GNPTAB DNAAF4 CXCR4 PLEC HLA-DPB1 OCRL RFXAP SCN11A CFB TNNI3 TINF2 DCLRE1C MAGEL2 TAF1 SCNN1B CARD11 USB1 GTF2IRD1 CCDC103 SNORD115-1 IL2RG HLA-DQB1 TBC1D23 DLL3 RFXANK MYO9A SCNN1G CD79A ICOS RFC2 TAP1 CD3D FOXJ1 AGRN PIK3R1 WIPF1 RSPH4A IL2RG ACTA1 SRP54 RPGR SNAP25 TSC1 CORO1A IRF8 NCF2 GAS8 ZNHIT3 FOXP1 EP300 JAGN1 ZBTB24 TGFB1 TNFRSF13B CD3E DNAL1 EXTL3 NCF1 SNRPN B2M CLIP2 SCNN1G SFTPC LRRC56 WAS RMRP FUCA1 RSPH9 PEX13 GATA4 CFI ERCC3 FOXP1 ITGA3 PCGF2 TNFRSF13C ATP6V0A2 DNMT3B LEP BCR ZBTB24 NELFA RNF125 NECTIN1 EPM2A TGM1 CCDC40 JAK3 NEK10 MYPN RAC1 CREBBP DNAI2 PLG DDR2 UGP2 NME8 COL6A1 SLC25A1 ECM1 CD3E NFKBIA IGLL1 CHRM3 PRTN3 COG6 CD8A STX1A DNAI1 CYBB IDUA GSN EPG5 TCIRG1 DNAJB13 EDARADD TERT CR2 SOX4 NSD2 GAA TARS1 LEPR ELP1 ALMS1 IL2RB SULT2B1 RAG2 SLC25A24 SMPD1 WDR19 CHAMP1 DNAJB13 FOXP3 RNU4ATAC PLP1 ARID1A CFAP410 BTK TCTN3 RFXANK MYH3 FCN3 SMARCE1 ALPL SLC18A3 IL17RA NR2F2 NKX2-1 SCNN1G CCBE1 SLC52A3 PWRN1 DCLRE1C RYR1 AGA CIITA CR2 LRRC6 PIGN CFAP298 DNAAF5 CCNO BLM CFTR NCF1 CR2 IL2RA LCK UMPS USP9X CD3D ARID2 RUNX2 SLC35C1 TIMM8A NGLY1 NFKB2 CCDC114 TPM3 SCNN1B ADA LRRC56 PEPD IPW KATNIP LYST GRHL3 CCDC151 NBN SYT2 SPAG1 PRKCD LAMB2 CTC1 PMM2 DNAAF3 FLNC DNAAF1 POLR3A LIPN STAT1 TECPR2 SCNN1B RAG1 SDR9C7 ASAH1 DNAAF6 CRELD1 MYSM1 OSTM1 GBA CYBA RNU4ATAC COL13A1 VAMP1 MGP SMARCC2 MCIDAS G6PC3 IL17RC PSAP KAT6B PIK3R1 CD81 SLC1A4 NOP10 NGLY1 MANBA SHROOM4 ALB SMARCD1 SCNN1A CD19 ALMS1 GUSB TTC25 SMN1 RIPK1 UNC119 IGHM CD79B CFAP221 SAMD9 CYP4F22 GTF2H5 GLI3 IGLL1 SLC29A3 RPGR SCNN1B STK36 PLOD1 DNAAF5 GMNN RAG1 GNS COL11A2 OFD1 TNFRSF11A MALT1 NFE2L2 CD19 DCTN4 COG4 SCNN1A CD40LG NME8 SELENON ADNP CFTR NPAP1 CFTR DOCK8 CFAP298 SMPD1 RAG1 P4HTM MAN2B1 SLC26A2 CFAP300 RAB3GAP2 ALG12 JAK3 GTF2E2 IL21 BCL10 NRAS PRKDC TNFRSF13C SH3KBP1 ZNF341 NXN RSPH9 RFXAP SPEF2 MSN LIG4 MCM4 TBCE GALNS SLC12A6 NIPBL STAT3 ZMYND10 IL7R NAGLU HELLS CTSC NIPAL4 RASGRP1 SMARCB1 SP110 LETM1 RSPH1 CCDC39 ARMC4 LAMTOR2 TNFRSF1A IKZF1 IKBKB DNAI2 MBTPS2 FBLN5 ACP5 PTPRC NFKB2 ZAP70 TPM2 TCIRG1 NEK10 ARMC4 MS4A1 MTHFD1 CARMIL2 UBE2A EGFR RYR1 ADA DNAI1 PLCG2 PTPN22 DNMT3B BAZ1B TAPBP RTEL1 ABCA12 SNX10 CSF2RA MESP2 SMARCA4 AK2 DNAH11 KCNJ6 HACD1 DCLRE1C SAMD9L PNP ITGA7 ALOXE3 HLA-DPA1 HERC2 SLC46A1 LRRC8A IER3IP1 TSC2 TGFB1 TRAF3IP2 HPS6 ADA ICOS FLNA TRIP4 FMO3 DPF2 GFI1 ARID1B IRAK4 MKRN3-AS1 VPS33A DNAAF2 NOTCH2 SFTPA2 PCNT CRLF1 ELANE DNAH5 NFKB1 PANK2 GBA GAS2L2 GTF2I CD247 STAT1 RAG2 CCDC151 WAS EPG5 SLC25A22 DYNC2I2 XIAP SLC35A1 GNPTAB TK2 MS4A1 IFNGR1 LEPR CRKL CIITA NPM1 ZMYND10 COL6A2 ATM RNF168 GAS2L2 CDCA7 PRPS1 EHMT1 ERF NHLRC1 TBX6 MUC5B VPS13A RFX5 ASAH1 DNAH5 HYDIN FCGR3A RELB ADAMTS3 SCN9A TTC12 SH2D1A PTPN22 LEP CYBA PGM3 IL17RA MKRN3 NOS1 AFF4 ERCC2 SDCCAG8 IFIH1 CD79B TBC1D24 CHD7 GATA2 POLE LRRC6 TERC TNFRSF13B TAP2 CFTR OFD1 WASHC5 RANBP2 IL7R MYL2 TRAIP CCDC22 IGH CCDC40 IL2RG SNORD116-1 ALOX12B NFKB1 STING1 NCF2 TRPS1 SGCG PARN CHAT TSC1 TBL2 CTCF ACTA1 CACNA1B UBB PIK3CD PEPD DNAAF3 TTC25 CARD11 DNAAF2 CXCR4 MASP2 IL6ST TBC1D24 DRC1 TBCD TCF3 CYBB PIK3R1 SMN1 RSPH3 COG4 TNFSF12 CSPP1 KIF20A USP9X NHP2 HYDIN NBN PYROXD1 CASP8 IL7R SCNN1G CCDC114 TNFSF12 BTK SPINK5 BLNK CD55 IDUA USB1 SIK1 FLNA CLEC7A MAP3K20 KPTN RFX5 FAT4 DKC1 KDM6A IDUA POLA1 TRIP11 PGM3 GUSB DNAH11 KRAS
    Protein Mutations 1
    H275Y
    SNP 0

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook